var title_f31_26_32160="Follicular cyst2";
var content_f31_26_32160=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Follicular ovarian cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transvaginal ultrasound of the left adnexa. Normal left ovary with two follicles that are shown by the arrows. The follicles are circular anechoic structures within the substance of the hypoechoic ovarian tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas D Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_26_32160=[""].join("\n");
var outline_f31_26_32160=null;
var title_f31_26_32161="Penumbra sign";
var content_f31_26_32161=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Penumbra sign in osteomyelitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 260px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRI scan shows the penumbra sign (a transitional zone with relatively high signal intensity between abscess and sclerotic bone marrow on T1-weighted MRI).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shih, HN, Shih, LY, Wong, YC. Diagnosis and treatment of subacute osteomyelitis. J Trauma 2005; 58:83. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_26_32161=[""].join("\n");
var outline_f31_26_32161=null;
var title_f31_26_32162="Calculator: Mortality risk in post-operative patients with cirrhosis";
var content_f31_26_32162=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"MELD9_form\" name=\"MELD9_form\" onkeydown=\"clrResults();\" onkeyup=\"MELD9_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Mortality risk in post-operative patients with cirrhosis",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         MELDScore = Math.round(10 * ((1.12 * ln(INR)) + (0.378 * ln(Bilirubin)) + (0.957 * ln(Creatinine)) + (0.643 * CirrhosisEtiology)))",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         ExpDays = e",
"         <sup>",
"          ((0.02382*(Age-60))+(0.88884*ASAMort)+(0.11798*(MELDScore-8)))",
"         </sup>",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         Mortality7Days = 100 * (1 - 0.98370",
"         <sup>",
"          ExpDays",
"         </sup>",
"         )",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         Mortality30Days = 100 * (1 - 0.93479",
"         <sup>",
"          ExpDays",
"         </sup>",
"         )",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         Mortality90Days = 100 * (1 - 0.89681",
"         <sup>",
"          ExpDays",
"         </sup>",
"         )",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Age",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Age_param\" onblur=\"MELD9_fx(); minMaxCheck();\" onchange=\"MELD9_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"MELD9_fx();\" style=\"width:105px;\">",
"             <option value=\"0.0833333333333333|0|mo\">",
"              mo",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|yr\">",
"              yr",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" valign=\"top\">",
"            <span class=\"medCalcFontOneBold\">",
"             ASA Class",
"            </span>",
"           </td>",
"           <td align=\"left\" colspan=\"2\">",
"            <span class=\"medCalcFontOne\">",
"             <input checked=\"checked\" name=\"ASA_Class_radio\" onclick=\"MELD9_fx();\" type=\"radio\" value=\"Class 3: Systemic disease with significant functional limitation|3\"/>",
"             Class 3: Systemic disease with significant functional limitation",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"left\">",
"            <br/>",
"           </td>",
"           <td align=\"left\" colspan=\"2\">",
"            <span class=\"medCalcFontOne\">",
"             <input name=\"ASA_Class_radio\" onclick=\"MELD9_fx();\" type=\"radio\" value=\"Class 4: Systemic disease that is a constant threat to life|4\"/>",
"             Class 4: Systemic disease that is a constant threat to life",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Bilirubin",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Bilirubin_param\" onblur=\"MELD9_fx(); minMaxCheck();\" onchange=\"MELD9_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Bilirubin_unit\" onchange=\"MELD9_fx();\" style=\"width:105px;\">",
"             <option value=\"100|0|gm/L\">",
"              gm/L",
"             </option>",
"             <option value=\"1000|0|gm/dL\">",
"              gm/dL",
"             </option>",
"             <option value=\"1|0|mg%\">",
"              mg%",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mg/dL\">",
"              mg/dL",
"             </option>",
"             <option value=\"100|0|mg/mL\">",
"              mg/mL",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Creatinine",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Creatinine_param\" onblur=\"MELD9_fx(); minMaxCheck();\" onchange=\"MELD9_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Creatinine_unit\" onchange=\"MELD9_fx();\" style=\"width:105px;\">",
"             <option value=\"100|0|gm/L\">",
"              gm/L",
"             </option>",
"             <option value=\"1000|0|gm/dL\">",
"              gm/dL",
"             </option>",
"             <option value=\"1|0|mg%\">",
"              mg%",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|mg/dL\">",
"              mg/dL",
"             </option>",
"             <option value=\"100|0|mg/mL\">",
"              mg/mL",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             INR",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"INR_param\" onblur=\"MELD9_fx(); minMaxCheck();\" onchange=\"MELD9_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\">",
"            &nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" valign=\"top\">",
"            <span class=\"medCalcFontOneBold\">",
"             Cirrhosis Etiology",
"            </span>",
"           </td>",
"           <td align=\"left\" colspan=\"2\">",
"            <span class=\"medCalcFontOne\">",
"             <input checked=\"checked\" name=\"Cirrhosis_Etiology_radio\" onclick=\"MELD9_fx();\" type=\"radio\" value=\"Alcoholic or cholestatic|0\"/>",
"             Alcoholic or cholestatic",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"left\">",
"            <br/>",
"           </td>",
"           <td align=\"left\" colspan=\"2\">",
"            <span class=\"medCalcFontOne\">",
"             <input name=\"Cirrhosis_Etiology_radio\" onclick=\"MELD9_fx();\" type=\"radio\" value=\"Viral or other|1\"/>",
"             Viral or other",
"            </span>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Results:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             MELD Score",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"MELD_Score_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td align=\"left\">",
"            &nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Mortality 7 Days",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Mortality_7_Days_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <span style=\"white-space: nowrap;\">",
"              <span class=\"medCalcFontOneBold\">",
"               %",
"              </span>",
"             </span>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Mortality 30 Days",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Mortality_30_Days_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <span style=\"white-space: nowrap;\">",
"              <span class=\"medCalcFontOneBold\">",
"               %",
"              </span>",
"             </span>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             Mortality 90 Days",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"Mortality_90_Days_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <span style=\"white-space: nowrap;\">",
"              <span class=\"medCalcFontOneBold\">",
"               %",
"              </span>",
"             </span>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <div class=\"notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       <sup>",
"        *",
"       </sup>",
"       This is the original version of the MELD score as developed by investigators at Mayo Clinic.  A number of modifications have been made by UNOS to the model for its implementation in organ allocation for  liver transplantation. UNOS has set a minimum MELD score of 6 and a maximum score of 40.",
"      </li>",
"      <li>",
"       The original version of the MELD score should only be used in patients who are &gt;=12 years of age.",
"      </li>",
"      <li>",
"       This calculator predicts early and late mortality in patients with cirrhosis undergoing major surgery.",
"      </li>",
"      <li>",
"       By definition, patients with cirrhosis must have an ASA Class of 3 or more.",
"      </li>",
"      <li>",
"       Patients with ASA Class of 5 should not undergo surgery.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div class=\"references\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Teh SH, Nagorney DM, Stevens SR, et. al. Risk factors for mortality after surgery in patients with cirrhosis.",
"        <i>",
"         Gastroenterology",
"        </i>",
"        . 2007 Apr;132(4):1261-9. Epub 2007 Jan 25.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_26_32162=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function MELD9_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.MELD9_form){",
"",
"",
"doCalc = true;",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (ASA_Class_radio[0].checked){ ASA_Class = 3; }",
"if (ASA_Class_radio[1].checked){ ASA_Class = 4; }",
"if (Bilirubin_param.value.indexOf(',') >= 0){ Bilirubin_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Bilirubin_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Bilirubin_unit.options[Bilirubin_unit.selectedIndex].value.split('|');",
"Bilirubin = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Creatinine_param.value.indexOf(',') >= 0){ Creatinine_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Creatinine_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Creatinine_unit.options[Creatinine_unit.selectedIndex].value.split('|');",
"Creatinine = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (INR_param.value.indexOf(',') >= 0){ INR_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(INR_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"INR = param_value;",
"if (Cirrhosis_Etiology_radio[0].checked){ Cirrhosis_Etiology = 0; }",
"if (Cirrhosis_Etiology_radio[1].checked){ Cirrhosis_Etiology = 1; }",
"dp = 0;",
"MELD_Score =  Math.round(10 * ((1.12 * ln(INR)) + (0.378 * ln(Bilirubin)) + (0.957 * ln(Creatinine)) + (0.643 * Cirrhosis_Etiology)));",
"",
"if (doCalc) MELD_Score_param.value = fixDP(MELD_Score, dp);",
"",
"",
"",
"ASAPlus = 0; ASAMort = 0; AgePlus = 0;",
"if (ASA_Class == 4){ ASAPlus = 5; ASAMort = 1; }",
"if(Age > 70) AgePlus = 3;",
"if (MELD_Score < 8){ Adjusted_MELD_Score = 8; } else { Adjusted_MELD_Score = MELD_Score; }",
"Adjusted_MELD_Score =  Adjusted_MELD_Score + AgePlus + ASAPlus;",
"",
"ExpDays =  eTo((0.02382 * (Age - 60)) + (0.88884 * ASAMort) + (0.11798 * (MELD_Score - 8)));",
"",
"Mortality_7_Days =  100 * (1 - power(0.98370, ExpDays));",
"",
"if (doCalc) Mortality_7_Days_param.value = fixDP(Mortality_7_Days, dp);",
"",
"",
"",
"Mortality_30_Days =  100 * (1 - power(0.93479, ExpDays));",
"",
"if (doCalc) Mortality_30_Days_param.value = fixDP(Mortality_30_Days, dp);",
"",
"",
"",
"Mortality_90_Days =  100 * (1 - power(0.89681, ExpDays));",
"",
"if (doCalc) Mortality_90_Days_param.value = fixDP(Mortality_90_Days, dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.MELD9_form){",
"",
"if (Age_param.value && Age < 12) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 12 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 120) {",
"Age_param.value = \"\";",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 120 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Bilirubin_param.value && Bilirubin < 0.1) {",
"Bilirubin = 0;",
"Bilirubin_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Bilirubin is 0.1 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Bilirubin_param.value && Bilirubin > 35) {",
"Bilirubin_param.value = \"\";",
"clrResults();",
"Bilirubin = 0;",
"doCalc = false;",
"alert(\"The maximum value for Bilirubin is 35 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Creatinine_param.value && Creatinine < 0.1) {",
"Creatinine = 0;",
"Creatinine_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Creatinine is 0.1 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Creatinine_param.value && Creatinine > 4) {",
"Creatinine_param.value = \"\";",
"clrResults();",
"Creatinine = 0;",
"doCalc = false;",
"alert(\"The maximum value for Creatinine is 4 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (INR_param.value && INR < 0.5) {",
"INR = 0;",
"INR_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for INR is 0.5 .\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (INR_param.value && INR > 10) {",
"INR_param.value = \"\";",
"clrResults();",
"INR = 0;",
"doCalc = false;",
"alert(\"The maximum value for INR is 10 .\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.MELD9_form){",
"",
"MELD_Score_param.value = '';",
"Mortality_7_Days_param.value = '';",
"Mortality_30_Days_param.value = '';",
"Mortality_90_Days_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"/* ]]> */"].join("\n");
var outline_f31_26_32162=null;
var title_f31_26_32163="Cefazolin: Patient drug information";
var content_f31_26_32163=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cefazolin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     see \"Cefazolin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/36/9797?source=see_link\">",
"     see \"Cefazolin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16329907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cefazolin For Injection;",
"     </li>",
"     <li>",
"      Cefazolin For Injection, USP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701736",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cefazolin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store as you have been told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11314 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-0E3ADE63EF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_26_32163=[""].join("\n");
var outline_f31_26_32163=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16329907\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015473\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015472\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015477\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015478\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015480\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015475\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015476\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015481\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015482\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=related_link\">",
"      Cefazolin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/36/9797?source=related_link\">",
"      Cefazolin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_26_32164="H pylori immunostain";
var content_f31_26_32164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Helicobacter pylori in gastric crypts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 600x magnification of a Helicobacter pylori immunostain with the luminal organisms shown in brown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Pamela J Jensen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_26_32164=[""].join("\n");
var outline_f31_26_32164=null;
var title_f31_26_32165="Ultrasound of parathyroid adenoma";
var content_f31_26_32165=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound of parathyroid adenoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 562px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse (A) and sagittal (B) ultrasound images of the left neck demonstrate a well defined nodule (arrow) that is isoechoic to the adjacent thyroid gland (T).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Pierre J Sasson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_26_32165=[""].join("\n");
var outline_f31_26_32165=null;
var title_f31_26_32166="HSV folliculitis";
var content_f31_26_32166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Herpes simplex virus (HSV) folliculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 356px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_26_32166=[""].join("\n");
var outline_f31_26_32166=null;
var title_f31_26_32167="Cystic fibrosis: Investigational therapies";
var content_f31_26_32167=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cystic fibrosis: Investigational therapies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/26/32167/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/26/32167/contributors\">",
"     Richard H Simon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/26/32167/contributors\">",
"     Thomas H Sisson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/26/32167/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/26/32167/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/26/32167/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/26/32167/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/26/32167/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3393751\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The survival rate of patients with cystic fibrosis (CF) continues to improve. In 1985, the median predicted survival was 25 years of age, while in 2008 it had increased to 37 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/1\">",
"     1",
"    </a>",
"    ]. In an effort to further prolong the life span of patients with CF, many potential new treatments are being actively investigated. This topic review will summarize some of the experimental therapies whose development has advanced to clinical trials in patients with CF. They include approaches to replace the abnormal cystic fibrosis transmembrane conductance regulator (CFTR) gene, reverse the consequences of the genetic defect on protein function, correct the ion flux abnormalities in the CF airway, promote clearance of respiratory secretions, and reduce or eliminate bacterial infection. Those trials that are listed in the",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     NIH Clinical Trials Registry",
"    </a>",
"    will be designated by including their NCT identifier codes, and further details about each trial are available through links to that database.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3393757\">",
"    <span class=\"h1\">",
"     GENE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prospects for developing gene therapy to treat CF improved markedly in 1989 with the sequencing and cloning of the CFTR gene. Because mutations in CFTR account for virtually all cases of CF, correcting abnormalities in this single gene should theoretically cure the disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39095?source=see_link\">",
"     \"Cystic fibrosis: Genetics and pathogenesis\"",
"    </a>",
"    .) Despite early progress in the gene therapy field, many significant obstacles continue to interfere with the development of this approach as a treatment for CF. To overcome these barriers, research in this field is focusing on developing vectors for the safe delivery of a normal CFTR gene to the airways of patients with CF.",
"   </p>",
"   <p>",
"    Currently, only one group, the",
"    <a class=\"external\" href=\"file://www.cfgenetherapy.org.uk/\">",
"     UK Cystic Fibrosis Gene Therapy Consortium",
"    </a>",
"    , is actively involved in clinical trials of patients with CF. This group has been employing liposomes to transfer plasmids containing a functional CFTR cDNA to the airway epithelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/2\">",
"     2",
"    </a>",
"    ]. Results from their single-dose pilot study involving a few human subjects demonstrated the successful delivery of the CFTR gene to the airway with the resultant expression of a normal CFTR protein. Unfortunately, the treatment also caused mild flu-like symptoms and a transient decrease in measures of pulmonary function. Details of this initiative are available at the",
"    <a class=\"external\" href=\"file://www.cfgenetherapy.org.uk/clinical/singledose.html\">",
"     Consortium&rsquo;s website",
"    </a>",
"    . A planned multi-dose trial has been delayed until methods to circumvent these problems are found.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3393763\">",
"    <span class=\"h1\">",
"     REVERSING THE CONSEQUENCES OF CFTR MUTATIONS ON PROTEIN FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 1700 different CFTR mutations have been identified in the CFTR gene. They have been grouped into different classes based upon their effects on CFTR structure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39095?source=see_link&amp;anchor=H4#H4\">",
"     \"Cystic fibrosis: Genetics and pathogenesis\", section on 'Genetic changes in CFTR'",
"    </a>",
"    .). Class-specific therapies are being developed and some have advanced to clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3393769\">",
"    <span class=\"h2\">",
"     Class I mutations: Defective protein production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsense mutations in CFTR introduce premature stop codons so that the messenger RNA is truncated and no mature CFTR protein is produced. This type of mutation accounts for 2 to 5 percent of cases of CF worldwide, but is much more frequent in some populations (eg, Ashkenazi Jews). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39095?source=see_link&amp;anchor=H5#H5\">",
"     \"Cystic fibrosis: Genetics and pathogenesis\", section on 'Class I mutations: Defective protein production'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential treatments for patients with this type of mutation include drugs that allow the ribosome to read through premature stop codons during translation, while still honoring true stop codons. An orally available drug, ataluren (formerly known as PTC124), partially corrects the electrophysiological abnormalities that are characteristic of the nasal epithelium in CF patients having at least one nonsense mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/3\">",
"     3",
"    </a>",
"    ]. Similar improvements in nasal epithelial chloride transport measurements were seen in a trial of ataluren in children, and in some children the effects persisted for as much as 14 days after cessation of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/4\">",
"     4",
"    </a>",
"    ]. Overall, 47 percent of the subjects responded with at least a -5mV total chloride transport improvement in response to ataluren. Furthermore, there were no apparent safety issues with this drug in the pediatric population. Phase 3 trials of ataluren are currently underway (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00803205?term=NCT00803205&amp;rank=1\">",
"     NCT00803205",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3393775\">",
"    <span class=\"h2\">",
"     Class II mutations: Defective protein processing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations causing defective protein processing are the most common cause of CF worldwide. These include the delta F508 (F508del) mutation, which causes improper folding of the CFTR protein during its synthesis. The incorrectly folded protein is then recognized by the cell as defective and the majority of it is degraded in the proteosome. As a result, very little mature F508del CFTR protein is trafficked to its targeted location on the apical surface of cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39095?source=see_link&amp;anchor=H6#H6\">",
"     \"Cystic fibrosis: Genetics and pathogenesis\", section on 'Class II mutations: Defective protein processing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the high frequency of F508del mutations in CF, a concerted effort has been put forth to identify drugs that can assist with F508del folding and permit its transfer to the apical surface of expressing cells. High-throughput screening of large combinatorial chemical libraries identified candidate molecules (called &ldquo;correctors&rdquo;) that allow F508del CFTR to be transported to the apical surface. One such drug, VX-809, has reached clinical trials. In a phase 2a trial to test safety and tolerability (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/results?term=NCT00865904\">",
"     NCT00865904",
"    </a>",
"    ), adult patients with homozygous F508del mutations were randomized to receive one of four doses of VX-809 or placebo for 28 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/6\">",
"     6",
"    </a>",
"    ]. VX-809 treatment resulted in a small but statistically significant decrease in sweat chloride values in a dose-dependent manner. This small trial did not detect improvements in pulmonary function or nasal potential difference, and in the subset of patients that provided rectal biopsy tissue, no maturation of F508del-CFTR was observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3393781\">",
"    <span class=\"h2\">",
"     Class III mutations: Defective regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A group of mutations including G551D interferes with activation of the CFTR chloride channel, and thereby inhibits normal chloride flux. High-throughput screening of combinatorial libraries has identified candidate molecules (called &ldquo;potentiators&rdquo;) that improve activation of these abnormal channels and enhance chloride flux in cells expressing at least some of these class III mutations. The G551D mutation is present in about 5 percent of patients with cystic fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/7\">",
"     7",
"    </a>",
"    ], making it one of the more common disease-causing mutations but still much less common than F508del. &nbsp;",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/43/8885?source=see_link\">",
"     Ivacaftor",
"    </a>",
"    (VX-770, Vertex pharmaceuticals) is a potentiator drug that has substantial benefits in patients with at least one G551D allele, and is recommended for treatment of patients with this mutation (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link&amp;anchor=H20592751#H20592751\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'CFTR modulators'",
"    </a>",
"    ). Future studies are planned to determine if ivacaftor is efficacious in patients who carry class III mutations other than G551D.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3393787\">",
"    <span class=\"h2\">",
"     Combination strategy for the F508del mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro experiments have shown that, in addition to being misfolded, F508del CFTR does not activate normally even when the protein is induced to traffic correctly to the cell surface. Thus, the F508del mutation manifests both Class II and Class III defects. Therefore, it is possible that both functional defects could be addressed by combined treatment with VX-809 and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/43/8885?source=see_link\">",
"     ivacaftor",
"    </a>",
"    (VX-770).",
"   </p>",
"   <p>",
"    A phase 2 clinical trial is in progress to assess the efficacy of combined treatment with VX-809 and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/43/8885?source=see_link\">",
"     ivacaftor",
"    </a>",
"    (VX-770) in adult patients with homozygous or heterozygous F508del mutations (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT01225211?term=ivacaftor&amp;rank=3\">",
"     NCT01225211",
"    </a>",
"    ). According to a",
"    <a class=\"external\" href=\"file://investors.vrtx.com/releasedetail.cfm?ReleaseID=677520\">",
"     press release",
"    </a>",
"    , interim analysis demonstrated a significant but modest improvement in lung function (mean absolute improvement in percent predicted FEV1 of 8.5 percent, p = 0.002) among homozygous patients treated with the drug combination for 56 days, as compared to those given placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/8\">",
"     8",
"    </a>",
"    ]. Among patients in the treatment arm, 35 percent",
"    <span class=\"nowrap\">",
"     (13/37)",
"    </span>",
"    achieved an absolute improvement in FEV1 of 5 percent or more, and 19 percent",
"    <span class=\"nowrap\">",
"     (7/37)",
"    </span>",
"    achieved an absolute improvement in FEV1 of 10 percent or more, as compared to no patients in the placebo arm",
"    <span class=\"nowrap\">",
"     (0/11).",
"    </span>",
"    This preliminary analysis focused only on patients with homozygous mutations in the treatment arm, although both heterozygotes and homozygotes were included in the placebo arm. The evaluation of combination treatment on lung function in F508del heterozygote patients is ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3393793\">",
"    <span class=\"h1\">",
"     CORRECTING ION FLUX ABNORMALITIES BY NON-CFTR TARGETED APPROACHES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3393800\">",
"    <span class=\"h2\">",
"     Activating alternative chloride channels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway epithelial cells possess chloride channels other than CFTR, such as the calcium-activated chloride channel, and activation of such channels might compensate for the loss of CFTR activity. Several agents designed to accomplish this are undergoing clinical trials.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Denufosol &ndash; Activation of a calcium-activated chloride channel can promote chloride secretion in airway cells lacking CFTR function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/9\">",
"       9",
"      </a>",
"      ]. One approach to activate this channel is via the stimulation of surface P2Y2 purinergic receptors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/10\">",
"       10",
"      </a>",
"      ]. Denufosol, a P2Y2 agonist, has been studied in a phase 3 trial using 352 subjects with mild CF lung disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/11\">",
"       11",
"      </a>",
"      ]. This treatment appeared to be promising, because a 24 week double blind trial of study drug by inhalation three times daily produced a 48 cc improvement in FEV1 (p&lt;0.047) versus a 3 cc improvement in the control group. However, preliminary results from a second phase 3 double blind trial of 466 patients failed to show a statistically significant effect on lung function (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT00625612?term=NCT00625612&amp;rank=1\">",
"       NCT00625612",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lancovutide &ndash; Lancovutide (Moli1901) increases calcium-activated chloride channel activity by increasing the intracellular calcium level. This agent has undergone a phase 2 clinical trial in patients with CF, in which inhaled lancovutide induced an improvement in pulmonary function tests (",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00671736\">",
"       NCT00671726",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/13\">",
"       13",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3393806\">",
"    <span class=\"h2\">",
"     Inhibiting excessive sodium absorption from airway lining fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absence of normal CFTR function causes excessive activity of the epithelial sodium channel, ENaC, which leads to dehydration of the apical epithelial cell surface. Because",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/58/17317?source=see_link\">",
"     amiloride",
"    </a>",
"    inhibits ENaC activity, this drug was tested in patients with CF. In a systematic review that included five randomized trials, treatment with amiloride had no benefit over placebo in pulmonary function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/14\">",
"     14",
"    </a>",
"    ]. Indeed, for the three trials longer than three months, there was a slight deterioration in forced vital capacity (FVC) as compared with placebo. The failure of amiloride to influence lung function in patients with cystic fibrosis may be related to its unfavorable airway pharmacokinetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/15\">",
"     15",
"    </a>",
"    ]. It is also conceivable that the strategic approach of ENaC inhibition will not result in the anticipated clinical benefits. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Other small molecular weight molecules that block ENaC activation or inhibit its activity are being tested in CF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      QAU145 &ndash; ENaC is activated via a proteolytic cleavage that can be accomplished by the enzyme prostatin, which is present in airway epithelium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/16\">",
"       16",
"      </a>",
"      ]. Aerosol delivery of QAU145, a small molecular inhibitor of prostatin, is being evaluated in subjects with CF (",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/results?term=NCT00506792\">",
"       NCT00506792",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      GS9411 &ndash; GS9411 is low molecular weight molecule with ENaC inhibiting properties. Clinical trials are in progress to evaluate the safety and efficacy of GS9411 delivered by aerosol to healthy volunteers",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/results?term=NCT00951522\">",
"       (NCT00951522",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3393812\">",
"    <span class=\"h1\">",
"     PROMOTING CLEARANCE OF RESPIRATORY SECRETIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3393819\">",
"    <span class=\"h2\">",
"     Delivering osmotically active agents to the airway surface",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhalation of a seven percent solution of sodium chloride increases mucociliary clearance, improves FEV1, and reduces the frequency of exacerbations of pulmonary disease in patients with CF. The primary mechanism for this effect is its osmotic activity that draws fluid onto the apical surface of the airway epithelium and thereby compensates for the increased sodium, chloride, and water absorption that occurs in the absence of proper CFTR function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link&amp;anchor=H6#H6\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Inhaled hypertonic saline'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional osmotically active agents are under study:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/60/43975?source=see_link\">",
"       Mannitol",
"      </a>",
"      &ndash; Treatment with mannitol by inhalation is associated with modest improvement in some clinical outcomes. This was shown in two similarly-designed phase 3 trials studying the efficacy and safety of inhaled dry powdered mannitol (",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00446680\">",
"       NCT00446680",
"      </a>",
"      and",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00630812\">",
"       NCT00630812",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. In each trial, more than 300 subjects were randomized to receive twice daily mannitol, 400 mg by inhalation, compared to a control group receiving a low (presumably subtherapeutic) dose of mannitol (40 mg). Subjects were not permitted to use hypertonic saline during the study. The primary endpoint for both trials was absolute change in FEV1 from baseline, averaged over the duration of the trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The first study met this endpoint, reporting a relative improvement in FEV1 of 92.9 mL in the treatment group compared to that of the control group (p &lt;0.001) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/17\">",
"       17",
"      </a>",
"      ]. Exacerbation rates were reduced (p = 0.045).",
"     </li>",
"     <li>",
"      The second trial just missed the endpoint, reporting a relative improvement in FEV1 of 54.1 mL in the treatment group compared to control (p = 0.059) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/18\">",
"       18",
"      </a>",
"      ]. Exacerbation rates were reduced, but did not reach statistical significance (p = 0.31). However, secondary endpoints and post-hoc analyses using other spirometry-based measures were statistically better in the treatment group. The improvement with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/60/43975?source=see_link\">",
"       mannitol",
"      </a>",
"      treatment was sustained during a 26-week study extension period.",
"      <br/>",
"      <br/>",
"      Mannitol was compared to DNase in a small, randomized, unblinded trial that used a crossover design with 12-week treatment blocks comparing mannitol alone, DNase alone, with both together [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/19\">",
"       19",
"      </a>",
"      ]. No statistically significant difference in FEV1 was noted between groups, but with only 28 subjects randomized, the power of the trial was likely too low to exclude clinically meaningful differences. Mannitol has not been directly compared to hypertonic saline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Xylitol &ndash; Xylitol is a low molecular weight sugar molecule that alters the fluid composition of the airway lining, which may improve native antibacterial activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. A phase 1-2 study is underway to test its safety in patients with CF (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/results?term=NCT00928135\">",
"       NCT00928135",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3393825\">",
"    <span class=\"h1\">",
"     ANTIBIOTICS AND ANTI-INFECTIVES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3393832\">",
"    <span class=\"h2\">",
"     Inhaled antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/39/22129?source=see_link\">",
"     Tobramycin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/25/1430?source=see_link\">",
"     aztreonam",
"    </a>",
"    have been approved by the Federal Food and Drug Administration for delivery by aerosol to patients with CF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/22/41322?source=see_link&amp;anchor=H16#H16\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\", section on 'Aerosolized antibiotics'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    The success of these antibiotics has induced a number of pharmaceutical companies to develop other inhaled antibiotics, some of which have entered clinical trials. Below is a list of agents that are currently being studied in patients with CF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/15/38128?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      by aerosol (",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/results?term=NCT00645788\">",
"       NCT00645788",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/36/6724?source=see_link\">",
"       Fosfomycin",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/39/22129?source=see_link\">",
"       tobramycin",
"      </a>",
"      combined as an aerosol (",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/results?term=NCT00794586\">",
"       NCT00794586",
"      </a>",
"      ). In a phase 2 trial, adults with CF and P. aeruginosa infection were first treated with a 28-day course of inhaled",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/25/1430?source=see_link\">",
"       aztreonam",
"      </a>",
"      , and experienced a mean improvement in FEV1 of 7 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/22\">",
"       22",
"      </a>",
"      ]. The patients were then randomized to treatment with inhaled",
"      <span class=\"nowrap\">",
"       fosfomycin/tobramycin",
"      </span>",
"      (FTI) or placebo. Those treated with FTI maintained the improvement in pulmonary function achieved after the course of aztreonam, whereas those treated with placebo experienced a decline in their pulmonary function towards their pre-aztreonam baseline.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/11/33968?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      by aerosol (",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00677365?term=NCT00677365&amp;rank=1\">",
"       NCT00677365",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Liposomal",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/43/12984?source=see_link\">",
"       amikacin",
"      </a>",
"      by aerosol (",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/results?term=NCT00777296\">",
"       NCT00777296",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/39/22129?source=see_link\">",
"       Tobramycin",
"      </a>",
"      administered by inhalation as a powder (",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/results?term=NCT00388505\">",
"       NCT00388505",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3393838\">",
"    <span class=\"h2\">",
"     Anti-pseudomonas antibody treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudomonas aeruginosa is an important target for treatment due to its high prevalence and adverse effects in patients with CF. Trials are underway to investigate treatment of the infection by intravenous infusion of an anti-pseudomonal recombinant human Fab&rsquo;-antibody fragment, KB001 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/23\">",
"     23",
"    </a>",
"    ] (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/results?term=NCT00638365\">",
"     NCT00638365",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3393844\">",
"    <span class=\"h1\">",
"     ANTI-INFLAMMATORY THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive inflammation contributes to the airway damage that occurs in CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/24\">",
"     24",
"    </a>",
"    ]. Treatments that suppress inflammation, such as oral glucocorticoids and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , reduce the rate of decline in lung function, but concern for side effects has limited their use. Additional approaches to reduce inflammatory responses are under investigation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SB-656933 &ndash; SB-656933 is an orally administered drug that attenuates the inflammatory response by antagonizing the chemokine receptor, CXCR2. SB-656933 is undergoing phase 2 trials in subjects with CF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/25\">",
"       25",
"      </a>",
"      ] (",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/results?term=NCT00903201\">",
"       NCT00903201",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      N-acetylcysteine and glutathione &ndash; Oxidants generated during inflammatory reactions may contribute to tissue injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/26\">",
"       26",
"      </a>",
"      ]. In CF, oxidant stress can be caused by free radicals generated by neutrophils and by altered redox states within damaged lung cells. N-acetylcysteine, a small sulfhydryl donor, may be able to reduce the burden of oxidants and assist in the repair of damaged tissue. A phase 2 study is underway in which N-acetylcysteine will be given orally to subjects with CF (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/results?term=NCT00809094\">",
"       NCT00809094",
"      </a>",
"      ). A phase 2 study in Germany is investigating inhaled glutathione (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/results?term=NCT00506688\">",
"       NCT00506688",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      &ndash; To determine if the anti-inflammatory properties of statins may be of benefit in CF, a phase 2 study of simvastatin is planned, using inflammatory markers and pulmonary function tests as outcome markers (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/results?term=NCT01092572\">",
"       NCT01092572",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      AZD9668 &ndash; Neutrophil-derived proteases are abundant in the airways of patients with CF. Neutrophil elastase is of particular interest because its proteolytic targets include many structural proteins within the lung as well as proteins involved in endogenous microbial defense such as antibodies. Inhaled alpha-1-antitrypsin (A1AT) has been administered to patients with CF in an attempt to block neutrophil elastase activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/27\">",
"       27",
"      </a>",
"      ]. In a study of 52 subjects, administration of A1AT by aerosol inhibited elastase activity in expectorated sputum but did not significantly change pulmonary function tests. As an alternative approach to block elastase, synthetic chemists have generated small molecular weight inhibitory molecules. One such example is AXD9668 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/28\">",
"       28",
"      </a>",
"      ], which is undergoing a phase 2 clinical trial in subjects with CF (",
"      <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/results?term=NCT00809094\">",
"       NCT00757848",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/9/38041?source=see_link\">",
"       Sildenafil",
"      </a>",
"      &ndash; Sildenafil is a 5-phosphodiesterase inhibitor with anti-inflammatory properties that suggest it may be beneficial in CF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32167/abstract/29\">",
"       29",
"      </a>",
"      ]. This has prompted the initiation of a phase 1-2 study in patients with CF (",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/results?term=NCT00659529\">",
"       NCT00659529",
"      </a>",
"      ). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/57/20371?source=see_link\">",
"       \"Patient information: Cystic fibrosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3393850\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substantial progress has been made in the treatment of patients with CF using strategies to address infection and excessive inflammation, which are the downstream effects of CFTR dysfunction. Some of the experimental treatments detailed in this topic review are designed to address the CFTR dysfunction that is the root cause of the disease. Strategic targets include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gene therapy &ndash; Research in this field is focusing on developing vectors for the safe delivery of the normal CFTR gene to compensate for the dysfunctional CFTR in patients with CF. (See",
"      <a class=\"local\" href=\"#H3393757\">",
"       'Gene therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drugs that overcome specific types of CFTR mutations include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with defective CFTR production caused by premature stop codons, drugs that allow the ribosome to read through the stop codons during translation but recognize true stop codons (See",
"      <a class=\"local\" href=\"#H3393769\">",
"       'Class I mutations: Defective protein production'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with misfolded CFTR caused by the delta F508 mutation, drugs that overcome the misfolding and allow it to be transferred to the apical surface of expressing cells. (See",
"      <a class=\"local\" href=\"#H3393775\">",
"       'Class II mutations: Defective protein processing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with defective activation of the chloride channel, drugs that improve activation of the channel and enhance chloride flux.",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/43/8885?source=see_link\">",
"       Ivacaftor",
"      </a>",
"      (VX-770) is a potentiator drug that has substantial benefits in patients with at least one G551D allele, and is now recommended for treatment of patients with this mutation. &nbsp;(See",
"      <a class=\"local\" href=\"#H3393781\">",
"       'Class III mutations: Defective regulation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link&amp;anchor=H20592751#H20592751\">",
"       \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'CFTR modulators'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other strategies to compensate for CFTR dysfunction include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Drugs that activate chloride channels other than the CFTR, such as the calcium-activated chloride channel. (See",
"      <a class=\"local\" href=\"#H3393800\">",
"       'Activating alternative chloride channels'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drugs that inhibit the activity of the epithelial sodium channel, thus preventing dehydration of the apical epithelial cell surface. (See",
"      <a class=\"local\" href=\"#H3393806\">",
"       'Inhibiting excessive sodium absorption from airway lining fluid'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Strategies to treat the downstream effects of CFTR dysfunction include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      New osmotic agents to promote clearance of respiratory secretions, including",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/60/43975?source=see_link\">",
"       mannitol",
"      </a>",
"      , and xylitol. (See",
"      <a class=\"local\" href=\"#H3393812\">",
"       'Promoting clearance of respiratory secretions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Delivery of a variety of antibiotics by inhalation, including",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/15/38128?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/11/33968?source=see_link\">",
"       levofloxacin",
"      </a>",
"      , and liposomal",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?12/43/12984?source=see_link\">",
"       amikacin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H3393832\">",
"       'Inhaled antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of Pseudomonas aeruginosa infection with a recombinant anti-pseudomonal antibody. (See",
"      <a class=\"local\" href=\"#H3393838\">",
"       'Anti-pseudomonas antibody treatment'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Drugs that reduce inflammation by antagonizing chemokine receptors, reducing oxidative damage, block proteases such as neutrophil elastase, or blocking 5-phosphodiesterase. (See",
"      <a class=\"local\" href=\"#H3393844\">",
"       'Anti-inflammatory therapy'",
"      </a>",
"      above.) &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     CFF patient registry report 2008:  www.cff.org/UploadedFiles/research/ClinicalResearch/2008-Patient-Registry-Report.pdf (Accessed on July 13, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/2\">",
"      Griesenbach U, Alton EW, UK Cystic Fibrosis Gene Therapy Consortium. Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv Drug Deliv Rev 2009; 61:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/3\">",
"      Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/4\">",
"      Sermet-Gaudelus I, Boeck KD, Casimir GJ, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 2010; 182:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/5\">",
"      Thomas PJ, Ko YH, Pedersen PL. Altered protein folding may be the molecular basis of most cases of cystic fibrosis. FEBS Lett 1992; 312:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/6\">",
"      Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012; 67:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/7\">",
"      Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365:1663.",
"     </a>",
"    </li>",
"    <li>",
"     Vertex Pharmaceuticals press release, May 29, 2012. Vertex Corrects and Provides Additional Data from Recent Interim Analysis of Phase 2 Combination Study of VX-809 and KALYDECO&trade; (ivacaftor) in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation. Available at: file://investors.vrtx.com/releasedetail.cfm?ReleaseID=677520 (Accessed on June 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/9\">",
"      Willumsen NJ, Boucher RC. Activation of an apical Cl- conductance by Ca2+ ionophores in cystic fibrosis airway epithelia. Am J Physiol 1989; 256:C226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/10\">",
"      Lazarowski ER, Boucher RC. Purinergic receptors in airway epithelia. Curr Opin Pharmacol 2009; 9:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/11\">",
"      Accurso FJ, Moss RB, Wilmott RW, et al. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am J Respir Crit Care Med 2011; 183:627.",
"     </a>",
"    </li>",
"    <li>",
"     Cystic Fibrosis Foundation press release about the TIGER 2 trial of denufosol, 1/3/2011. Available at: file://www.cff.org/aboutCFFoundation/NewsEvents/01-03-Inspire-Announces-Denufosol-Results.cfm (Accessed on May 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/13\">",
"      Grasemann H, Stehling F, Brunar H, et al. Inhalation of Moli1901 in patients with cystic fibrosis. Chest 2007; 131:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/14\">",
"      Burrows EF, Southern KW, Noone PG. Sodium channel blockers for cystic fibrosis. Cochrane Database Syst Rev 2012; 3:CD005087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/15\">",
"      Noone PG, Regnis JA, Liu X, et al. Airway deposition and clearance and systemic pharmacokinetics of amiloride following aerosolization with an ultrasonic nebulizer to normal airways. Chest 1997; 112:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/16\">",
"      Myerburg MM, McKenna EE, Luke CJ, et al. Prostasin expression is regulated by airway surface liquid volume and is increased in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2008; 294:L932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/17\">",
"      Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011; 38:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/18\">",
"      Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012; 185:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/19\">",
"      Minasian C, Wallis C, Metcalfe C, Bush A. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial. Thorax 2010; 65:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/20\">",
"      Zabner J, Seiler MP, Launspach JL, et al. The osmolyte xylitol reduces the salt concentration of airway surface liquid and may enhance bacterial killing. Proc Natl Acad Sci U S A 2000; 97:11614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/21\">",
"      Durairaj L, Launspach J, Watt JL, et al. Safety assessment of inhaled xylitol in subjects with cystic fibrosis. J Cyst Fibros 2007; 6:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/22\">",
"      Trapnell BC, McColley SA, Kissner DG, et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med 2012; 185:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/23\">",
"      Milla CE, Accurso FJ, Chmiel J, et al. Modulating Pseudomonas aeruginosa chronic inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis. Am J Respir Crit Care Med 2010; 181:A1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/24\">",
"      Nichols DP, Konstan MW, Chmiel JF. Anti-inflammatory therapies for cystic fibrosis-related lung disease. Clin Rev Allergy Immunol 2008; 35:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/25\">",
"      Nicholson GC, Tennant RC, Carpenter DC, et al. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist. Pulm Pharmacol Ther 2007; 20:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/26\">",
"      Rahman I, MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J 2000; 16:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/27\">",
"      Griese M, Latzin P, Kappler M, et al. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007; 29:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/28\">",
"      Ohmoto K, Yamamoto T, Okuma M, et al. Development of orally active nonpeptidic inhibitors of human neutrophil elastase. J Med Chem 2001; 44:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32167/abstract/29\">",
"      Poschet JF, Timmins GS, Taylor-Cousar JL, et al. Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2007; 293:L712.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13510 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-42B5A9483A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_26_32167=[""].join("\n");
var outline_f31_26_32167=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3393850\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3393751\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3393757\">",
"      GENE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3393763\">",
"      REVERSING THE CONSEQUENCES OF CFTR MUTATIONS ON PROTEIN FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3393769\">",
"      Class I mutations: Defective protein production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3393775\">",
"      Class II mutations: Defective protein processing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3393781\">",
"      Class III mutations: Defective regulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3393787\">",
"      Combination strategy for the F508del mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3393793\">",
"      CORRECTING ION FLUX ABNORMALITIES BY NON-CFTR TARGETED APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3393800\">",
"      Activating alternative chloride channels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3393806\">",
"      Inhibiting excessive sodium absorption from airway lining fluid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3393812\">",
"      PROMOTING CLEARANCE OF RESPIRATORY SECRETIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3393819\">",
"      Delivering osmotically active agents to the airway surface",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3393825\">",
"      ANTIBIOTICS AND ANTI-INFECTIVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3393832\">",
"      Inhaled antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3393838\">",
"      Anti-pseudomonas antibody treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3393844\">",
"      ANTI-INFLAMMATORY THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3393850\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/22/41322?source=related_link\">",
"      Cystic fibrosis: Antibiotic therapy for lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39095?source=related_link\">",
"      Cystic fibrosis: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/57/20371?source=related_link\">",
"      Patient information: Cystic fibrosis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_26_32168="CT of liver abscess in acute cholecystitis";
var content_f31_26_32168=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Liver abscess complicating acute cholecystitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 501px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomographic (CT) scan in a patient with acute cholecystitis complicated by perforation and liver abscess formation.",
"    <br/>",
"    (A) The CT scan shows a gall stone (yellow arrow) surrounded by an irregular accumulation of fluid with a hyperemic rim (yellow arrowhead).",
"    <br/>",
"    (B) The fluid can be seen extending from the gallbladder fossa into the liver parenchyma (yellow arrowhead).",
"    <br/>",
"    (C) Percutaneous aspiration of pus confirmed the presence of an abscess and a drain was placed (yellow arrow). Following drainage of the abscess, a small amount of contrast was injected into the decompressed cavity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_26_32168=[""].join("\n");
var outline_f31_26_32168=null;
var title_f31_26_32169="Use of methotrexate in the treatment of rheumatoid arthritis";
var content_f31_26_32169=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of methotrexate in the treatment of rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/26/32169/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/26/32169/contributors\">",
"     Joel M Kremer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/26/32169/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/26/32169/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/26/32169/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/26/32169/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/26/32169/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    (MTX) is a designer compound that was first used for the treatment of rheumatoid arthritis (RA) and psoriasis in 1951 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/1\">",
"     1",
"    </a>",
"    ]. It emerged at the same time as glucocorticoids, however, and received little attention in the therapy of rheumatic diseases until retrospective reports appeared in the early 1980s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Short-term placebo controlled prospective studies in the mid-1980s demonstrated its potent efficacy and superiority to placebo in patients with chronic severe RA, and long-term open prospective studies then showed that the response was sustained and that toxicity was manageable (see below). These insights have led to the metamorphosis of MTX into its present status as the dominant slow-acting drug to treat patients with RA.",
"   </p>",
"   <p>",
"    The pharmacology of MTX and its use in the treatment of RA will be reviewed here. MTX has also been used effectively in a variety of other mostly rheumatic diseases including ankylosing spondylitis, Felty's syndrome, inclusion body myositis, reactive arthritis, and granulomatosis with polyangiitis (Wegener&rsquo;s). These disorders, as well as the major side effects of MTX, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32134?source=see_link\">",
"     \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;MTX can be given via oral, intramuscular, and subcutaneous routes. Oral MTX is variably absorbed in the dose range used to treat RA. As an example, a 7.5 mg weekly dose is absorbed better than a 15 to 20 mg dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/4\">",
"     4",
"    </a>",
"    ]. Bioavailability (f) is defined as the ratio of oral drug absorption divided by intravenous drug absorption. Since f may drop off by a mean of 13.5 percent as the dose of MTX is increased from a starting dose of 7.5 mg to the typical maintenance weekly doses employed in RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/4\">",
"     4",
"    </a>",
"    ], a patient may do better clinically when switched from oral (PO) to intramuscular (IM) or subcutaneous (SC) administration of the same dose of the drug. At a 17.5 to 20 mg weekly dose of MTX, for example, a 13.5 percent difference in f between the PO and IM routes of administration is equivalent to one full 2.5 mg MTX tablet. As the variation in the confidence intervals for the drop-off in f extends to 27 percent, selected patients may have an even greater difference in f between parenteral and oral dosing. Thus, patients may appear to respond better to parenteral therapy, when the actual explanation is that more drug is reaching the circulation.",
"   </p>",
"   <p>",
"    At higher doses, decreased bioavailability may be even more pronounced. This was illustrated in a pharmacokinetic analysis of 15 patients taking more than 25",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    of MTX (mean of 30",
"    <span class=\"nowrap\">",
"     mg/week);",
"    </span>",
"    the ratio of oral to subcutaneous absorption was decreased by approximately one-third [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MTX is primarily cleared via the kidneys, with 80 to 90 percent being excreted remaining unchanged in the urine. Thus, any impairment of glomerular filtration rate will result in sustained serum levels of the drug that may induce bone marrow or other toxicities. Nonsteroidal antiinflammatory drugs (NSAIDs) may decrease the renal excretion of MTX; however, a systematic review of randomized trials and large studies involving patients with RA found that NSAIDs could be safely given together with MTX, assuming that appropriate monitoring for drug toxicity is performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/6\">",
"     6",
"    </a>",
"    ]. The use of antiinflammatory doses of salicylates with MTX should be avoided, although lower doses are easily tolerated and should not be a problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Food does not affect MTX absorption to a significant degree [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/8\">",
"     8",
"    </a>",
"    ]. It may, therefore, be given with a meal or in the fasting state. In addition, MTX has minimal interaction with other drugs as only 50 percent is protein bound. However, there is the risk of increased toxicity when combined with other folate depleting drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    . MTX appears to be well-tolerated in patients taking trimethoprim-sulfamethoxazole prophylaxis (usually as one double-strength tablet three times weekly, such as on a Monday-Wednesday-Friday regimen), but this combination should be avoided when it is used in a twice-daily regimen for treatment of an active infection. Significant bone marrow and other toxicities have been observed with use of a daily sulfa antibiotic regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;MTX is a structural analogue of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    that can competitively inhibit the binding of dihydrofolic acid (FH2) to the enzyme dihydrofolate reductase (DHFR). DHFR is responsible for reducing FH2 to folinic acid (FH4), the active intracellular metabolite. Thus, MTX decreases the amount of intracellular FH4 available and affects the metabolic pathways within the cell that are FH4 dependent. These pathways include purine and pyrimidine metabolism, as well as amino acid and polyamine synthesis.",
"   </p>",
"   <p>",
"    MTX is a prodrug that becomes active only when polyglutamated within cells. The process of polyglutamation is slow and takes as long as 27.5 weeks to reach steady state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/9\">",
"     9",
"    </a>",
"    ]. This delay in steady-state polyglutamation explains the time to achievement of the plateau effect of clinical response previously described with MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite an understanding of the cellular action of MTX, the mechanism by which it improves the signs and symptoms of RA is not certain. One possibility is enhanced extracellular concentrations of adenosine, an autocoid with robust antiinflammatory activity, due to the extracellular dephosphorylation of adenine nucleotides via ecto-5'-nucleotidase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Supporting evidence of a role for adenosine includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The demonstration in animals that the nonspecific adenosine receptor antagonists,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      and caffeine, reduce the beneficial effects of MTX [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/13\">",
"       13",
"      </a>",
"      ]. There is no evidence of an antagonistic effect of caffeine or theophylline in humans treated with MTX, although the possibility of an interaction is intriguing and deserves study.",
"     </li>",
"     <li>",
"      Rodents that lack adenosine receptors do not have the same antiinflammatory effect from MTX as animals with these adenosine receptors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The observation of an association between certain allelic variants of enzymes involved in the metabolism of adenosine and clinical response of patients with early RA to MTX therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other mechanisms may include the inhibition of methylation reactions vital for cellular activities and replication, clonal deletion via apoptosis of activated peripheral T cells, decreased production of proinflammatory cytokines by activated T cells, suppression of IL-1 beta production by mononuclear cells, repression of the clonal growth of peripheral and synovial T and B cells, increased production of IL-10, and suppression of intracellular adhesion by activated T cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/16-21\">",
"     16-21",
"    </a>",
"    ]. The question of how the drug works is made even more difficult by the fact that MTX may also bind directly to other folate-dependent enzymes, including those which are integral to purine biosynthesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     USE IN PATIENTS WITH RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;MTX is commonly used for the treatment of patients with RA. Use of this agent may have a beneficial effect on survival although the support for this effect is limited to one large cohort study at a single clinical center. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Possible survival benefit'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Healing of erosive disease has been observed with MTX, but the magnitude of the response is inferior to that observed with TNF inhibition. There is substantial evidence of clinical benefit, which is discussed below. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Efficacy for arthritis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Efficacy for arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The short-term efficacy of MTX in the treatment of RA was initially demonstrated in a few small, randomized, placebo-controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The longer-term efficacy was subsequently evaluated in a number of observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/24-29\">",
"     24-29",
"    </a>",
"    ]. The following illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective multicenter study evaluated the effectiveness of MTX over a five-year period in 123 patients with RA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/25\">",
"       25",
"      </a>",
"      ]. When compared with the assessment at study entry, MTX was associated with significant improvement in all clinical disease variables (such as joint",
"      <span class=\"nowrap\">",
"       pain/tenderness",
"      </span>",
"      and joint swelling index), measures of functional status, and the erythrocyte sedimentation rate.",
"     </li>",
"     <li>",
"      An 84-month prospective study of 26 patients demonstrated that the benefit continued beyond the short-term; significant improvement in joint symptoms in this cohort was still present after 36 months of therapy with weekly MTX [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/24\">",
"       24",
"      </a>",
"      ]. Of the 12 patients remaining in the study at the 84 month visit, there were persistent reductions in the number of painful joints, the number of swollen joints, joint pain index, joint swelling index, and physician and patient global assessments. A significant reduction in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose was also achieved in the 14 patients taking prednisone at study entry.",
"      <br/>",
"      <br/>",
"      Ten patients withdrew from the study between 0 and 36 months, and four patients between 36 and 84 months. Drug toxicity required discontinuation in 11.5 percent.",
"     </li>",
"     <li>",
"      In a series of 24 patients with new onset RA (11 and 13 patients with and without radiographic erosions, respectively), the use of MTX as the first disease modifying antirheumatic drug halted disease progression in approximately 50 percent of patients, particularly among those without baseline erosions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not all studies have found consistent long-term radiographic benefits with MTX. In one study, 271 patients with RA in whom another disease modifying antirheumatic drug (DMARD) was ineffective were treated with MTX and followed for periods of up to 108 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/30\">",
"     30",
"    </a>",
"    ]. Although improvement was observed in the affected joint count and the erythrocyte sedimentation rate, the assessment of joint radiographs via the Larsen score revealed progressive disease despite continued therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Possible survival benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cohort study of 1240 patients with RA at one clinical center in North America addressed the question of a possible survival benefit among those treated with MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/31\">",
"     31",
"    </a>",
"    ]. During follow-up, 191 patients died. MTX was prescribed for 588 patients; treatment decisions were not made in a randomized fashion. The group that received MTX had poorer prognostic indicators and more frequent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    use than the MTX-naive group (37 versus 22 percent, respectively). Approximately 70 percent of both groups were women, and the average age was 57 years.",
"   </p>",
"   <p>",
"    After adjustment for possible confounding factors including age, gender, marital status, disease duration, body mass index, disability score, blood pressure, presence of absence of diabetes, and use of cholesterol lowering drugs, the hazard ratio for all cause mortality among MTX treated patients was 0.4 (95% CI 0.2-0.8).",
"   </p>",
"   <p>",
"    When deaths were divided into those due to cardiovascular disease and other causes, the hazard ratios were 0.3 and 0.6, respectively. The reduction in cardiovascular risk was statistically significant, while that of non-cardiovascular mortality was not. The patients in this study were treated beginning in the 1980s and 1990s, prior to the general availability of anticytokine therapy. Use of traditional disease modifying antirheumatic drugs (DMARDs) other than MTX did not appear to have a similar survival advantage (hazard ratio 1.0).",
"   </p>",
"   <p>",
"    Further investigation of the effect of MTX treatment upon survival in patients with RA is needed, but the results of this large cohort study provide additional support for the use of MTX in treating patients with RA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of patient selection for a slow acting drug, such as MTX, is always difficult and is highly dependent upon the dialogue between the patient and a clinician experienced with the many complexities of the drug and the RA disease process. There is no right or wrong approach; a level of comfort on the part of all participants ultimately determines drug choice. MTX should NOT be used in women who are contemplating becoming pregnant or are pregnant. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    MTX was initially studied in RA patients who failed prior DMARDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/23-27\">",
"     23-27",
"    </a>",
"    ]. However, an argument can be made for using MTX in all patients requiring therapy beyond nonsteroidal antiinflammatory drugs (NSAIDs) based upon the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall effectiveness of MTX in the treatment of RA",
"     </li>",
"     <li>",
"      The demonstration that it is best to treat early in order to avoid radiographic destruction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The finding that hepatic toxicity associated with MTX can be avoided by monitoring blood tests at regular intervals (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32134?source=see_link\">",
"       \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The increased mortality associated with RA (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/11/184?source=see_link&amp;anchor=H12#H12\">",
"       \"Disease outcome and functional capacity in rheumatoid arthritis\", section on 'Mortality'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, some clinicians point to the disquieting reports of lymphoma while on MTX therapy and the pulmonary toxicity associated with this drug and would rather not trade a \"known\" problem (eg, RA) for an \"unknown\" one. Despite such concerns, consensus treatment recommendations developed by the American College of Rheumatology and by the European League against Rheumatism advocate treating most patients with moderate or severe disease initially with MTX, unless there is a contraindication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Until a perfect drug for RA is designed, practitioners will always wrestle with efficacy-toxicity issues. However, considering the overall weight of evidence, it is our practice to use MTX more often than not in patients who do not respond to NSAID therapy. In most patients, particularly those with moderate to severe disease, MTX may be initiated at the same time as NSAID therapy.",
"   </p>",
"   <p>",
"    The effect of MTX in the dose range used to treat RA patients on the effectiveness of immunizations is unknown. Thus, patients with RA who are about to be treated with MTX should, if not previously given, be immunized with DPT, killed polio vaccine, pneumococcal vaccine, influenza, and hepatitis B, but not MMR, oral (live) polio vaccine, or yellow fever. Furthermore, nonimmunized patients should avoid contact with household contacts who are receiving live polio vaccine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Alcohol use and MTX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drinking alcoholic beverages while using low dose MTX is discouraged because of the risk of hepatotoxicity. Abstinence may be the best approach, but minimal intermittent alcohol intake may be tolerated. Patients who drink alcoholic beverages regularly and are unwilling to stop or to agree to only imbibe occasionally should be treated cautiously and followed for abnormalities of transaminase enzymes or serum albumin concentrations at six to eight week intervals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dosing of MTX",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose at which MTX was initiated for the treatment of RA in all of the early randomized trials and which was used historically in clinical practice was usually 7.5 mg per week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/23,25,26\">",
"     23,25,26",
"    </a>",
"    ]. It has become common with greater experience with MTX to use a higher starting dose, and some rheumatologists begin patients with normal renal function at a dose of as much as 12.5 or 15 mg weekly.",
"   </p>",
"   <p>",
"    Patients who start with a higher weekly dose will achieve steady state concentrations of MTX polyglutamates more quickly and, thus, achieve better disease control more rapidly than patients who are treated with more gradual incremental increases of their weekly dose. However, patients starting at a higher weekly dose are more likely to experience an initial toxicity such as stomatitis, nausea, gastrointestinal intolerance, or fatigue.",
"   </p>",
"   <p>",
"    There is no universally accepted method to determine which of several folate enzymes might predict toxicity to MTX prior to initial dosing, although several publications have pointed to an association of methylene tetrahydrofolate reductase (MTHFR) polymorphisms with toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/36\">",
"     36",
"    </a>",
"    ]. MTHFR regenerates reduced folate species intracellularly; the MTX effect on this enzyme system is associated with increased cellular toxicity and the potential for hyperhomocysteinemia.",
"   </p>",
"   <p>",
"    Although low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is not nephrotoxic, excretion is almost exclusively via the kidneys. Thus, it is prudent to monitor renal function and to reduce the dose, or discontinue the drug, if renal insufficiency develops.",
"   </p>",
"   <p>",
"    MTX use in RA is contraindicated if the estimated glomerular filtration rate (eGFR) is less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/37\">",
"     37",
"    </a>",
"    ]. Among patients with an eGFR of 30 to 59",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    a lower initial dose is warranted, and a more gradual dose increase, close monitoring, and a lower maximum weekly dose should be considered. There are no data to support a particular dose adjustment regimen, and caution is warranted when starting MTX in patients with moderate compromise in renal function. In such patients, we usually do not administer doses greater than 7.5 to 10 mg once weekly. The maximum dose used depends upon the patient&rsquo;s clinical response and their age, size, comorbidities, and degree of disease activity. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Dose titration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The formulas used to calculate the eGFR (MDRD (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/61/10194?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) and Cockcroft-Gault (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?29/57/30609?source=see_link\">",
"     calculator 2",
"    </a>",
"    )) contain the serum creatinine, which must be stable, and factors that affect muscle mass (lean body weight, age, gender, and race) and, therefore, affect the serum creatinine independent of GFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H20659769#H20659769\">",
"     \"Assessment of kidney function\", section on 'Estimation equations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Dose titration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal schedule for dose escalation is uncertain. We suggest initiating therapy at a dose between 7.5 and 15 mg once weekly for most patients, depending upon the degree of disease activity, size, and age of the patient, the presence of comorbidities, and renal function. As examples, we would treat a 70-year-old patient weighing 55 kg with moderately active disease with an initial dose of 7.5 mg once weekly, while an otherwise healthy 30-year-old patient weighing 80 kg with highly active disease would be started on 15 mg once weekly.",
"   </p>",
"   <p>",
"    The MTX dose is increased as tolerated and as needed to control symptoms and signs of arthritis. Our usual approach is to increase the dose after four weeks at a rate of 2.5 mg (one",
"    <span class=\"nowrap\">",
"     tablet)/week",
"    </span>",
"    as indicated by disease activity and as tolerated. In patients with continued high disease activity, we may increase by up to 5",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    if few comorbidities are present and if the increase in the dose continues to be well-tolerated. The maximum dose is 25",
"    <span class=\"nowrap\">",
"     mg/week.",
"    </span>",
"   </p>",
"   <p>",
"    Alternative schedules include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with severely active disease, some rheumatologists increase the oral MTX dose after the first four weeks by 5 mg weekly to a maximum dose of 25",
"      <span class=\"nowrap\">",
"       mg/week.",
"      </span>",
"     </li>",
"     <li>",
"      Some advisory groups advocate a starting dose of between 10 to 15",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      and increase the dose by 5 mg every two to four weeks, depending upon the clinical response and tolerability, up to a maximum dose of 20 to 30",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients in whom doses of at least 15 mg once weekly are ineffective or poorly tolerated, a trial of subcutaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    administration is an alternative to switching to another DMARD or to adding a TNF inhibitor. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Parenteral therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An alternative approach to switching to parenteral MTX is splitting the oral dose, giving it every 12 hours on the same day each week. In this manner, a dose of oral MTX which would have decreased bioavailability could be split into two lesser doses, each with improved bioavailability. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pharmacology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients should be monitored for efficacy and side effects of therapy at four to eight week intervals, and it is advisable to see patients every four weeks initially. Efficacy should be monitored by joint counts, improvement in functional status, and periodic joint radiographs every one to two years. Potential MTX toxicity is monitored with complete blood counts, chemistry profiles, and careful questioning about pulmonary, gastrointestinal, or central nervous system problems. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A reduction in the MTX dose or every other week dosing may be tried in patients on long-term MTX therapy who are judged to be stable and who have achieved what is believed to be their optimal response. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Every other week dosing'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Duration of therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Split dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;When MTX was first used, many practitioners adopted a regimen of dividing the dose into three equivalent amounts given every 12 hours for three doses. However, this schedule was developed by dermatologists to suppress rapidly dividing cells in psoriatic skin and has questionable rationale in the treatment of rheumatic diseases.",
"   </p>",
"   <p>",
"    However, as noted above, split dosing of oral MTX has the advantage of improved bioavailability and is thus more likely to result in a commensurate clinical improvement in clinical effects. However, this hypothesis has not been formally studied in prospective investigations. Furthermore, no trials have directly compared toxicity in patients taking the drug all at once versus split dosing, and neither approach is clearly wrong. There are patients who seem to tolerate the drug better when given in divided dose regimens. The reasons for this are unclear, but split dosing may be reserved for these individuals. Daily MTX or dosing schedules which provide for administration of the MTX dose on two to four days over the course of a week are significantly",
"    <strong>",
"     more toxic",
"    </strong>",
"    and should never be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Parenteral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients prefer oral over parenteral therapy, although some practitioners believe that certain gastrointestinal toxicities may be avoided by administering MTX either subcutaneously or intramuscularly. Anecdotal observations support this concept, although no trials have formally compared safety, tolerability, or efficacy when the drug is administered by these different routes.",
"   </p>",
"   <p>",
"    Benefit from switching to parenteral administration was seen in one arm of a trial evaluating treatment strategies for RA, in which a reduction in disease activity was observed in patients previously unable to achieve remission on maximally tolerated oral doses of MTX (of up to 30",
"    <span class=\"nowrap\">",
"     mg/week),",
"    </span>",
"    who were switched to subcutaneous administration of their dose. Similar improvement was seen in patients who were switched due to either insufficient efficacy or adverse effects, but no control group was available for comparison [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The liquid MTX formulation (prepared for parenteral use) may be consumed orally by mixing it with juice; this preparation is cheaper than tablets and may be used if expense is a serious issue and if the patient can be relied upon to measure the precise volume of drug. It is not recommended for patients with decreased finger dexterity, limited vision, or impaired cognition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Every other week dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every other week dosing may be tried in patients on long-term MTX therapy who are judged to be stable and who have achieved what is believed to be their optimal response. The outcome varies in part with whether or not the patient is in remission at the time that the regimen is changed. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Duration of therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One randomized trial included 51 patients who had been on MTX for at least nine months and who were in remission for at least six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/43\">",
"     43",
"    </a>",
"    ]. The patients were assigned to weekly or every other week MTX, which reduced the monthly dose by one-half. The frequency of maintenance of remission at 24 weeks was the same in the two groups (95 versus 91 percent). All the patients whose synovitis recurred during every other week therapy were controlled after resumption of weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The outcomes were not as good in another trial of patients who were clinically stable but not in remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/44\">",
"     44",
"    </a>",
"    ]. Among the 23 patients who were switched to every other week MTX, 12 had no change in their clinical status for the six month duration of the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/44\">",
"     44",
"    </a>",
"    ]. The remaining 11 patients experienced a worsening in disease activity and had to be placed back on a weekly dosing regimen. Regression analysis of clinical and demographic features failed to reveal any predictive variables that would help in the decision to try every other week therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally continue MTX treatment indefinitely in patients with RA who require this medication. This approach is both effective and safe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/27,39,45,46\">",
"     27,39,45,46",
"    </a>",
"    ]. We do not recommend complete withdrawal of MTX, unless indicated for toxicity, since it usually leads to a flare of RA within three to six weeks.",
"   </p>",
"   <p>",
"    Selection of patients for dose reduction and the optimal approach have not been adequately addressed in clinical trials. Based upon our clinical experience, in patients with stable, well-controlled disease on 20 to 25",
"    <span class=\"nowrap\">",
"     mg/week,",
"    </span>",
"    we try to reduce the dose by 2.5 mg every one to two months to 15",
"    <span class=\"nowrap\">",
"     mg/week,",
"    </span>",
"    unless there is a resultant increase in disease activity.",
"   </p>",
"   <p>",
"    In patients already on 15",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    or less who desire a trial of a reduced dose or who have bothersome side effects but well-controlled, stable disease, we perform a trial of every other week dosing, while carefully monitoring for a possible flare in disease activity (see above). The original weekly dose schedule should be resumed if the patient experiences a disease flare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Folic acid supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients receiving MTX should be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    1 mg daily or folinic acid weekly (racemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    2.5 mg to 5 mg or L-isomer of leucovorin 1 to 2 mg) to prevent hematologic and other side effects. Use of daily folic acid or weekly folinic acid supplementation also prevents the increase in the plasma concentration of homocysteine that otherwise occurs as a result of MTX administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/47\">",
"     47",
"    </a>",
"    ]. There is no clear rationale to withhold the dose of folic acid on the day of MTX administration as folic acid and MTX enter the cell via different pathways. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In vitro data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    can interfere with cellular uptake of MTX by blocking the action of the reduced folate carrier protein that transports the major circulating form of folate, 5-methyltetrahydrofolate, as well as 5-formyltetrahydrofolate, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/48\">",
"     48",
"    </a>",
"    ]. The clinical significance of this finding is uncertain, but the possibilities that co-administration of sulfasalazine could attenuate the effectiveness of MTX and cause or exacerbate intracellular folate deficiency have both been raised as potentially important interactions that need further investigation. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Combination with other drugs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Combination with other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who do not respond to MTX alone may improve with combinations of MTX and other drugs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A six-month randomized double-blind trial compared combination therapy of MTX (at a maximally tolerated dose of 15",
"      <span class=\"nowrap\">",
"       mg/wk)",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (2.5 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in two daily divided doses) with MTX plus placebo in 148 patients with severe RA who had residual inflammation and disability despite partial but substantial responses to prior MTX treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/49\">",
"       49",
"      </a>",
"      ]. As compared with the MTX plus placebo group, the patients who also received cyclosporine had a net improvement in tender joint count (25 percent), swollen joint count (25 percent), overall disease activity (19 percent), joint pain (23 percent), and degree of disability (26 percent). Side effects were not substantially increased in the treatment group.",
"     </li>",
"     <li>",
"      A second double-blind trial enrolled 102 patients with RA who had a previous poor response to at least one disease modifying drug; the patients were treated with MTX alone (7.5 mg to 17.5",
"      <span class=\"nowrap\">",
"       mg/week),",
"      </span>",
"      the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      (500 mg twice daily) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      (200 mg twice daily), or all three drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/50\">",
"       50",
"      </a>",
"      ]. The dose of MTX was adjusted in an attempt to achieve remission in all patients. The primary end point was successful completion of two years of treatment with 50 percent improvement in symptoms of arthritis and no evidence of drug toxicity. This criterion was met in 77 percent of patients treated with all three drugs versus 33 percent treated with MTX alone and 40 percent treated with sulfasalazine and hydroxychloroquine. Seven patients in the MTX group and three patients in each of the other two groups discontinued treatment because of drug toxicity.",
"     </li>",
"     <li>",
"      A subsequent trial randomized 171 patients with RA, who had an inadequate response to MTX alone, to one of three groups that received one of three MTX containing regimens that were MTX,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      ; MTX plus hydroxychloroquine and placebo; or MTX plus sulfasalazine and placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/51\">",
"       51",
"      </a>",
"      ]. Patients all had active disease and were followed for two years. The MTX dose was escalated from 7.5 mg per week to a maximum of 17.5",
"      <span class=\"nowrap\">",
"       mg/week.",
"      </span>",
"      Sulfasalazine was initially given at a dose of 500 mg BID and increased to 1 gram BID. The hydroxychloroquine dose was 200 mg BID.",
"      <br/>",
"      <br/>",
"      Patients on the three drug combination had a significantly greater proportion of ACR 20 and 50 responses than either of the two drug plus placebo combinations (ACR 20 responses of 78 percent, 60 percent, and 49 percent for those receiving three drugs, MTX plus hydroxychloroquine, and MTX plus sulfasalazine, respectively; ACR 50 responses of 55, 40, and 29 percent, respectively). One can speculate that the superior performance of the MTX-hydroxychloroquine combination to MTX-sulfasalazine could be associated with the inhibition of cellular uptake of MTX when used with SSZ described above [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/48\">",
"       48",
"      </a>",
"      ]. There was no significant difference in toxicity among the three groups.",
"     </li>",
"     <li>",
"      The effect of adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      or placebo to ongoing MTX therapy was evaluated in a study of 428 patients with persistent disease who were randomly assigned to one of the following five groups: placebo infusion every month, or infliximab at either 3 or 10",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      with each dose being administered either every month or every other month [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/52\">",
"       52",
"      </a>",
"      ]. At 54 weeks, the ACR 20, 50, and 70 responses for the 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      dose administered every other month were 42, 21 and 11 percent, respectively. A dose response was observed, with benefits usually found within the first six weeks of therapy. As determined by the modified Sharp score, active therapy resulted in a substantial reduction in radiographic progression, which was independent of what the dosing regimen was or whether an ACR 20 response was achieved.",
"      <br/>",
"      <br/>",
"      There were similar rates of infectious complications (35 and 44 percent) and serious infections (8 and 6 percent) in the placebo and combined infliximab groups, respectively. The malignancy rate was comparable to that observed with the national Surveillance Epidemiology and End Results (SEER) database, with lymphoproliferative disorders observed in 4 of 555 infliximab treated patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other manifestations of RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clear guidelines for treatment of the non-joint manifestations of RA with MTX. The assumption should not be made that, because arthritis is improved, other findings of RA will necessarily follow a similar course. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subcutaneous nodules worsen in many patients who receive the drug [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41223?source=see_link\">",
"       \"Ganglia and nodules\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"       \"Major side effects of low-dose methotrexate\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The role of MTX in the treatment of rheumatoid lung disease is limited; it should probably be avoided in view of its potential to cause interstitial lung disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32169/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anecdotal reports have emerged about the potential usefulness of MTX in Felty's syndrome and rheumatoid vasculitis. However, controlled studies are needed to verify these observations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18695?source=see_link\">",
"     \"Drug therapy in Felty's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/19/22841?source=see_link\">",
"     \"Treatment of rheumatoid vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of documented embryotoxicity and teratogenicity, use of MTX should be avoided in women who are contemplating becoming, or who are, pregnant. Women of childbearing potential should use effective contraception before and during MTX treatment. If there is any uncertainty about the possibility of pregnancy, blood testing is appropriate prior to initiating MTX. These issues and recommendations regarding discontinuation of MTX in anticipation of pregnancy are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link&amp;anchor=H17#H17\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/61/21463?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/44/24264?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=see_link\">",
"       \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/29/39378?source=see_link\">",
"       \"Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/52/12098?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4350517\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      (MTX) can be given via oral, intramuscular, and subcutaneous routes. Oral MTX is variably absorbed in the dose range used to treat RA, particularly at the higher part of this range. However, food does not affect MTX absorption to a significant degree. MTX is primarily cleared via the kidneys, with most being excreted unchanged in the urine. Co-administration with other folate depleting drugs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"       probenecid",
"      </a>",
"      may increase the risk of toxicity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MTX is a structural analogue of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      that can competitively inhibit the binding of dihydrofolic acid (FH2) to the enzyme dihydrofolate reductase, which is responsible for reducing FH2 to folinic acid (FH4), the active intracellular metabolite. Thus, MTX decreases the amount of intracellular FH4 available and affects the metabolic pathways within the cell that are FH4 dependent. However, the mechanism by which it improves the signs and symptoms of RA is likely to be complex. Potential mechanisms of action also include enhancement of extracellular concentrations of adenosine. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of MTX in RA improves short- and long-term clinical outcomes, and it appears to reduce joint damage and improve long-term survival. We initiate treatment in patients with moderate to severe RA using MTX together with nonsteroidal antiinflammatory drugs (NSAIDs) and use it in patients who have not responded to other therapies, such as NSAIDs or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      . Appropriate immunizations should be performed prior to starting MTX. MTX should NOT be used in women who are contemplating becoming pregnant or who are pregnant, or in patients with liver disease or excessive alcohol intake. We prefer that patients abstain from use of alcohol while receiving MTX, if possible. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Use in patients with RA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Efficacy for arthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Possible survival benefit'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Patient selection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Alcohol use and MTX'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We generally initiate therapy with a dose between 7.5 and 15 mg weekly, depending upon the patient&rsquo;s age, size, comorbidities, and degree of disease activity. Higher dose initiation is more likely to achieve steady-state intracellular concentrations of MTX polyglutamates more rapidly, but there may be a trade off with an initial experience of more commonly experienced nuisance toxicities such as stomatitis and nausea. We usually increase the dose after the first month of therapy, depending upon the clinical response, tolerability, and the factors noted above by 2.5 to 5",
"      <span class=\"nowrap\">",
"       mg/week.",
"      </span>",
"      The maximum dose we generally employ is approximately 25",
"      <span class=\"nowrap\">",
"       mg/week.",
"       <br/>",
"       <br/>",
"       For",
"      </span>",
"      patients in whom 15 to 25 mg once weekly is ineffective or poorly tolerated, a trial of subcutaneous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      administration is an alternative, along with splitting the oral dose into two doses 12 hours apart and giving it all on the same day. Daily MTX or dosing schedules that require administration of the drug on two to four days over the course of a week are significantly",
"      <strong>",
"       more toxic",
"      </strong>",
"      and should never be used. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Dosing of MTX'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Dose titration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Split dosing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Parenteral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients receiving MTX should be treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      1 mg daily or folinic acid weekly (racemic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      2.5 mg to 5 mg or L-isomer of leucovorin 1 to 2 mg) to prevent hematologic and other side effects. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Folic acid supplementation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with RA who require treatment with MTX should generally be treated indefinitely, since complete withdrawal of MTX usually leads to a flare of RA within three to six weeks and since this approach is effective and safe. In patients with well-controlled disease on 20 to 25",
"      <span class=\"nowrap\">",
"       mg/week,",
"      </span>",
"      we reduce the dose by 2.5",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      every one to two months to a dose of 15",
"      <span class=\"nowrap\">",
"       mg/week,",
"      </span>",
"      as tolerated, while carefully monitoring for a possible flare in disease activity. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who do not respond to MTX alone may improve with combinations of MTX and other drugs, including both nonbiologic and biologic disease-modifying antirheumatic drugs. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Combination with other drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no clear guidelines for treatment of the non-joint manifestations of RA with MTX. Subcutaneous nodules worsen in many patients who receive the drug. In patients with underlying lung disease, MTX should probably be avoided in view of its potential to cause interstitial lung disease. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Other manifestations of RA'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/1\">",
"      GUBNER R, AUGUST S, GINSBERG V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951; 221:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/2\">",
"      Willkens RF, Watson MA. Methotrexate: a perspective of its use in the treatment of rheumatic diseases. J Lab Clin Med 1982; 100:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/3\">",
"      Hoffmeister RT. Methotrexate therapy in rheumatoid arthritis: 15 years experience. Am J Med 1983; 75:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/4\">",
"      Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997; 36:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/5\">",
"      Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004; 31:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/6\">",
"      Colebatch AN, Marks JL, Edwards CJ. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev 2011; :CD008872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/7\">",
"      Kremer JM, Hamilton RA. The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol 1995; 22:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/8\">",
"      Hamilton RA, Kremer JM. The effects of food on methotrexate absorption. J Rheumatol 1995; 22:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/9\">",
"      Dalrymple JM, Stamp LK, O'Donnell JL, et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008; 58:3299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/10\">",
"      Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986; 29:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/11\">",
"      Morabito L, Montesinos MC, Schreibman DM, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998; 101:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/12\">",
"      Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996; 39:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/13\">",
"      Montesinos MC, Yap JS, Desai A, et al. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum 2000; 43:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/14\">",
"      Montesinos MC, Desai A, Delano D, et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003; 48:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/15\">",
"      Wessels JA, Kooloos WM, De Jonge R, et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2006; 54:2830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/16\">",
"      Gerards AH, de Lathouder S, de Groot ER, et al. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) 2003; 42:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/17\">",
"      Nesher G, Moore TL. The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine. Arthritis Rheum 1990; 33:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/18\">",
"      Genestier L, Paillot R, Fournel S, et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/19\">",
"      Ferraccioli GF, Bartoli E. Xenobiotics or biological response modifiers? Methotrexate remains the anchor drug for rheumatoid arthritis. Clin Exp Rheumatol 1998; 16:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/20\">",
"      Seitz M, Zwicker M, Wider B. Enhanced in vitro induced production of interleukin 10 by peripheral blood mononuclear cells in rheumatoid arthritis is associated with clinical response to methotrexate treatment. J Rheumatol 2001; 28:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/21\">",
"      Johnston A, Gudjonsson JE, Sigmundsdottir H, et al. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005; 114:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/22\">",
"      Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/23\">",
"      Andersen PA, West SG, O'Dell JR, et al. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 1985; 103:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/24\">",
"      Weinblatt ME, Weissman BN, Holdsworth DE, et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum 1992; 35:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/25\">",
"      Weinblatt ME, Kaplan H, Germain BF, et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 1994; 37:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/26\">",
"      Williams HJ, Willkens RF, Samuelson CO Jr, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985; 28:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/27\">",
"      Kremer JM. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years. Arthritis Rheum 1997; 40:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/28\">",
"      Maravic M, Bologna C, Daures JP, et al. Radiologic progression in early rheumatoid arthritis treated with methotrexate. J Rheumatol 1999; 26:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/29\">",
"      Rich E, Moreland LW, Alarc&oacute;n GS. Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug. J Rheumatol 1999; 26:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/30\">",
"      Rau R, Schleusser B, Herborn G, Karger T. Long-term treatment of destructive rheumatoid arthritis with methotrexate. J Rheumatol 1997; 24:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/31\">",
"      Choi HK, Hern&aacute;n MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/32\">",
"      Weinblatt ME. Rheumatoid arthritis: treat now, not later! Ann Intern Med 1996; 124:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/33\">",
"      Fuchs HA, Kaye JJ, Callahan LF, et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989; 16:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/34\">",
"      Saag KG, Yazdany J, Alexander C, et al. Defining quality of care in rheumatology: the American College of Rheumatology white paper on quality measurement. Arthritis Care Res (Hoboken) 2011; 63:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/35\">",
"      Smolen JS, Landew&eacute; R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/36\">",
"      van Ede AE, Laan RF, Blom HJ, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001; 44:2525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/37\">",
"      Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/38\">",
"      Karie S, Gandjbakhch F, Janus N, et al. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford) 2008; 47:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/39\">",
"      Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/40\">",
"      Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009; 68:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/41\">",
"      Psoriasis-liver-methotrexate interactions. Arch Dermatol 1973; 108:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/42\">",
"      Bakker MF, Jacobs JW, Welsing PM, et al. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann Rheum Dis 2010; 69:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/43\">",
"      Luis M, Pacheco-Tena C, Cazar&iacute;n-Barrientos J, et al. Comparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized study. Arthritis Rheum 1999; 42:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/44\">",
"      Kremer JM, Davies JM, Rynes RI, et al. Every-other-week methotrexate in patients with rheumatoid arthritis. A double-blind, placebo-controlled prospective study. Arthritis Rheum 1995; 38:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/45\">",
"      Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009; 68:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/46\">",
"      Yazici Y, Sokka T, Kautiainen H, et al. Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005; 64:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/47\">",
"      van Ede AE, Laan RF, Blom HJ, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 2002; 41:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/48\">",
"      Jansen G, van der Heijden J, Oerlemans R, et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum 2004; 50:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/49\">",
"      Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995; 333:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/50\">",
"      O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/51\">",
"      O'Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/52\">",
"      Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32169/abstract/53\">",
"      Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004; 43:143.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7507 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-528937E1C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_26_32169=[""].join("\n");
var outline_f31_26_32169=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4350517\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      USE IN PATIENTS WITH RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Efficacy for arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Possible survival benefit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Alcohol use and MTX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dosing of MTX",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Dose titration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Split dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Parenteral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Every other week dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Folic acid supplementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Combination with other drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other manifestations of RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4350517\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/61/10194?source=related_link\" title=\"calculator 1\">",
"      Calculator: Glomerular filtration rate estimate by abbreviated MDRD study equation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?29/57/30609?source=related_link\" title=\"calculator 2\">",
"      Calculator: Creatinine clearance estimate by Cockcroft-Gault equation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/11/184?source=related_link\">",
"      Disease outcome and functional capacity in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18695?source=related_link\">",
"      Drug therapy in Felty's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41223?source=related_link\">",
"      Ganglia and nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32134?source=related_link\">",
"      Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/29/39378?source=related_link\">",
"      Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=related_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/52/12098?source=related_link\">",
"      Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/61/21463?source=related_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/44/24264?source=related_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/19/22841?source=related_link\">",
"      Treatment of rheumatoid vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_26_32170="Psychological, rehabilitative, and integrative therapies for cancer pain";
var content_f31_26_32170=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Psychological, rehabilitative, and integrative therapies for cancer pain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/26/32170/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/26/32170/contributors\">",
"     E Alessandra Strada, PhD, MSCP, FT",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/26/32170/contributors\">",
"     Russell K Portenoy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/26/32170/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/26/32170/contributors\">",
"     Janet Abrahm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/26/32170/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/26/32170/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/26/32170/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H44713397\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is one of the most feared consequences of cancer and cancer treatment. Among hospitalized patients with cancer, the prevalence of pain is from 62 to 86 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/1\">",
"     1",
"    </a>",
"    ]. Although adequate pain relief can be achieved in 70 to 90 percent of patients when well-accepted treatment guidelines for cancer pain are followed, the availability of effective therapy has not eliminated the problem of undertreatment. A systematic review concluded that among patients with advanced cancer, pain levels are reported as moderate to severe in about 40 to 50 percent, and very severe or excruciating in 25 to 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=see_link&amp;anchor=H2#H2\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\", section on 'The problem of undertreatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pain affects the psychological, social, and spiritual domains of patients' lives; in turn, the experience of pain can be influenced by emotional, social, and spiritual factors. The burden of pain is manifested not only through suffering, but also through impaired function, decreased activity, and alterations in one&rsquo;s sense of identity and social role. Uncontrolled or poorly relieved cancer pain has a profoundly negative impact on quality of life, and it increases suffering for caregivers as well.",
"   </p>",
"   <p>",
"    Thus, the adverse effects of cancer pain are complex and highly individual. In some cases, distress is related to the associated mood effects or functional impairments that occur as a result of uncontrolled pain. In other cases, it is the meaning that is attributed to pain that drives suffering. The assumption that pain is an indicator of progressive illness can cause increased fear and emotional distress for patients and caregivers alike. &nbsp;",
"   </p>",
"   <p>",
"    Pain and its associated outcomes may be ameliorated by a diverse array of interventions. Opioid-based pharmacotherapy is a mainstay of treatment for moderate to severe pain in patients with active cancer. In appropriate patients, nonpharmacologic strategies may provide satisfactory pain relief with fewer drug side effects,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    better outcomes with regard to physical and psychosocial functioning. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=see_link&amp;anchor=H4#H4\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\", section on 'General principles of pain management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=see_link\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonpharmacologic therapies for cancer pain include primary treatments for the etiology of the pain (eg, radiotherapy), invasive symptomatic therapies (eg, nerve blocks), and noninvasive symptomatic therapies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=see_link\">",
"     \"Cancer pain management: Interventional therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potentially beneficial noninvasive strategies are extremely diverse and can be divided into three large groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psychological approaches",
"     </li>",
"     <li>",
"      Rehabilitative approaches",
"     </li>",
"     <li>",
"      Integrative (complementary) approaches.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Knowledge of the many options is important for all clinicians who treat patients with pain related to cancer or other serious illnesses. Integration of selected noninvasive symptomatic treatments into a comprehensive strategy that includes pharmacotherapy is an important goal of cancer pain management.",
"   </p>",
"   <p>",
"    This topic review will cover psychological, rehabilitative, and integrative (complementary) approaches to management of cancer pain. Assessment of cancer pain, a review of specific cancer pain syndromes, general principles of cancer pain management, the clinical use of opioid analgesics, non-opioid analgesics (including adjuvant analgesics), and invasive symptomatic therapies for cancer pain management are covered elsewhere. (See appropriate topic reviews.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713404\">",
"    <span class=\"h1\">",
"     PSYCHOLOGICAL APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of well-conducted randomized trials support the utility of psychological interventions for cancer-related pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. The majority of these interventions were initially developed for patients with chronic, non-malignant pain and subsequently applied to the treatment of patients with cancer.",
"   </p>",
"   <p>",
"    The benefit of psychosocial approaches to cancer-associated pain was assessed in a meta-analysis that included 37 randomized trials of psychosocial interventions (psychotherapy, cognitive-behavioral therapy, relaxation, hypnosis, desensitization with imagery or biofeedback, meditation) in 4199 cancer patients in whom pain was measured as an outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/4\">",
"     4",
"    </a>",
"    ]. The mean effect size for pain severity, the primary outcome, was 0.34 (95% CI 0.23-0.460), and for pain interference, it was 0.40 (95% CI 0.21 TO 0.60). These data support the utility of psychosocial interventions as a component of multimodality treatment of cancer-related pain.",
"   </p>",
"   <p>",
"    The success of these approaches in the management of cancer pain provides support for the well-accepted view that pain affects psychological functioning, that psychological functioning affects pain and pain-related distress, and that neither pain nor suffering should ever be considered solely the result of nociception (the activation of neural mechanisms that subserve the perception of pain) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/8\">",
"     8",
"    </a>",
"    ]. Individual response to pain can be mediated by the meaning that is attributed to the pain sensation, past experience, levels of anxiety and depression, and other psychosocial factors. Addressing thoughts and emotions related to the experience of pain may help relieve stress, anxiety, and other mood disturbances associated with pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713411\">",
"    <span class=\"h2\">",
"     Cognitive-behavioral interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;When delivered to patients with cancer, cognitive-behavioral therapy typically focuses on maintaining quality of life through improved self-efficacy, developing a sense of control over the illness and its consequences, and learning self-regulation skills to improve emotional functioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Additionally, cognitive-behavioral techniques are focused on reducing the impact of pain on the performance of normal daily activities by addressing patients&rsquo; and caregivers' interpretation of and emotional reaction to pain and illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to the cognitive-behavioral model, an individual&rsquo;s interpretation of external events and bodily sensations directly affects their emotional reaction to these events and subsequent behavior. Every cognitive behavioral approach starts by identifying and modifying unhelpful thinking patterns that are believed to increase distress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Dichotomous thinking, catastrophization, and overgeneralization are considered dysfunctional cognitive patterns because they typically arise from limited information and do not entirely reflect reality (",
"    <a class=\"graphic graphic_table graphicRef62075 \" href=\"mobipreview.htm?42/31/43515\">",
"     table 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    The goal of cognitive-behavioral therapy is to present the patient with a reality-based alternative version or interpretation of events, in order to elicit a more adaptive emotional response and improved coping. As an example, a patient with cancer who is experiencing pain may interpret the situation as hopeless, focusing on the interpretation of pain as a sign that the illness is progressing, that death is a likely outcome, and there is nothing that can be done. The result of this dysfunctional thought process may be significant emotional distress, and an increase in anxiety, depression, and overall suffering. A cognitive-behavioral intervention would encourage the patient to explore additional meanings of the pain that might allow for a greater sense of control. &nbsp;",
"   </p>",
"   <p>",
"    Cognitive-behavioral therapy is a structured approach that engages the patient in setting specific goals and monitoring results. The process includes patient education, behavioral skill training, and cognitive skill training [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient education is typically provided in the first session. Patients receive a detailed explanation of the rationale for the treatment approach, and they are taught to recognize the relationship between how they think, how they feel, and how they behave.",
"     </li>",
"     <li>",
"      Behavioral skill training focuses on teaching patients practical skills that aid coping and adaptation to the illness. For example, patients are taught simple relaxation techniques that they can utilize in stressful or anxiety-provoking situations. They may be taught to pace their activities to reduce fatigue or frustration, which may also help related mood disturbances. They may learn to incorporate pleasurable activities and experiences in their daily lives (pleasant activity scheduling).",
"     </li>",
"     <li>",
"      Cognitive skill training focuses on teaching patients how to identify and modify patterns of maladaptive thinking, and how to substitute with more adaptive ones (cognitive restructuring). As part of cognitive skill training, patients are encouraged to examine whether, in the process of trying to make sense of the cancer or the pain, there may be errors in their thinking or mistaken beliefs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following case example illustrates the benefits gained from cognitive-behavioral therapy. A patient with advanced ovarian cancer is experiencing persistent neuropathic pain in the upper and lower extremities as a result of chemotherapy. While her medication regimen was successfully controlling pain, she still had regular episodes of breakthrough pain which were highly distressing. When invited by her daughter to go on a cruise with other family members, she refused because of pain. Through cognitive-behavioral therapy, the patient acknowledged that she interpreted flares of breakthrough pain as harbingers of progressive disease and imminent death. She also indicated a belief that she would never be able to have a normal life again and did not deserve to incorporate pleasant experiences in her life. She concluded that she should not plan anything as extravagant as a cruise and that, if she went, her pain and negative mood would burden her family. In her mind, a cruise evoked images of happiness, health, fun, and youth, and because her thoughts and beliefs convinced her that this overarching joy was out of reach, she decided to avoid the experience altogether. She communicated her decision to her family, and remarkably, experienced a significant increase in pain. &nbsp;",
"   </p>",
"   <p>",
"    Cognitive-behavioral therapy was informed by the reality of her medical condition. Although the disease was advanced, her oncologist was clear that there was no rapid progression, and although her prognosis was limited, death was not near, and pain did not foretell its imminence. It was true that fatigue and pain could limit her ability to engage in all activities during the cruise, her mood was often poor, and that the stress of planning the trip, traveling, and meeting others in a new environment and social context might increase anxiety and thereby raise the likelihood of pain. However, her avoidance of the trip was largely the result of incorrect, distorted, or maladaptive thinking. She had concluded that life was essentially over, that she was a burden to her family, and could no longer hope for satisfying and pleasurable activities, pursuits, or goals.",
"   </p>",
"   <p>",
"    The therapist's first task was to help the patient identify problematic thoughts and beliefs, examine critically their value and veracity, and assist her in restructuring her thinking to consider all the possibilities and choices that are available. Within several sessions, the patient was able to accomplish this, and decided to accept the trip with her family. The outcome was positive and the trip became a special memory for the family after the patient's death.",
"   </p>",
"   <p>",
"    While numerous studies have investigated the role of cognitive-behavioral therapy in the treatment of mood disturbances in patients with cancer, few have considered cancer-related pain as the outcome variable:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two well-designed randomized controlled trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/22,23\">",
"       22,23",
"      </a>",
"      ] demonstrated that behavioral skill training could reduce cancer-related pain during a short follow-up period of six months.",
"     </li>",
"     <li>",
"      A meta-analysis of randomized trials examining cognitive behavioral techniques for distress and pain in breast cancer patients, which included two randomized trials in which pain was an outcome measure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/24,25\">",
"       24,25",
"      </a>",
"      ], concluded that patients who were administered cognitive behavioral techniques had significantly less distress and pain compared to those in control groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A review of the available literature by the NIH Technology Assessment Panel on Integration of Behavioral and Relaxation Approaches for the Treatment of Chronic Pain and Insomnia found only moderate evidence for the effectiveness of cognitive-behavioral techniques for relief of chronic pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Two other trials of cognitive-behavioral therapy to reduce treatment-related pain (mainly from mucositis) in patients undergoing hematopoietic cell transplantation failed to show a benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the small number of trials does not allow definitive evidence-based conclusions, cognitive-behavioral therapy is generally considered a potentially effective adjunct for the treatment of chronic cancer-related pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713418\">",
"    <span class=\"h2\">",
"     Mind-body therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cancer pain may benefit from one or more of a group of therapies that share a common perspective: emphasizing the potential value of training the &ldquo;mind&rdquo; (by shifting cognitions or creating an emotional state) in a way that favorably influences bodily functions. These therapies are usually considered as an adjunct to pharmacotherapy, as a component of a broader approach that includes cognitive behavioral therapy or other unrelated noninvasive therapies. However, occasionally, mind-body therapies are offered alone as specific treatments for a single discrete problem (eg, pain related to a specific procedure). All of these treatments are intended to reduce pain and anxiety, and increase self-efficacy. They usually require a competent health professional to do the training, but some may be taught by a knowledgeable primary care provider. Patients who benefit can continue the approach over a long period, often with no additional support, or only an occasional session of retraining.",
"   </p>",
"   <p>",
"    The mind-body treatments are sometimes collectively classified under the rubric of complementary and alternative medicine (CAM) therapies, but this may unnecessarily stigmatize some of them. Therapies such as relaxation training, guided imagery, hypnosis and biofeedback are not alternative treatments, but rather, should be considered mainstream treatments in pain medicine that are complementary to other approaches. In some cases, these interventions have more supporting evidence than most of the other treatments that are used in conventional medicine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/13/40154?source=see_link&amp;anchor=H26#H26\">",
"     \"Complementary and alternative therapies for cancer\", section on 'Complementary supportive care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although many small trials support benefit from several of these therapies, a systematic review in 2006 concluded that while hypnosis, imagery, acupuncture and healing touch seemed promising for adjunctive treatment of cancer pain, particularly in the short-term, the evidence was not conclusive as to benefit because of the paucity of methodologically rigorous trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713425\">",
"    <span class=\"h3\">",
"     Relaxation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relaxation techniques share two components: the repetitive focus on a word, sound, prayer, phrase, body sensation, or muscular activity; and the adoption of a passive attitude towards intrusive thoughts. &nbsp;",
"   </p>",
"   <p>",
"    As a group, relaxation techniques attempt to induce a so-called relaxation response characterized by decreased arousal and diminished sympathetic activity (eg, decreased heart rate and lower blood pressure). This is accompanied by increased electroencephalographic slow wave activity. When used therapeutically, relaxation techniques may be subdivided into two methods, deep and brief, or by the specific strategy used to induce the relaxed state, including progressive muscle relaxation, autogenic training, and breath training. The data are currently insufficient to conclude that one technique is more effective than another for any given condition.",
"   </p>",
"   <p>",
"    There is a small chance of adverse reactions during relaxation training. In a survey of 116 clinicians who conducted relaxation practice with 17,542 patients, the most common adverse reactions were intrusive thoughts, fear of losing control, upsetting sensory experiences, muscle cramps, sexual arousal, and psychotic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse reactions to relaxation practice have also been described as relaxation-induced anxiety or relaxation-induced panic. Relaxation-induced anxiety is described as a gradual increase in behavioral, physiologic, and psychological anxiety, whereas relaxation-induced panic is severe anxiety of rapid onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients with a history of generalized anxiety disorder or panic disorder and those with a history of hyperventilation are more likely to experience these adverse effects. Although the risk is small, patients with these histories should be carefully monitored during the relaxation process. Before trying relaxation techniques with patients, physicians should conduct a thorough assessment of patients' prior psychiatric history, especially anxiety disorders and also assess the current level of arousal.",
"   </p>",
"   <p>",
"    Patients should also be introduced to deep breathing techniques that often accompany relaxation in a gradual manner. Until a relaxation technique is mastered by the patient under supervision from a clinician, patients with risk factors (eg, anxiety disorders) should be discouraged from practicing deep breathing on their own for more than a couple of minutes at a time.",
"   </p>",
"   <p>",
"    A benefit for relaxation has been shown in several small randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/24,28,32-34\">",
"     24,28,32-34",
"    </a>",
"    ], but in some cases, the benefits have been transient. In a trial of 59 patients with cancer pain requiring opioid therapy who were randomly assigned to one of three active cognitive behavioral treatments (distraction, positive mood, or relaxation interventions) or to a control, patients in the relaxation and distraction groups reported significantly decreased pain intensity immediately after intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/34\">",
"     34",
"    </a>",
"    ]. However, at two weeks after enrollment, no differences were apparent between any of the treatment groups.",
"   </p>",
"   <p>",
"    An early systematic review concluded that relaxation techniques were effective in reducing chronic pain in a variety of medical conditions, including cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/26\">",
"     26",
"    </a>",
"    ]. However, a later systematic literature review concluded that low methodologic quality and small sample size limited the conclusions that could be drawn from the available literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713432\">",
"    <span class=\"h3\">",
"     Imagery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imagery utilizes recall of pleasant sights, smells, sounds, tastes, or somatic sensations (touch, movements, or positions) to create a positive cognitive and emotional state that can prevent or ameliorate pain or other sources of distress. The use of imagery for the treatment of human ailments began thousands of years ago. In the Asclepian temples of Greece, imagery was evoked in a state of consciousness that occurred in the lucid period just before sleep, which is now described as hypnogogic sleep. Aristotle, Hippocrates, and Galen were trained in this method of imagery and used it regularly with their patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guided imagery utilizes a verbal modality to create states of focused attention that are thought to alter the experience of pain. This technique may have multiple applications, including pain management. Other coping techniques, such as distraction, mental dissociation, muscle relaxation, and controlled abdominal breathing, are also practiced as part of the imagery application.",
"   </p>",
"   <p>",
"    Although some writings have attempted to link specific types of imagery with positive outcomes in specific physiological systems (eg, immune or cardiac), there is no evidence of this specificity. When used for clinical purposes, imagery procedures are usually divided into one of three categories: diagnostic imagery, mental rehearsal imagery, and end-state imagery. Once developed with the therapist, the latter two types of representations can be retained by patients as discrete memories that can be accessed as needed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnostic imagery provides the information needed to design individualized and meaningful imagery sessions for each patient. Patients are asked to describe their pain in personally detailed sensory and emotional terms, and this information is then used to design individualized mental rehearsal or other therapeutic interventions.",
"     </li>",
"     <li>",
"      Mental rehearsal imagery is a technique that is often used to prepare patients for painful treatments or surgical procedures (eg, biopsies). It is primarily used to relieve anxiety, pain, and side effects that are exacerbated by a heightened emotional reaction. Typically, a relaxation strategy is taught to the patients, who are then led through a &ldquo;guided imagery trip&rdquo; from the treatment through the recovery period.",
"      <br/>",
"      <br/>",
"      During mental rehearsal imagery, it is important to be factual, to avoid emotionally-charged or fear-provoking words, and to reframe the medical procedure in realistic yet positive terms.",
"     </li>",
"     <li>",
"      End-state imagery is a technique intended to produce a specific physiologic or biological change in the body. Its clearest objective is to reduce sympathetic nervous system arousal. End-state imagery has been successfully used to alleviate chemotherapy-induced nausea and to assist in the control of cancer pain.",
"      <br/>",
"      <br/>",
"      End state imagery for the treatment of pain is called analgesic imagery; it is either pain-transforming or pain-incompatible. Pain-transforming imagery concentrates on changing specific aspects of the pain experience, such as the contextual aspect of the painful experience (eg, imagining that the moment the chemotherapy needle touches the skin and before it is inserted, it releases a massive amount of powerful analgesic medication that completely numbs the arm). Pain incompatible-imagery can be used to evoke positive emotions and feelings of relaxation, excitement, or peace that are not compatible with the image of pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guided imagery can be directive, as when the therapist suggests images to the patient, who then uses them as a sort of hook to develop further a personalized imagery. Or, it can be more interactive, as when the therapist does not provide the patient with a specific image, but only suggests generally the feeling that should be elicited by the image, allowing the patient to create an image that corresponds to or is able to evoke the desired emotional state.",
"   </p>",
"   <p>",
"    Most guided imagery treatment plans begin by assisting the patient in the mental creation of a physical place where he or she feels comfortable, cared for, and peaceful. The therapist may gently invite the patient to &ldquo;allow an image to form, of a place where you feel peaceful, comfortable, and cared for&rdquo;. Use of words as &ldquo;safe, protected&rdquo; are best avoided with patients with a history of trauma, because they may indirectly function as reminders of the traumatic experience and may, therefore, increase the general level of arousal and cause anxiety.",
"   </p>",
"   <p>",
"    Published outcomes from research on mental rehearsal imagery are almost uniformly positive, reporting significant reductions in pain and anxiety, length of postoperative hospital stay, pain medication use, and fewer treatment-related side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/28,29,33,36,37\">",
"     28,29,33,36,37",
"    </a>",
"    ]. However, a systematic review concluded that low methodologic quality and small sample size limited the conclusions that could be drawn from the available literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713439\">",
"    <span class=\"h3\">",
"     Hypnotic analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypnosis can be defined as an induced state of attentive, focused concentration with suspension of some peripheral awareness. Major components of the hypnotic state include absorption (capacity to contemplate deeply a selected theme or focal point), controlled alteration of one's attention, dissociation (the capacity to compartmentalize different aspects of an individual experience) and suggestibility (the capacity for heightened responsiveness to instructions) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients vary widely in their ability to achieve a hypnotic state. Typically, individuals have been classified as &ldquo;high hypnotizables&rdquo; or &ldquo;low hypnotizables&rdquo;, as assessed by validated instruments such as the Penn State Scale of Hypnotizability (PSSH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/41\">",
"     41",
"    </a>",
"    ] or the Stanford Hypnotic Clinical Scale (SHCS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/42\">",
"     42",
"    </a>",
"    ]. These scales of hypnotic susceptibility provide a relatively stable measurement of individual differences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/43\">",
"     43",
"    </a>",
"    ]. Cooperation and suggestibility are important foundations for hypnotizability. The trait of suggestibility alone, however, does not determine the potential for hypnotic induction and suggestibility, does not determine whether or not a hypnotic trance can be achieved and does not imply that any particular outcomes will be achieved. To allay concerns, some patients need reassurance that hypnosis cannot induce behaviors that would not be desired or are contrary to the patient's values.",
"   </p>",
"   <p>",
"    Hypnosis can promote relaxation, decrease anxiety and increase pain threshold. It may alter the perception of pain by decreasing the unpleasantness of the sensation, or reducing the attention paid to the painful sensation and refocusing attention elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. Hypnosis can help patients experience less emotional upset and anxiety when they undergo stressful surgical procedures, such as excisional breast biopsies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/48\">",
"     48",
"    </a>",
"    ]. Recent studies have investigated the expectancies and emotional distress that may mediate any benefits associated with a hypnotic intervention for breast cancer surgical patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/49\">",
"     49",
"    </a>",
"    ]; for co-occurring pain, fatigue, and sleep disturbance in patients with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/50\">",
"     50",
"    </a>",
"    ]; and for improving beast radiation-related fatigue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several randomized controlled studies have shown that hypnosis is effective in reducing pain, as well as anxiety, related to invasive procedures performed in cancer diagnosis and treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early study included 54 women with metastatic carcinoma of the breast; 24 served as controls and 30 women participated in weekly group therapy sessions over the course of a year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/52\">",
"       52",
"      </a>",
"      ]. Of those in group therapy, 19 patients learned and practiced hypnosis for pain control, while 11 attended group therapy but did not learn hypnosis. There were significant differences between the groups in pain. The mean pain sensation was lowest for the group therapy plus hypnosis group, higher for the group receiving group therapy without hypnosis, and the highest for the control group.",
"     </li>",
"     <li>",
"      In a controlled study of 67 patients undergoing bone marrow transplant, hypnosis was significantly better than therapist support or cognitive behavioral therapy in reducing reported oral pain from mucositis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial of 200 women undergoing breast cancer surgery demonstrated that a 15-minute presurgery hypnosis session was superior to attention control (nondirected empathic listening) at reducing pain, nausea, fatigue, discomfort, emotional upset at discharge, and institutional costs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An analysis of the published literature performed by the NIH Technology Assessment Panel concluded that there was strong evidence to support benefit from hypnosis in management of chronic cancer pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/26\">",
"       26",
"      </a>",
"      ]; however, a later more rigorous systematic review concluded that low methodologic quality and small sample size limited the conclusions that could be drawn from the available literature [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713446\">",
"    <span class=\"h3\">",
"     Biofeedback",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biofeedback involves the use of a machine to allow monitoring and feedback control over a specific physiological parameter. The instrument transforms a physiological response, such as skin temperature, into an electrical signal, which is amplified and displayed in the form of a visible",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    audible stimulus such as a changing tone, a light bar, or a moving line on a computer screen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. By monitoring the stimulus and learning to control the physiological response that generates it, biofeedback can facilitate healthier cognitive and behavioral response patterns to pain and stress. It can help patients learn to modify the internal, subjective experience by providing corrective information to either validate the strategy that is being used to achieve a desired state (eg, relaxation) or show its inadequacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The physiological responses that are most commonly used for biofeedback are respiration, heart rate or pulse, peripheral skin temperature, electrical skin conductance, and muscle tension (surface electromyography [EMG]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/57\">",
"     57",
"    </a>",
"    ]. Surface EMG biofeedback, for example, has been used for the treatment of cancer-related pain by targeting muscle groups associated with the patient's response to pain; relaxing these muscles can also help induce a general relaxation response, which can further alter pain perception or reduce anxiety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Biofeedback might be considered for any motivated patient with pain or distress, if the resource exists and patients have the ability to participate. Patients with chronic or recurrent depression may respond negatively to stress reduction approaches that tend to decrease the patient's already low level of arousal. Additionally, clinicians must be aware that coffee, nicotine, steroids and sedatives can be problematic, because they may alter reading of measure, thus obfuscating results.",
"   </p>",
"   <p>",
"    The value of surface EMG biofeedback was shown in a small trial in which 37 patients with advanced cancer and chronic pain were randomly assigned to EMG biofeedback-assisted relaxation (six sessions over four weeks) or conventional care only [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/60\">",
"     60",
"    </a>",
"    ]. The main endpoint was pain, as assessed at baseline and following the intervention using a version of the Brief Pain inventory (BPI). In an analysis of the 24 patients who completed the study (12 experimental, 12 control), relaxation training supplemented with biofeedback was effective in reducing cancer&ndash;related pain, whereas in the control group, pain increased.",
"   </p>",
"   <p>",
"    Additional studies are needed to replicate this result and compare this approach to other types of biofeedback. The NIH Technology Assessment Panel and a later meta-analysis both concluded that there was only moderate evidence to support benefit from any form of biofeedback in the management of chronic cancer pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/26,29\">",
"     26,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713453\">",
"    <span class=\"h1\">",
"     REHABILITATION AND PHYSICAL MEDICINE INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rehabilitative interventions may have a primary goal of functional improvement, symptom control, or both. These interventions can be categorized in various ways. Therapeutic exercise, usually initiated or guided by a physical therapist, is a key approach; hydrotherapy may facilitate or enhance exercise and may be particularly helpful in the medically ill. Other interventions include the use of orthoses, ambulation aides, and other devices, and a group of treatments known collectively as &ldquo;modalities&rdquo;. The latter group includes the application of heat and cold, vibration, ultrasound, and electrical stimuli (eg, as with a transcutaneous electrical nerve stimulation [TENS] device).",
"   </p>",
"   <p>",
"    Specific treatments for selected disorders, such as lymphedema, are also included within the category of rehabilitative therapies. Treatments that involve manipulation or massage are sometimes included in this category, but depending on the context, are more often considered to be complementary medicine approaches. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713460\">",
"    <span class=\"h2\">",
"     Therapeutic exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic exercise (physical therapy) involves the systematic implementation of planned physical movements, postures, or activities designed to ameliorate impairment, improve function, and enhance overall wellbeing. Patients who have pain that has a musculoskeletal basis may be able to achieve better symptom control and potentially better function, through focused physical therapy that specifically targets the painful region. Improved pain and wellbeing may also result indirectly, presumably due to the physiologic benefits associated with conditioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/61\">",
"     61",
"    </a>",
"    ]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exercise-induced increases in the endogenous endorphins and enkephalins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/62\">",
"     62",
"    </a>",
"    ]. Some other benefits of therapeutic exercise include favorable effects on blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/63\">",
"     63",
"    </a>",
"    ], promotion of muscle strength and flexibility, and improvement in aerobic capacity and hormonal adaptation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In cancer patients, therapists must work with physicians to confirm the safety and appropriateness of exercise, and clarify the specific targets and goals of care. In some cases, exercise will be planned as a time-limited intervention that may ameliorate symptoms and improve function after disease-modifying therapy, such as surgery or chemotherapy. In other situations, including advanced illness, a trial of therapeutic exercise may be considered primarily to reduce symptom distress and improve self-efficacy and quality of life. Regardless of the context, the type, frequency, and duration of exercise should be informed by the performance status of the patient and the overall goals of care. As a patient's illness progresses and overall health declines, the goals of any form of exercise should be expressed clearly to the patient and the family. Input through consultation with a physiatrist and repeated interaction with the oncologist is often needed to ensure that the specific approaches are consistent with the medical status of the patient and the goals of care. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H676924897\">",
"    <span class=\"h3\">",
"     Hydrotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of exercise may be enhanced by hydrotherapy, an approach that is used in disorders, such as rheumatoid arthritis, ankylosing spondylitis, and fibromyalgia, that are characterized by severe pain and impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. Hydrotherapy involves the submersion of a small or large body surface area, usually in a small tank or tub. The water temperature usually does not exceed 40 C, but it can be adjusted depending on the condition being treated and the desired effect.",
"   </p>",
"   <p>",
"    Hydrotherapy provides a reduced-gravity environment that facilitates benefit from physical therapy because of the effect of buoyancy and decreased stress on joints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/68\">",
"     68",
"    </a>",
"    ]. Additionally, hydrotherapy facilitates muscle relaxation and improves overall emotional state. Patients may experience a decrease in the typical pain experienced with movement, and this may enhance both physical and psychological outcomes.",
"   </p>",
"   <p>",
"    Although never systematically studied in patients with cancer-related pain, its potential utility in this population should be considered based upon positive experience in other conditions and very low risk. The appropriateness of hydrotherapy patients with cancer-related pain should be determined after a thorough evaluation conducted by a physical therapist in conjunction with the physician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713467\">",
"    <span class=\"h2\">",
"     Orthoses and other devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pain on movement may benefit from a splint that is designed to limit those motions that incite the pain. In the cancer population, and particularly in the setting of advanced illness, the use of an orthosis may be preferable to other interventions, such as physical therapy, that attempt to improve function. A return to full function may not be possible, or it may not be the primary treatment goal.",
"   </p>",
"   <p>",
"    Examples of orthoses include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immobilizers of the shoulder and arm for a painful brachial plexopathy",
"     </li>",
"     <li>",
"      Corsets for persistent pain after treatment for vertebral metastases",
"     </li>",
"     <li>",
"      Wrist or ankle splints for distal extremity weakness or pain related to neuropathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evaluation by an occupational therapist, with input by the physician, can clarify the availability and cost of various options.",
"   </p>",
"   <p>",
"    Other devices may be considered. Stump pain may be ameliorated by a well-fitting prosthesis, an ambulation aid may reduce pain exacerbation with walking, and devices designed to facilitate specific functions such as toileting or eating can have analgesic consequences or reduce the risk of secondary painful complications related to immobility. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713474\">",
"    <span class=\"h2\">",
"     Physical modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic application of heat or cold, ultrasound, and electrical nerve stimulation to focal sites of pain is widely accepted, although there have been very few studies evaluating short-term efficacy, long-term effectiveness, and safety of these physical modalities in populations with cancer pain, and the evidence in other populations is extremely limited.",
"   </p>",
"   <p>",
"    These modalities may be especially useful as adjuncts for mild to moderate pain and while awaiting the effect of a breakthrough analgesic. They are never adequate alone for managing moderate or severe cancer pain. There are no comparative data to guide suggestions concerning the selection of specific modalities when used as adjunctive treatment for pain, and the choice of technique is empirical. Based on inference and concern about adverse cutaneous effects, guidelines often suggest avoiding the topical application of these stimuli to areas with reduced sensation and those that are directly superficial to tumor masses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23390067\">",
"    <span class=\"h3\">",
"     Cold",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cold application with ice packs, malleable chemical gel packs, and vapocoolant sprays may reduce muscle spasm, inflammation, and edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. The mechanism of action is an initial vasoconstriction, followed by vasodilation. Despite widespread use, there are no controlled studies of cold-induced analgesia for cancer pain. Application of cold should be avoided in ischemic and irradiated tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23390074\">",
"    <span class=\"h3\">",
"     Heat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various superficial and deep heating methods have been applied to control pain and are popular among cancer pain patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/69,73\">",
"     69,73",
"    </a>",
"    ]. Heat is analgesic in part by increasing blood flow and decreasing joint stiffness. It also may induce a state of mental relaxation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/69\">",
"     69",
"    </a>",
"    ]. Superficial heating with hot packs, heating pads, or baths improves cutaneous blood flow and relaxes muscles and ligaments to a depth of 0.5 cm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23390227\">",
"    <span class=\"h3\">",
"     TENS and other electrostimulation devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transcutaneous electrical nerve stimulation (TENS) is widely used, despite insufficient evidence to confirm efficacy in any type of chronic pain, including cancer-related pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Case reports and uncontrolled studies suggest efficacy, although the duration of benefit may be limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/76-78\">",
"     76-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two small randomized trials have been conducted of TENS in patients with cancer pain, neither of which demonstrate benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial investigated acupuncture-like TENS for cancer pain,",
"      <span class=\"nowrap\">",
"       nausea/vomiting,",
"      </span>",
"      or both in 15 terminally ill patients, and compared outcomes with a control group who received a sham TENS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/80\">",
"       80",
"      </a>",
"      ]. TENS was administered for 30 minutes daily for five days. There were no statistically significant differences between the two groups.",
"     </li>",
"     <li>",
"      A second small, randomized, double-blind trial did not identify a benefit from either TENS or transcutaneous spinal electroanalgesia (TSE), compared to sham TSE in 49 women with pain secondary to previous breast cancer treatment (eg, postmastectomy pain syndrome, radiation-induced brachial plexopathy) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/79\">",
"       79",
"      </a>",
"      ]. Subjects received each treatment continuously for three weeks with a one-week washout period. All three procedures resulted in decreased pain and improved quality of life, without clear evidence that TENS or TSE was more effective than sham TSE.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systematic review concluded that there was insufficient evidence to judge whether TENS should be used in adults with cancer-related pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/81\">",
"     81",
"    </a>",
"    ]. Nevertheless, clinical experience suggests that some patients with cancer-related pain benefit from TENS, and TENS is included in the list of potential nonpharmacologic interventions for adult cancer pain in guidelines from the National Comprehensive Cancer Network (NCCN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/82\">",
"     82",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    TENS can be tried during a home trial or as a supervised trial when working with a physical therapist. Given the lack of certainly about the stimulation parameters most likely to help in an individual patient, a serious trial of TENS requires many days and should explore various sites and timing of stimulation, as well as a variety of stimulation parameters (amplitude, frequency, and pattern).",
"   </p>",
"   <p>",
"    Another device (Calmare) that delivers patient-specific electrocutaneous stimulation to the skin has shown promise for treatment of neuropathic pain.&nbsp;The stimulation device, known as which is also referred to as Scrambler Therapy, is different than traditional TENS and has been evaluated in small trials involving patients with chronic non-cancer neuropathic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/83\">",
"     83",
"    </a>",
"    ] and patients with refractory chemotherapy-induced painful peripheral neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/84\">",
"     84",
"    </a>",
"    ]. Based upon these trials, additional studies with this device are warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23390263\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other modalities also may be tried by the therapist after communication with the physician concerning the nature of the pain. Focal musculoskeletal pains are common in patients with cancer and often unrelated to the cancer or its treatment. The use of ultrasound or other modalities may be considered for these pains in the same way that the therapist organizes treatment for myofascial pain unrelated to cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713481\">",
"    <span class=\"h2\">",
"     Lymphedema treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rehabilitative approaches may be appropriate as primary therapy for specific disorders, the pain of which may decline with improvement of the underlying pathology. The best example of this is lymphedema. Lymphedema related to cancer treatment is common and often painful. Rigorous physical therapy protocols for lymphedema include specific education focused on skin care and avoidance of trauma, manual lymph drainage, intermittent pneumatic compression, compression bandaging, and exercises. If the girth in the affected limb can be reduced, patients usually experience a decline in uncomfortable heaviness or stretch, and or in secondary myofascial pains. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33817?source=see_link&amp;anchor=H5#H5\">",
"     \"Prevention and treatment of lymphedema\", section on 'Treatment'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713488\">",
"    <span class=\"h1\">",
"     INTEGRATIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Integrative therapy may be viewed as a care model in which conventional medical approaches are combined with any of a large number of so-called complementary or alternative medicine (CAM) treatments. This strategy is explicitly intended to pursue a holistic course that includes specific objectives, such as pain control, and a broader goal to support the overall quality of life of the patient.",
"   </p>",
"   <p>",
"    Integrative therapy programs are evolving in the United States and are still in a nascent stage; in contrast, many of the specific CAM strategies are very widely used. Among cancer patients, there is great interest in the use of CAM as antitumor therapy, and efforts to evaluate such treatments within the framework of conventional medical evidence are ongoing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/83\">",
"     83",
"    </a>",
"    ]. Rigorous study of these treatments in appropriately designed randomized trials is extremely important to avoid the potential for negative outcomes from the use of treatments that promise to extend life but are without merit, particularly if patients choose these treatments over conventional medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/13/40154?source=see_link&amp;anchor=H2#H2\">",
"     \"Complementary and alternative therapies for cancer\", section on 'Alternative cancer treatments'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with cancer pain commonly seek out CAM therapies. These can be categorized in many ways. However, a system proposed by the National Institutes of Health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/84\">",
"     84",
"    </a>",
"    ] suggests that the many treatments included in this category could be divided as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alternative medical systems, such as Traditional Chinese Medicine (TCM), Ayurveda, homeopathy, and naturopathy",
"     </li>",
"     <li>",
"      Mind-body interventions, such as meditation, hypnosis, dance, music and art therapy, prayer and mental healing",
"     </li>",
"     <li>",
"      Biological-based therapies, such as herbal therapies, specialized diet therapies, orthomolecular nutrition, and individual biological therapies",
"     </li>",
"     <li>",
"      Manipulative and body-based methods, such as massage and chiropractic",
"     </li>",
"     <li>",
"      Energy therapies, such as biofield and bioelectromagnetic-based therapies &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physicians who care for patients with cancer pain should be able to provide meaningful advice about the more common CAM approaches. For some approaches, evidence or experience, combined with a demonstrable safety profile, is sufficient to support a trial, if available and economically feasible for the individual.",
"   </p>",
"   <p>",
"    For other treatments, the evidence to support benefit is nonexistent. If a patient chooses to try a CAM approach that has no known benefit, but is clearly safe, it may be best to be supportive (even while informing the patient that there is no reason to believe that the costs are justified), recognizing that benefits in terms of mood or self-efficacy may occur as a placebo effect.",
"   </p>",
"   <p>",
"    Finally, some treatments, such as spinal manipulation in the setting of bone pain from metastatic disease, or the use of herbal remedies with unknown ingredients, have the potential for harm in the setting of cancer pain, and the physician should strongly recommend against these. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713495\">",
"    <span class=\"h2\">",
"     Mind-body approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described previously, some mind-body therapies are better considered mainstream rather than CAM treatments; relaxation therapy, imagery, hypnosis, and biofeedback should be appreciated as potential adjunctive approaches in many patients with chronic pain. (See",
"    <a class=\"local\" href=\"#H44713418\">",
"     'Mind-body therapies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other mind-body therapies, such as meditation or prayer, are usually categorized as CAM. Although music therapy sometimes considered a CAM therapy, its growing evidence base and widespread acceptance suggests that it, too, would be better classified as a conventional treatment with wide potential use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713502\">",
"    <span class=\"h3\">",
"     Meditation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although religious forms of mediation have been practiced for thousands of years, meditation has only recently received significant research attention as a medical intervention in Western culture. Meditation forms can be classified as concentrative or non-concentrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concentrative techniques limit stimuli input by instructing the patient to focus attention on a single unchanging or repetitive stimulus (eg, sound, breathing, focal point). If the patient's attention wanders, he or she is directed to bring the attention gently back to the focal object.",
"     </li>",
"     <li>",
"      Non-concentrative techniques expand the patients' attention to include the observation, in a non-judgmental way, of one's mental activities and thoughts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Though fundamentally a secular activity, meditation is still associated with religious significance for many. Nonetheless, there is an increasing focus on spiritual, non-religious aspects of meditation by emphasizing concepts of communion with nature, universal connection, and compassionate love.",
"   </p>",
"   <p>",
"    Benefits associated with meditation include an improved sense of relaxation and lower levels of perceived stress, more positive thinking, self-confidence, compassion, and tolerance of oneself and others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/85\">",
"     85",
"    </a>",
"    ]. However, adverse events may also occur. In a study of a small group of meditators, participants reported a 63 percent incidence of at least one adverse event, which included disorientation, confusion, depression, increased awareness of one's negative qualities and emotions, increased fears and anxiety, boredom, and pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713509\">",
"    <span class=\"h3\">",
"     Music therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Music therapy attempts to ameliorate physical and emotional distress through the use of music. Music can improve distress caused by pain, decrease muscle tension and promote relaxation, decrease anxiety, improve chemotherapy-related nausea and emesis, and improve overall mood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/87-89\">",
"     87-89",
"    </a>",
"    ]. Music therapy can also help manage postoperative nausea and vomiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two systematic reviews of music for pain relief concluded that music therapy reduces pain intensity levels and opioid requirements by a small amount [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. However, in a later study, music therapy had a statistically significant effect on anxiety, perception of hospitalization or procedure, relaxation and stress levels in brain tumor patients undergoing surgery, but it had no impact on pain levels or mood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If feasible, the use of music in treatment areas and hospital rooms may help to improve mood and decrease anxiety in cancer patients. Additionally, introducing structured music therapy sessions into individual patient's treatment may improve a number of quality of life indicators. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713516\">",
"    <span class=\"h2\">",
"     Biofield therapies: Reiki and therapeutic touch",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Institutes of Health Center for Complementary and Alternative Medicine (NCCAM) classifies Reiki as a biofield modality &ldquo;that involves touch or placement of the hands in or through a biofield, the existence of which has not been scientifically proven&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/94\">",
"     94",
"    </a>",
"    ]. Reiki is often classified as a form of energy healing; it has received increasing interest in clinical and research settings and is becoming more commonplace in the context of cancer treatment, palliative care, and hospice.",
"   </p>",
"   <p>",
"    In the only randomized trial to address the benefit of Reiki for cancer pain, 24 patients with cancer pain received either standard opioid therapy plus rest or opioid therapy plus two Reiki treatments one hour after their first afternoon analgesic dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/95\">",
"     95",
"    </a>",
"    ]. Reiki plus opioids significantly reduced pain immediately after treatment compared to pretreatment baseline, but the use of reiki did not significantly reduce opioid use. Furthermore, the study was terminated prematurely because of the unwillingness of patients to be randomly assigned to the control arm.",
"   </p>",
"   <p>",
"    Other data suggest that Reiki can reduce stress and induce a relaxation response, which may be therapeutic in a manner similar to mind-body interventions. A study of 30 HIV patients suffering from an array of disease-related symptoms who were trained to practice first degree Reiki healing reported reductions in pain and anxiety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/96\">",
"     96",
"    </a>",
"    ]. However, these observations cannot establish efficacy and should not be taken to suggest a specific mode of action.",
"   </p>",
"   <p>",
"    Therapeutic touch is defined as an &ldquo;intentionally directed process of energy modulation during which the practitioner uses the hands as a focus to facilitate healing&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/97\">",
"     97",
"    </a>",
"    ]. Like Reiki, there is no evidence to support the physiologic implications of this definition. In a randomized controlled study, experienced practitioners were unable to detect the investigators' &ldquo;energy field&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/98\">",
"     98",
"    </a>",
"    ]. The authors concluded that this provided evidence that the beneficial claims associated with therapeutic touch are groundless.",
"   </p>",
"   <p>",
"    Nonetheless, some observations demonstrate that cancer patients may perceive benefit when this approach is tried [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. A single randomized trial evaluating therapeutic massage also assessed healing touch as an intervention for symptom control in patients with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/101\">",
"     101",
"    </a>",
"    ]. This study included 230 subjects with cancer pain who were randomly assigned to therapeutic massage, healing touch, presence alone, or standard care. Healing touch did provide immediate pain reduction compared to the pretreatment baseline, but did not reduce pain over the four weeks of the intervention.",
"   </p>",
"   <p>",
"    A Cochrane review (which was not limited to studies conducted in cancer patients) concluded that touch therapies such as Reiki and therapeutic touch may have a modest effect in pain relief, but that more studies are needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the current state of the literature, the biofield therapies should be understood as non-evidence-based, possibly yielding positive responses from non-specific relaxation responses or placebo effects. Nevertheless, it seems unquestionable that many patients perceive benefit, and if practitioners are available, and the cost is affordable, there is no reason to discourage patients with cancer pain from trying these interventions. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713523\">",
"    <span class=\"h2\">",
"     Manual interventions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H676926816\">",
"    <span class=\"h3\">",
"     Massage therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Massage therapy has been used as a form of medical therapy since ancient times. Some of the earliest references are found in ancient Chinese medical texts. The Yellow Emperor's Classic of Internal Medicine, written more than 2500 years ago and believed to be the first book on Chinese medicine, includes information on Tuina, an ancient form of massage, and acupressure (applied finger pressure to points that are putatively sensitized by organ impairment) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Massage is defined as the systematic manipulation of the soft tissues of the body to enhance health and healing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/104\">",
"     104",
"    </a>",
"    ]. It includes a group of manual techniques that include applying fixed or movable pressure. The primary characteristics are the application of touch and movement.",
"   </p>",
"   <p>",
"    Although studies have been done in adult and pediatric patients with either limited or advanced cancer that suggest at least temporary benefit for pain, other symptoms and mood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/105-109\">",
"     105-109",
"    </a>",
"    ], others do not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/101,110,111\">",
"     101,110,111",
"    </a>",
"    ], and methodological limitations preclude definitive conclusions about these outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/29,112\">",
"     29,112",
"    </a>",
"    ]. Nevertheless, collective experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/107\">",
"     107",
"    </a>",
"    ], combined with demonstrable effects on massaged tissues that suggest the potential for a specific mode of action, provide a rationale for the wide acceptance of this technique in pain management. In the cancer population, however, caution must be applied to reduce any potential for risk associated with massage of tissues that may be denervated by nerve injury, or prone to damage due to the direct effects of a neoplasm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713530\">",
"    <span class=\"h3\">",
"     Acupuncture and acupoint stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over a decade ago, the National Institutes of Health (NIH) and Food and Drug Administration (FDA) declared in a consensus statement that acupuncture is not an experimental therapy but a sound medical technique comparable in effectiveness to common conventional medical treatments for certain clinical conditions, such as nausea and pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/113\">",
"     113",
"    </a>",
"    ]. However, the effectiveness of acupuncture for patients with cancer pain remains uncertain. Although some studies have suggested that acupuncture can be useful in ameliorating cancer-related pain, [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/114-117\">",
"     114-117",
"    </a>",
"    ], there is a paucity of well-conducted rigorous trials that include a sham acupuncture control group, which is necessary because of the strong placebo effect of both acupuncture and sham acupuncture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/29,115,118\">",
"     29,115,118",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/50/28457?source=see_link&amp;anchor=H21#H21\">",
"     \"Acupuncture\", section on 'Low back pain'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/13/40154?source=see_link&amp;anchor=H27#H27\">",
"     \"Complementary and alternative therapies for cancer\", section on 'Acupuncture and related therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A single randomized trial of 90 patients with cancer pain that included a sham acupuncture control group concluded that auricular acupuncture significantly reduced pain intensity relative to sham acupuncture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/116\">",
"     116",
"    </a>",
"    ]. However, a 2011 Cochrane review of this and two other randomized controlled trials of acupuncture (neither of which had a sham acupuncture control group) totaling 204 patients with cancer pain concluded that there was insufficient evidence to judge whether acupuncture was effective in treating cancer pain in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/119\">",
"     119",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    More well designed trials using rigorous methodology are required to evaluate the effectiveness of acupuncture techniques. Nonetheless, the existing data suggest that acupuncture might be effective for some patients with cancer pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/114\">",
"     114",
"    </a>",
"    ]. When used for pain, a reasonable approach would be to recommend no more than several sessions to judge benefit. If pain does not respond, or as it does in a small proportion of patients, appears to worsen, treatment should be discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713537\">",
"    <span class=\"h2\">",
"     Homeopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Derived from the Greek words Homoios, &ldquo;similar&rdquo; and Pathos, &ldquo;suffering&rdquo;, homeopathy was founded by the German physician Samuel Hahnemann in the 1790s. It is based on the premise that cure can result from stimulation of the body's natural healing abilities. This is achieved by introducing into the body a substance that, in a healthy person, can induce symptoms that are identical to the symptoms of the disease. The philosophical foundations of homeopathy can be found in Hippocrates' teachings of the Law of Similars, or &ldquo;like cures like&rdquo;. Homeopathic remedies are dilutions of substances that are derived from plants, minerals, and animals; patients are prescribed the remedies that most closely match their symptom profile. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/17/26903?source=see_link\">",
"     \"Homeopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One case report series and two prospective observational studies found that homeopathy was helpful in controlling posttreatment pain and radiation-induced itching, and in relieving adverse affects associated with estrogen withdrawal in breast cancer patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/120-122\">",
"     120-122",
"    </a>",
"    ]. However, in a systematic review of six trials in which homeopathy was used as a sole or additional treatment in cancer care found that methodologic quality was variable and the evidence was insufficient to support its use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/26/32170/abstract/123\">",
"     123",
"    </a>",
"    ]. At this point, the therapy must be considered non-evidence based, unlikely to cause harm, but with outcomes that may be nonspecific or related to placebo effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/36/579?source=see_link\">",
"       \"Patient information: Managing pain when you have cancer (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/33/25105?source=see_link\">",
"       \"Patient information: Alternative medicine (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/51/21300?source=see_link\">",
"       \"Patient information: Complementary and alternative medicine treatments (CAM) for cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44713544\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse effects of cancer pain are complex and highly individual. In some cases, distress is related to the associated mood effects or functional impairments that occur as a result of uncontrolled pain. In other cases, it is the meaning that is attributed to pain (eg, that it implies progression of malignant disease) that drives suffering. Given the multidimensional nature of pain, a diverse array of interventions may provide benefit. (See",
"    <a class=\"local\" href=\"#H44713397\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is a broad consensus that patients with moderate to severe chronic cancer pain should receive opioid-based pharmacotherapy. Outcomes related to the pain, and to pain-related impairment of mood and function may be enhanced by the adjunctive use of non-invasive psychological, rehabilitative, and integrative therapies. Such nonpharmacologic strategies may provide satisfactory pain relief with fewer drug side effects,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    better outcomes with regard to physical and psychosocial functioning.",
"   </p>",
"   <p>",
"    Data from randomized trials and meta-analyses support the utility of psychosocial interventions as a component of multimodality treatment of cancer related pain. Potentially beneficial psychological strategies include cognitive-behavioral interventions and mind-body therapies (relaxation, imagery, hypnosis and biofeedback). (See",
"    <a class=\"local\" href=\"#H44713404\">",
"     'Psychological approaches'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Rehabilitative and physical medicine approaches include therapeutic exercise (physical therapy), the use of orthoses and other assistive devices, and physical modalities such as application of cold, heat, or transcutaneous electrical nerve stimulation (TENS). (See",
"    <a class=\"local\" href=\"#H44713453\">",
"     'Rehabilitation and physical medicine interventions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Integrative (complementary) therapies that may provide benefit include meditation, music therapy, biofield therapies (Reiki and therapeutic touch), massage therapy, and possibly, acupuncture. (See",
"    <a class=\"local\" href=\"#H44713488\">",
"     'Integrative therapies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is insufficient evidence to recommend any of these therapies for chronic cancer pain. However, patients may perceive some benefit from these and other physical, rehabilitative, and integrative therapies, and there are few, if any, harms for most therapies. Clinicians should be aware of these strategies, know which are available in the community, and consider referral when patients may be able to benefit.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/1\">",
"      Daut RL, Cleeland CS. The prevalence and severity of pain in cancer. Cancer 1982; 50:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/2\">",
"      van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007; 18:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/3\">",
"      Tatrow K, Montgomery GH. Cognitive behavioral therapy techniques for distress and pain in breast cancer patients: a meta-analysis. J Behav Med 2006; 29:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/4\">",
"      Sheinfeld Gorin S, Krebs P, Badr H, et al. Meta-analysis of psychosocial interventions to reduce pain in patients with cancer. J Clin Oncol 2012; 30:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/5\">",
"      Bennett MI, Bagnall AM, Jos&eacute; Closs S. How effective are patient-based educational interventions in the management of cancer pain? Systematic review and meta-analysis. Pain 2009; 143:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/6\">",
"      Devine EC. Meta-analysis of the effect of psychoeducational interventions on pain in adults with cancer. Oncol Nurs Forum 2003; 30:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/7\">",
"      Luebbert K, Dahme B, Hasenbring M. The effectiveness of relaxation training in reducing treatment-related symptoms and improving emotional adjustment in acute non-surgical cancer treatment: a meta-analytical review. Psychooncology 2001; 10:490.",
"     </a>",
"    </li>",
"    <li>",
"     Keefe, FJ, Abernethy, AP, Porter, LS, et al. Non-pharmacologic management of pain. In: Palliative and Supportive Oncology, Berger, AM, Shuster, JL, Roenn, JH (Eds), Lippincott Williams &amp; Wilkins, New York 2006. p.67-74.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/9\">",
"      Keefe FJ, Rumble ME, Scipio CD, et al. Psychological aspects of persistent pain: current state of the science. J Pain 2004; 5:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/10\">",
"      Arntz A, Dreessen L, De Jong P. The influence of anxiety on pain: attentional and attributional mediators. Pain 1994; 56:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/11\">",
"      Porter LS, Keefe FJ, Garst J, et al. Self-efficacy for managing pain, symptoms, and function in patients with lung cancer and their informal caregivers: associations with symptoms and distress. Pain 2008; 137:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/12\">",
"      Keefe FJ, Ahles TA, Porter LS, et al. The self-efficacy of family caregivers for helping cancer patients manage pain at end-of-life. Pain 2003; 103:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/13\">",
"      Cook AJ, Degood DE. The cognitive risk profile for pain: development of a self-report inventory for identifying beliefs and attitudes that interfere with pain management. Clin J Pain 2006; 22:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/14\">",
"      Fernandez E, Turk DC. The utility of cognitive coping strategies for altering pain perception: a meta-analysis. Pain 1989; 38:123.",
"     </a>",
"    </li>",
"    <li>",
"     Porter LS, Baucom DH, Gremore TM, et al. Couples and breast cancer: a pilot study of a couple-based cognitive-behavioral intervention. Poster presented at the American Psycho-oncology Society Annual Meeting. Austin, Texas, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/16\">",
"      McCracken LM, Turk DC. Behavioral and cognitive-behavioral treatment for chronic pain: outcome, predictors of outcome, and treatment process. Spine (Phila Pa 1976) 2002; 27:2564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/17\">",
"      Turk DC. Cognitive-behavioral approach to the treatment of chronic pain patients. Reg Anesth Pain Med 2003; 28:573.",
"     </a>",
"    </li>",
"    <li>",
"     Thorn BE. Cognitive therapy for chronic pain, Guilford, New York 2004.",
"    </li>",
"    <li>",
"     Eimer BN, Freeman A. Pain management psychotherapy: a practical guide, Wiley, New York 1998.",
"    </li>",
"    <li>",
"     Enhanced cognitive-behavioral therapy for couples: a contextual approach, Epstein NB, Baucom DH (Eds), Psychological Association, Washington DC 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/21\">",
"      Vlaeyen JW, Morley S. Cognitive-behavioral treatments for chronic pain: what works for whom? Clin J Pain 2005; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/22\">",
"      Berglund G, Bolund C, Gustafsson UL, Sj&ouml;d&eacute;n PO. One-year follow-up of the 'Starting Again' group rehabilitation programme for cancer patients. Eur J Cancer 1994; 30A:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/23\">",
"      Dalton JA, Keefe FJ, Carlson J, Youngblood R. Tailoring cognitive-behavioral treatment for cancer pain. Pain Manag Nurs 2004; 5:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/24\">",
"      Arathuzik D. Effects of cognitive-behavioral strategies on pain in cancer patients. Cancer Nurs 1994; 17:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/25\">",
"      Gaston-Johansson F, Fall-Dickson JM, Nanda J, et al. The effectiveness of the comprehensive coping strategy program on clinical outcomes in breast cancer autologous bone marrow transplantation. Cancer Nurs 2000; 23:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/26\">",
"      Integration of behavioral and relaxation approaches into the treatment of chronic pain and insomnia. NIH Technology Assessment Panel on Integration of Behavioral and Relaxation Approaches into the Treatment of Chronic Pain and Insomnia. JAMA 1996; 276:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/27\">",
"      Syrjala KL, Cummings C, Donaldson GW. Hypnosis or cognitive behavioral training for the reduction of pain and nausea during cancer treatment: a controlled clinical trial. Pain 1992; 48:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/28\">",
"      Syrjala KL, Donaldson GW, Davis MW, et al. Relaxation and imagery and cognitive-behavioral training reduce pain during cancer treatment: a controlled clinical trial. Pain 1995; 63:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/29\">",
"      Bardia A, Barton DL, Prokop LJ, et al. Efficacy of complementary and alternative medicine therapies in relieving cancer pain: a systematic review. J Clin Oncol 2006; 24:5457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/30\">",
"      Jacobsen R, Edinger JD. Side effects of relaxation treatment. Am J Psychiatry 1982; 139:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/31\">",
"      Adler CM, Craske MG, Barlow DH. Relaxation-induced panic [RIP]. When resting isn't peaceful. Integr Psychiatry 1987; 5:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/32\">",
"      Bordeleau L, Szalai JP, Ennis M, et al. Quality of life in a randomized trial of group psychosocial support in metastatic breast cancer: overall effects of the intervention and an exploration of missing data. J Clin Oncol 2003; 21:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/33\">",
"      Sloman R, Brown P, Aldana E, Chee E. The use of relaxation for the promotion of comfort and pain relief in persons with advanced cancer. Contemp Nurse 1994; 3:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/34\">",
"      Anderson KO, Cohen MZ, Mendoza TR, et al. Brief cognitive-behavioral audiotape interventions for cancer-related pain: Immediate but not long-term effectiveness. Cancer 2006; 107:207.",
"     </a>",
"    </li>",
"    <li>",
"     Achterberg J. Imagery in healing: shamanism and modern medicine, Shambala, Boston 1985.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/36\">",
"      Roffe L, Schmidt K, Ernst E. A systematic review of guided imagery as an adjuvant cancer therapy. Psychooncology 2005; 14:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/37\">",
"      Lee R. Guided imagery as supportive therapy in cancer treatment. Alternative Medicine 1999; 2:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/38\">",
"      Gatlin CG, Schulmeister L. When medication is not enough: nonpharmacologic management of pain. Clin J Oncol Nurs 2007; 11:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/39\">",
"      N&eacute;ron S, Stephenson R. Effectiveness of hypnotherapy with cancer patients' trajectory: emesis, acute pain, and analgesia and anxiolysis in procedures. Int J Clin Exp Hypn 2007; 55:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/40\">",
"      Elkins G, Jensen MP, Patterson DR. Hypnotherapy for the management of chronic pain. Int J Clin Exp Hypn 2007; 55:275.",
"     </a>",
"    </li>",
"    <li>",
"     Pepe MM. The Penn State scale of hypnotizability: Unpublished doctoral dissertation, The Pennsylvania State University, The Pennsylvania State University.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/42\">",
"      Morgan AH, Hilgard JR. The Stanford Hypnotic Clinical Scale for adults. Am J Clin Hypn 1978; 21:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/43\">",
"      Graffin NF, Ray WJ, Lundy R. EEG concomitants of hypnosis and hypnotic susceptibility. J Abnorm Psychol 1995; 104:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/44\">",
"      Kihlstrom JF. Hypnosis. Annu Rev Psychol 1985; 36:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/45\">",
"      Schnur JB, Montgomery GH. Hypnosis and cognitive-behavioral therapy during breast cancer radiotherapy: a case report. Am J Clin Hypn 2008; 50:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/46\">",
"      Carlson LE, Bultz BD. Mind-body interventions in oncology. Curr Treat Options Oncol 2008; 9:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/47\">",
"      Flory N, Lang E. Practical hypnotic interventions during invasive cancer diagnosis and treatment. Hematol Oncol Clin North Am 2008; 22:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/48\">",
"      Schnur JB, Bovbjerg DH, David D, et al. Hypnosis decreases presurgical distress in excisional breast biopsy patients. Anesth Analg 2008; 106:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/49\">",
"      Montgomery GH, Hallquist MN, Schnur JB, et al. Mediators of a brief hypnosis intervention to control side effects in breast surgery patients: response expectancies and emotional distress. J Consult Clin Psychol 2010; 78:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/50\">",
"      Kwekkeboom KL, Cherwin CH, Lee JW, Wanta B. Mind-body treatments for the pain-fatigue-sleep disturbance symptom cluster in persons with cancer. J Pain Symptom Manage 2010; 39:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/51\">",
"      Montgomery GH, Kangas M, David D, et al. Fatigue during breast cancer radiotherapy: an initial randomized study of cognitive-behavioral therapy plus hypnosis. Health Psychol 2009; 28:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/52\">",
"      Spiegel D, Bloom JR. Group therapy and hypnosis reduce metastatic breast carcinoma pain. Psychosom Med 1983; 45:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/53\">",
"      Montgomery GH, Bovbjerg DH, Schnur JB, et al. A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients. J Natl Cancer Inst 2007; 99:1304.",
"     </a>",
"    </li>",
"    <li>",
"     Basmaijan JV. Biofeedback: principles and practice for clinicians, Williams and Wilkins, Baltimore 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/55\">",
"      Astin JA. Mind-body therapies for the management of pain. Clin J Pain 2004; 20:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/56\">",
"      Astin JA, Shapiro SL, Eisenberg DM, Forys KL. Mind-body medicine: state of the science, implications for practice. J Am Board Fam Pract 2003; 16:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/57\">",
"      Spiegel D. Facilitating emotional coping during treatment. Cancer 1990; 66:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/58\">",
"      Neblett R, Mayer TG, Gatchel RJ. Theory and rationale for surface EMG-assisted stretching as an adjunct to chronic musculoskeletal pain rehabilitation. Appl Psychophysiol Biofeedback 2003; 28:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/59\">",
"      Cram JR. Surface EMG recordings and pain-related disorders: a diagnostic framework. Biofeedback Self Regul 1988; 13:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/60\">",
"      Tsai PS, Chen PL, Lai YL, et al. Effects of electromyography biofeedback-assisted relaxation on pain in patients with advanced cancer in a palliative care unit. Cancer Nurs 2007; 30:347.",
"     </a>",
"    </li>",
"    <li>",
"     Hoffman MD, Sheldahl LM, Kraemer WJ. Therapeutic exercise. In: Physical Medicine and Rehabilitation - Principles and Practice, 4th, DeLisa JA, Gans BM (Eds), Lippincott, Williams and Wilkins, Philadelphia 2005. Vol 1, p.398.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/62\">",
"      Farrell PA, Gates WK, Maksud MG, Morgan WP. Increases in plasma beta-endorphin/beta-lipotropin immunoreactivity after treadmill running in humans. J Appl Physiol 1982; 52:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/63\">",
"      Fagard RH. Exercise characteristics and the blood pressure response to dynamic physical training. Med Sci Sports Exerc 2001; 33:S484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/64\">",
"      Folland JP, Williams AG. The adaptations to strength training : morphological and neurological contributions to increased strength. Sports Med 2007; 37:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/65\">",
"      Hall J, Skevington SM, Maddison PJ, Chapman K. A randomized and controlled trial of hydrotherapy in rheumatoid arthritis. Arthritis Care Res 1996; 9:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/66\">",
"      Evcik D, Yigit I, Pusak H, Kavuncu V. Effectiveness of aquatic therapy in the treatment of fibromyalgia syndrome: a randomized controlled open study. Rheumatol Int 2008; 28:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/67\">",
"      Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2008; :CD002822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/68\">",
"      Konlian C. Aquatic therapy: making a wave in the treatment of low back injuries. Orthop Nurs 1999; 18:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/69\">",
"      Rhiner M, Ferrell BR, Ferrell BA, Grant MM. A structured nondrug intervention program for cancer pain. Cancer Pract 1993; 1:137.",
"     </a>",
"    </li>",
"    <li>",
"     Lehmann JF, deLateur BJ. Ultrasound shortwave, microwave, laser, superficial heat, and cold in the treatment of pain. In: Textbook of Pain, Wall PD, Melzack R (Eds), Churchill Livingstone, Edinburgh 1994. p.1237.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/71\">",
"      Ernst E, Fialka V. Ice freezes pain? A review of the clinical effectiveness of analgesic cold therapy. J Pain Symptom Manage 1994; 9:56.",
"     </a>",
"    </li>",
"    <li>",
"     Jacox A, Carr DB, Payne R, et al. Management of Cancer Pain. Clinical Practice Guideline No. 9. AHCPR Publication No. 94-0592. Rockville, MD. Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, Public Health Service, March 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/73\">",
"      Barbour LA, McGuire DB, Kirchhoff KT. Nonanalgesic methods of pain control used by cancer outpatients. Oncol Nurs Forum 1986; 13:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/74\">",
"      Nnoaham KE, Kumbang J. Transcutaneous electrical nerve stimulation (TENS) for chronic pain. Cochrane Database Syst Rev 2008; :CD003222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/75\">",
"      Hurlow A, Bennett MI, Robb KA, et al. Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults. Cochrane Database Syst Rev 2012; 3:CD006276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/76\">",
"      Avellanosa AM, West CR. Experience with transcutaneous electrical nerve stimulation for relief of intractable pain in cancer patients. J Med 1982; 13:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/77\">",
"      Avellanosa AM, West CR. Experience with transcutaneous electrical nerve stimulation for relief of intractable pain in cancer patients. J Med 1982; 13:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/78\">",
"      Ostrowski MJ. Pain control in advanced malignant disease using transcutaneous nerve stimulation. Br J Clin Pract 1979; 33:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/79\">",
"      Robb KA, Newham DJ, Williams JE. Transcutaneous electrical nerve stimulation vs. transcutaneous spinal electroanalgesia for chronic pain associated with breast cancer treatments. J Pain Symptom Manage 2007; 33:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/80\">",
"      Gadsby JG, Franks A, Jarvis P, et AL. Acupuncture-like transcutaneous electrical nerve stimulation within palliative care: a pilot study. Complement Ther Med 1997; 5:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/81\">",
"      Robb K, Oxberry SG, Bennett MI, et al. A cochrane systematic review of transcutaneous electrical nerve stimulation for cancer pain. J Pain Symptom Manage 2009; 37:746.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines available online at  www.nccn.org.",
"    </li>",
"    <li>",
"     Memorial Sloan Kettering Cancer Center, Integrative Medicine Service file://www.mskcc.org/mskcc/html/1979.cfm (Accessed on February 21, 2012).",
"    </li>",
"    <li>",
"     The Institute for Alternative and Complementary Medicine file://shrp.umdnj.edu/programs/ICAM/ (Accessed on February 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/85\">",
"      Shapiro DH Jr. Overview: clinical and physiological comparison of meditation with other self-control strategies. Am J Psychiatry 1982; 139:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/86\">",
"      Shapiro DH Jr. Adverse effects of meditation: a preliminary investigation of long-term meditators. Int J Psychosom 1992; 39:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/87\">",
"      Siedliecki SL, Good M. Effect of music on power, pain, depression and disability. J Adv Nurs 2006; 54:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/88\">",
"      Standley J. Clinical application of music therapy and chemotherapy: the effects on nausea and emesis. Music Ther Perspect 1992; 9:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/89\">",
"      Zimmerman L, Pozehl B, Duncan K, Schmitz R. Effects of music in patients who had chronic cancer pain. West J Nurs Res 1989; 11:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/90\">",
"      Thompson HJ. The management of post-operative nausea and vomiting. J Adv Nurs 1999; 29:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/91\">",
"      Cepeda MS, Carr DB, Lau J, Alvarez H. Music for pain relief. Cochrane Database Syst Rev 2006; :CD004843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/92\">",
"      Igawa-Silva W, Wu S, Harrigan R. Music and cancer pain management. Hawaii Med J 2007; 66:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/93\">",
"      Walworth D, Rumana CS, Nguyen J, Jarred J. Effects of live music therapy sessions on quality of life indicators, medications administered and hospital length of stay for patients undergoing elective surgical procedures for brain. J Music Ther 2008; 45:349.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Center for Complementary and Alternative Medicine (NCCAM) file://nccam.nih.gov (Accessed on February 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/95\">",
"      Olson K, Hanson J, Michaud M. A phase II trial of Reiki for the management of pain in advanced cancer patients. J Pain Symptom Manage 2003; 26:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/96\">",
"      Miles P. Preliminary report on the use of Reiki HIV-related pain and anxiety. Altern Ther Health Med 2003; 9:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/97\">",
"      Mulloney SS, Wells-Federman C. Therapeutic touch: a healing modality. J Cardiovasc Nurs 1996; 10:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/98\">",
"      Rosa L, Rosa E, Sarner L, Barrett S. A close look at therapeutic touch. JAMA 1998; 279:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/99\">",
"      Simington JA, Laing GP. Effects of therapeutic touch on anxiety in the institutionalized elderly. Clin Nurs Res 1993; 2:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/100\">",
"      Turner JG, Clark AJ, Gauthier DK, Williams M. The effect of therapeutic touch on pain and anxiety in burn patients. J Adv Nurs 1998; 28:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/101\">",
"      Post-White J, Kinney ME, Savik K, et al. Therapeutic massage and healing touch improve symptoms in cancer. Integr Cancer Ther 2003; 2:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/102\">",
"      So PS, Jiang Y, Qin Y. Touch therapies for pain relief in adults. Cochrane Database Syst Rev 2008; :CD006535.",
"     </a>",
"    </li>",
"    <li>",
"     Monte T. World medicine: the East and West guide to healing your body, Putnam, New York 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/104\">",
"      Goats GC, Keir KA. Connective tissue massage. Br J Sports Med 1991; 25:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/105\">",
"      Ferrell-Torry AT, Glick OJ. The use of therapeutic massage as a nursing intervention to modify anxiety and the perception of cancer pain. Cancer Nurs 1993; 16:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/106\">",
"      Weinrich SP, Weinrich MC. The effect of massage on pain in cancer patients. Appl Nurs Res 1990; 3:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/107\">",
"      Cassileth BR, Vickers AJ. Massage therapy for symptom control: outcome study at a major cancer center. J Pain Symptom Manage 2004; 28:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/108\">",
"      Listing M, Reisshauer A, Krohn M, et al. Massage therapy reduces physical discomfort and improves mood disturbances in women with breast cancer. Psychooncology 2009; 18:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/109\">",
"      Kutner JS, Smith MC, Corbin L, et al. Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer: a randomized trial. Ann Intern Med 2008; 149:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/110\">",
"      Wilkie DJ, Kampbell J, Cutshall S, et al. Effects of massage on pain intensity, analgesics and quality of life in patients with cancer pain: a pilot study of a randomized clinical trial conducted within hospice care delivery. Hosp J 2000; 15:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/111\">",
"      Sturgeon M, Wetta-Hall R, Hart T, et al. Effects of therapeutic massage on the quality of life among patients with breast cancer during treatment. J Altern Complement Med 2009; 15:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/112\">",
"      Ernst E. Massage therapy for cancer palliation and supportive care: a systematic review of randomised clinical trials. Support Care Cancer 2009; 17:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/113\">",
"      Park J, Linde K, Manheimer E, et al. The status and future of acupuncture clinical research. J Altern Complement Med 2008; 14:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/114\">",
"      Standish LJ, Kozak L, Congdon S. Acupuncture is underutilized in hospice and palliative medicine. Am J Hosp Palliat Care 2008; 25:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/115\">",
"      Lu W, Dean-Clower E, Doherty-Gilman A, Rosenthal DS. The value of acupuncture in cancer care. Hematol Oncol Clin North Am 2008; 22:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/116\">",
"      Alimi D, Rubino C, Pichard-L&eacute;andri E, et al. Analgesic effect of auricular acupuncture for cancer pain: a randomized, blinded, controlled trial. J Clin Oncol 2003; 21:4120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/117\">",
"      Dang W, Yang J. Clinical study on acupuncture treatment of stomach carcinoma pain. J Tradit Chin Med 1998; 18:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/118\">",
"      Lee H, Schmidt K, Ernst E. Acupuncture for the relief of cancer-related pain--a systematic review. Eur J Pain 2005; 9:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/119\">",
"      Paley CA, Johnson MI, Tashani OA, Bagnall AM. Acupuncture for cancer pain in adults. Cochrane Database Syst Rev 2011; :CD007753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/120\">",
"      Schlappack O. Homeopathic treatment of radiation-induced itching in breast cancer patients. A prospective observational study. Homeopathy 2004; 93:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/121\">",
"      Thompson EA, Reilly D. The homeopathic approach to the treatment of symptoms of oestrogen withdrawal in breast cancer patients. A prospective observational study. Homeopathy 2003; 92:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/122\">",
"      Orellana Alvarellos G, Ruiz de Vi&ntilde;aspre Alvear P, Kaszkin-Bettag M. A series of case reports: clinical evaluation of a complex homeopathic injection therapy in the management of pain in patients after breast cancer treatment. Altern Ther Health Med 2010; 16:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/26/32170/abstract/123\">",
"      Milazzo S, Russell N, Ernst E. Efficacy of homeopathic therapy in cancer treatment. Eur J Cancer 2006; 42:282.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14249 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-4C9EBFD82E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_26_32170=[""].join("\n");
var outline_f31_26_32170=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H44713544\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44713397\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44713404\">",
"      PSYCHOLOGICAL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44713411\">",
"      Cognitive-behavioral interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44713418\">",
"      Mind-body therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44713425\">",
"      - Relaxation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44713432\">",
"      - Imagery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44713439\">",
"      - Hypnotic analgesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44713446\">",
"      - Biofeedback",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44713453\">",
"      REHABILITATION AND PHYSICAL MEDICINE INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44713460\">",
"      Therapeutic exercise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H676924897\">",
"      - Hydrotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44713467\">",
"      Orthoses and other devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44713474\">",
"      Physical modalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23390067\">",
"      - Cold",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23390074\">",
"      - Heat",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23390227\">",
"      - TENS and other electrostimulation devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23390263\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44713481\">",
"      Lymphedema treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44713488\">",
"      INTEGRATIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44713495\">",
"      Mind-body approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44713502\">",
"      - Meditation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44713509\">",
"      - Music therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44713516\">",
"      Biofield therapies: Reiki and therapeutic touch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44713523\">",
"      Manual interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H676926816\">",
"      - Massage therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44713530\">",
"      - Acupuncture and acupoint stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44713537\">",
"      Homeopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44713544\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/14249\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/14249|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/31/43515\" title=\"table 1\">",
"      Dysfunc cog styles",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/50/28457?source=related_link\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=related_link\">",
"      Cancer pain management: General principles and risk management for patients receiving opioids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=related_link\">",
"      Cancer pain management: Interventional therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/13/40154?source=related_link\">",
"      Complementary and alternative therapies for cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/17/26903?source=related_link\">",
"      Homeopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/33/25105?source=related_link\">",
"      Patient information: Alternative medicine (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/51/21300?source=related_link\">",
"      Patient information: Complementary and alternative medicine treatments (CAM) for cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33817?source=related_link\">",
"      Prevention and treatment of lymphedema",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_26_32171="Pathogens following BMT-III";
var content_f31_26_32171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pathogens likely to cause infections in bone marrow/stem cell transplant recipients not receiving standard prophylaxis-III",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Late postengraftment (allogeneic BMT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Encapsulated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        S. pneumoniae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Haemophilus influenzae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Neisseria meningitidis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Klebsiella spp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        S. aureus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        P. aeruginosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Fungi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Same as for the preengraftment period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Varicella zoster virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epstein Barr virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Respiratory viruses (Same as for the preengraftment period)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Protozoa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        P. carinii",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_26_32171=[""].join("\n");
var outline_f31_26_32171=null;
var title_f31_26_32172="Lumbosacral radiculopathy";
var content_f31_26_32172=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Likelihood ratios for lumbosacral radiculopathy, in patients with sciatica*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Finding&bull;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sensitivity, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specificity, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Positive LR",
"       </td>",
"       <td class=\"subtitle1\">",
"        Negative LR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Motor examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Weak ankle dorsiflexion",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        4.9",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ipsilateral calf wasting",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        5.2",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Sensory examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leg sensation abnormal",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        NS",
"       </td>",
"       <td>",
"        NS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Reflex examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abnormal ankle jerk",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        4.3",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Other tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Straight-leg raising maneuver",
"       </td>",
"       <td>",
"        73-98",
"       </td>",
"       <td>",
"        11-61",
"       </td>",
"       <td>",
"        NS",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Crossed straight-leg raising maneuver",
"       </td>",
"       <td>",
"        23-43",
"       </td>",
"       <td>",
"        88-98",
"       </td>",
"       <td>",
"        4.3",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LR: likelihood ratio; NS: not significant.",
"     <br>",
"      * Diagnostic standard: for",
"      <em>",
"       lumbosacral radiculopathy",
"      </em>",
"      , surgical finding of disc herniation compressing nerve root.",
"      <br>",
"       &bull; Definition of findings: for",
"       <em>",
"        ipsilateral calf wasting",
"       </em>",
"       , maximum calf circumference at least 1 cm smaller than contralateral side; for",
"       <em>",
"        straight-leg raising maneuvers",
"       </em>",
"       , flexion at hip of supine patient's leg, extended at the knee, causes radiating pain in affected leg (pain confined to back or hip is negative response); for",
"       <em>",
"        crossed straight-leg raising maneuver",
"       </em>",
"       , raising contralateral provokes pain in affected leg.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: McGee, S. Evidence-Based Physical Diagnosis. WB Saunders Company, Philadelphia 2001. Copyright &copy;2001 Elsevier Science, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_26_32172=[""].join("\n");
var outline_f31_26_32172=null;
var title_f31_26_32173="Decline HCV incidence";
var content_f31_26_32173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Estimated incidence of acute HCV infection in the United States, 1960-1999",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 221px; background-image: url(data:image/gif;base64,R0lGODlh4QHdANUAAP///4CAgAAAAKqqqkBAQMDAwNXV1aCgoBAQEICZ/yAgIFBQUDAwMNDQ0HBwcODg4LCwsJCQkPDw8GBgYBBA//Dz/8DN/0Bm/+Dm/2CA/9DZ/yBN/zBZ/6Cz/wAz/5Cm/1Bz/1VVVbDA/3CN/+rq6q+vr8rKyr+/v7W1tWpqavX19d/f3/r6+sXFxdra2mBmgCAyf+Xl5bW71bq6upWh1HWI1GR71M/PzwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADhAd0AAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw2MBCgICCgHEzM2LEcjRAhHO1daBBAsPQg8LBNfg4XjZ2wDd3+Lp6m7Q0tPr8PFnxsjKYwUB+foBBfL+/1zw7QtAYBnAg8HoJTOIJh/Ch73aSaPWkCHEi7bIcfOWxiHGj7Q0muNYEaTJWBKjUZxn8aRLVQrtdWz5ElUFCzhFJEhgoWYZ/48+M2HAaaHDzgQZLijl4KGpB6VKkXJAWGACAQIT+s0MqoiohQ9HQUCl4JQCVBBHP3hVQkEDQAjuBEDYypXP151QLzj1wAFqhqMdiGLQMiIDwAUMDhQocIDBArp162joMIIph78JRBCtoAYDBc7+CDgg4gAdy8hxMIgYoXcDWgug5Vz48M9BsqvHRpdEraaCzgsUzGaObUfEhn8SCEgjIAEybzE3E4DY8HSEiMF+NvT892BxOefPuXzNYHlEB7eDkD5scKD57vBYJlfmm0FtIgwesAMsIABBAPdLFNDAEA9EEEAEAEJw4HdGAAVfFKqx5oFrPBGnyF8P4VPQEg0EIP+Aacohw4AQtjGAAAIMEuHgg0r4lgBwwolgoSMWHFdXiKZBIIEExxQgQX8AQKNbgzSxKER001V3XSYbdCBPTEUiwZ9pQxzT3YcATJnlQARFGV4H5PFlHnqcfHBBPCkhs1KAWBIhZJZYainQPhsaicEIFHBgnygVUKBfOiKd44SWQ9g2gRANCDAiXI8dsSJvFoDgQQZkkpLBCPAEShKH0DDgIwALLMQPAMdAEOoBSDzKVQUfbLBBAjOOosFn66T5DhMhItOPO8s0wEB/QxLJmwYZmCVCKxc4uQ6UaqjqUgfAjfDnKh1MZSQUzn6EQQJ5dhDrKm0te8xCzXoJkQUZTLr/3SyFqWPrmj+ZC1AFHbiawLSy4PdtM5pSGS9IGBSb7C4g0CZOv+AdBC0FGeB7i3HpvJuwPBUk4Kq3wGiXDrMTr4OuByCsC4x01zaRLTj0ckDBvcxUkF88jHV8zZ1mKesMhvAQJLMzIgBHKTg1huOhO/6ScfIwrLr6wb7MNAnOAXEVXYy8wBAL8rHrQBuOVUPo/F4zIqgsLcV+ghOzEGef1kwFeNrsz6VdLLYYFAcQMKBoUtQ94Clz6lMnMRr05TA8szIthTQIoGqyAP0EoDgU+KQ4St/5/C3MBytfNPAWyJjzaz8SELTAXOaUNrqHjaOKDwRWkV6ANw4AuOU2jkeA/5XspByNSwXTiYxQtVx0DgDUj5kYwK8NSHBiAFahDgCWHiIQ4gOM2taoEM6LeMyhp+huiwauGS5PuFoIP2WiBU0gwIECKP5A9t84b9vr69OjIuPPf/Oj1HI4EOzOt+CWwUDSrvIJQAhQy8qH9IEP/GEPf9DDH+qUs4/77QodbboD19jgPVlU4AIcqJS2PCA+J+jqACfaxokUE4EDJMpTB1gA/ADgPNRBYwEFYJ0F8yeEDNohAv7Jx+PM0EFYiIACIyghQApmQGQsYG8NCFUy5gKBX9UPgvGToATHdT0aYrGH/ItDrnz4L17gCWs1gVg1GiA3AQEQFoHjwOBMsgE0Nv9DQe/bm9pw0YHMRYZkzrAN4xbAvT3WgncU8F1QXDZHXyBgAp7ymiFnAT4QKBEkOEtCAwgwxCLgLQp6s8In/8A4AlQljGAo4ikS4IEBPscCFFjC+7TiqE4moU2RswIZ+UAABiggVPAyGtVsAkIRPocDbjPCLIcXAFM9kYaOQ+BVKCIB2xGghQvpTgC20QCrxM4czSwNTQiivm8cYJsReMA5EWgQgjggmm1oAAJEhDthzuKIGbjkS7SWBP4sQzkK+JUCAKCcb9jGAcAkqAD8hwDbSK9DjHsAAhgQgInC6UPzHKL1PPQN5cyzAMoRQkg3uks1uLFcsjhjyQDQpzn6U6H/QvgVGAGAAGVwNFHc20abbCgXANiGjesDAFwsUtOZKsc9IYVpMmbaBgmYjnRfY0UcG/mcDBhGSkFNalKxJCrHvXQIO2VcDRn30q8yFUtJhalSMYhKMowRqlGQwDkRJAS5Oq6eXRumKPqYgJUSwTPfeqlWD8jDUPFjnSeCQBWfp4ACvI9xicKhAhAAp2WYVaEQgFpHCQsqASzAAfMEwK8yW9IzBFUCDGgrElD7of4051fKGVGq9PoJRCpypZszgmAJu1X9TWCe/gFAFJGRRQFAtB8HOAYDBlTWoA6hAccoqFqFewzEHBC6rVWtGEaHvS4+gT8jUk4OPdtZuKqItp2o/6Q+eQO8KLCHvHnIYQP/l4YJKAA396XvEljry0N5aBn/3dJALHeKD7TSr0lIZBQAqsc7QK0/E8DrGcZI3Lj+VrmhC2qAKdelVHwwhAhOgnouAo1lGPZNtgkm9tCLCVjmM8RJ0NdFoOapXx3gAckogJVmewqVwlgJTLwIaMk1vGMowJZ5LQUGOCDHHy9BjSxSJSX6iCknM6GOXFjmMk2FlX48wCoTYG4A2NMPazpAcoA4QHsIidJQVKBYt7WyET4AgoAE1Z/EC4AMJUrRE3lxnsxb6PFoOQgFREB9t5okJ8B3gfXCmJFbaC77KIoqaEyAIGLtaWdlSOhBMC61pXkjJf8M7Eo5MyGTWJA0DUP0TgFcOh+P1YoEIIkM8wbCP/XTLhek3IgPbsCYplYCLLeQKP9QMAIOYIxnXwiBAjjguEKYQAScnehBCLIADCgkEVnMCBc72tTI3IJtFKC+ZnKxOVUUUayxB1z9AqKaOhqzqB/RtmBPgZ++YONiGlxGTCy5yfaWQkt9IcgKR3XKSAx4Fazqi/7oA8li4HUh3qxghQ+BBAbIuMY3znEDyMAGHQ+5yA1AglPIZA0SHwSjv10yAwzg5TCPucxnTvOax9wApyiN3Phtz1Ef2OJFcLnNh050m+PcFGPU9RZS/gfe/RroRhB60ac+9aOX4pwPnzchvA3/9ahT/etEt7opTioGDhOYEdxKZteFIHWwu/3mp5AnPcvOpbPfh8lUtXjb3/52sY9CAcoArbb7vYgjVnntR9g738Hud1E4UJLbZgTF7Yj4oC9+8Y0PxS9zmG2t8yFwja58EhR/+aqf4sH94fnUFGHgvop+9KXvOyo6lM42G8LpwH79EEgf+6FnXh1MlwMsLal7JfC+9zX/fSdKuRzP2yHtxV8CxkdO/YzXgAbV53jJSWG30lxllJEfxL9zH30t4LsWDShH+p0vB8OXfwx9Ir8r6gR5wvdh8jCTG93sRlB3KyGUcFBAs7BJNXUV0sN+bgB6LPcLiANxDSJBDthP25Qa/7QyC/yBOLa2en7Qev/QOQ/wOQAQOtlAOg/wVDWkOs3UOmgDO7KTS7VzO2uQW7PgABGogXuAewAhPMQjWv6BPMrjH83zRdEzPdUDXw+0K4qyPWtQL7agZ+ZAABkYcdymBsO3gMJgPh+CPoHGPu4zQ/IzSPVzDDuEJfvDBhpDC4kTbUqnBcFXBtCHEDroalPCQM5zhDw0ViBVPw4yQzy0BiM2C4+3hkbARuVgV+2RBG0oBhhQTBBxQilEU4lTAC30QowhQ0KoRZLoWTmkbXxYWmQgY7PAAAygWA1VBXJnELClKIg4hWXgfhchDc8kXFKkAFRkRflwiY2zRU40hmzVBv9oQQtwgQwoUgW2KFTkFSpRmIhewDYUQHnv1wZBQwvvU3tUUFG2AWAadmd1x4phAHp594xngGWy4FR2w11SkCgKko3YaFnbSAeY43rgKAd0NgtSVBXe5QRDEw3sMxopxmNx4HRxFo9sAGmxMA2mVH9O0B1V4WoPgGONtWOOwo3iET5yFkWc1ATgVwdwU5AQYErZYAUBVmTJ4IDKeAUCZBKXdQWTNSpMAE93MCuy8Fs11T4IuAWLCGImUU4A5kLLUDcjCE4QIE5CwGVZATX2AE/R1E3ZgCrwxGUUcU7OpHplEG6wIAGhUoo1GR+Yk0QuIVDf0B+d81n0cCUY1T55JkP/DvWVbIVjFDUBj4ElRTgaACVQbNBerWA368dBEikFGkBnwXEBzvgRX6WK3EAQPfJSQ9Up8NQmjGk3yeAAdIUlofJalJVUMrUG8ecKcmF34ScGfQkCwVEw8ocRg4kOfHYA6rMYd6ZhrNaHjSlUBDBPI4JWvHVAg9UGArgK49J8B6cFnxmaHzCaKOlZc4FLmihekoZsyvaW6DBPDlBOVdFsfoYlJcYoapVWnVGBqxBFBXgV/pdKe1kEGNABoEkBoskiHtWHAKA+E0VWq2luTtQcbYJCDfUhHygiA9ImQ7YAzXGbbTAbr6AYbaCMFjAf5ymQjABlrGCR3pmV9AKaG2Ad/wgaCWfICrvpieDJlwnAFAXzjRNqCH+4CkZoe0tAL8WyARkgIx9aCfjhoZ/wWQMqL32pF7MhnLoXakcAgBcCj6rwW9/3nV+gKr6RARvAMBizouwkJRNoQoJIhTayCknnHBhAZ3yRADZqb7OUWeYAZnsTQ6JhV1vyOs+USyLIXe8TlBtilNtEjpzZBuL4EA6xGkUKAkcaffwxTwTAZxVFWR4iQ40VUhy1p17UD8aDPBcYm+2TltDlHw4wUO54JqngI/q2b3Q3YDAgJgH5evyhG5aGaQVQVCGYHAf0hQ0kIAtUbogZVG1yIpeGZm4wcKjAfNHQpJBTdy/gooj3VR7yav/b5EOAiomoM4f5oJqWparoEEXHMIx0sJHdo077UINeUJKm9lXM5mzDNW049KsRAAF+5jwrJImK8Z6M5ViclIdS2QYwCafhaW9mlW6K8gCzNk8K8AC/amQD4jzDNUWqNjT5emR3cBlHEbACO7AEW7AGuxOZKgrSCo51SAkWcLAQG7ERm7ChsLDP2LBIegUWm7FyRkhR2HMcOwXTl30kS7LbdxjRYI6KFrJOcHzIN3PKtw7qJF29ybJM4LIvC3eIUAIGwAKM0AAO8CvBVbM2a3w5a3qI8HIlYAIqoAgFda5SWLRRgLNHOwAx+wcyZwInWwgxBGEfm6FS+wRUe7RX6wf/NHcCMYAIw0WrILmuHzq2OXsCJTu3dFu31WdzKLAChKAQQ7uyYYsEcPuycmu3hFu4c2tzLaC3g0AACuAAXxsGGwuOgYt8ZdsHMzcDLuCzheCqnfm3SzC5vVe5fABzKHADTau2n2NoWcmxoBt7orsHS7u1iGAiCOBsbFsFkfuMrVt6r2sNm6khW2CIEgZNntsEu3t5vVsNCGA7EEBuW5CKsmV2BcEl1Fu91nu92Ju92ru93Nu93vu94Bu+4iu+KRAC5nu+6Ju+6ru+7Iu+KTC+8Bu/8NtpdpCPDoQF1omMAkYn0yu/4HsV/vu9ABzA3jvABLy9BnzA2pvACny9DNzA/9b7wBDcjntgOyqLBQEWksISo3rJwSjntlOQuy0JwlIgwktgwnmQwc61wR38wR5Moqvbti8cwxEXNVqAYtV2Xm6Awqs4w0QLsjSMuySMLUPMBT7JuAaHBQ6pYwLgqjysBE8ckT7st/ZHxUD8w3HgVMjwTVqQXCPZw1PcuUEcwkX8BFHMwjBsxXDQvPbpwmFcxWoMuWWMj3M8wm98xXTQDslGqWgwN23gxyZFv2cAyGlAyIUsyGVgyH2MyGSgyHNgv0lcvJIcBRwGrZN8yZicyZq8yZzcyZ78yaAcypGqR3ZlXgqypApCjYJAdqU8BG3kWEO5IIbAylBJBKf8HanMuf98QMvNZMuwNgQKcoiEwMtwFcwJcleTAFHowF8LVVe/Ior9UCKPCAjK7MyK0szPIw3LIM3KGgjVHILPjM3qYyL4w826jAffzMy6Mc4ftZ7XLFvezFHW/Cvr/M7RZs+SgCNC8CY7pj4r8SOU9SaAoM9B0sw7JjcZBdAFDaTjYHD83MTZnGH/ASQCPdAObdAQjQwS/ULubMl1QNAP/QAcrT4upIokPQmE4iFyiT94+q5ygqF4kNLNLF5DYJRw8g2EssphtdL9oD4BxQAS8NK36wYyzdPu/NNBrYoaDAhFrVCqOSL/BV5eVMdyQCg4VpZIuJAKhNMwfQdWTVztLATHoDr/cdLVMd0mV42oZXbNCABUXD3Uf4zWYI0/nZJ6pJKEK8zUco3Vd+1LQaVcx0DVcZDTHeLFQhBa56OK1hkIhO04YohASyVcij2iem0ahS2G6FPQjrkolO0HjW3YmQ0N31AgERAqjKwHn/3YpG3a5hABpX2/j9AAnfIpihEq9byFd20qNEnNs90ctY3NyrPbuX0qgyDbikLb9DMaOIYArONqwy3cf2DcnuLbyW0O/dHch9JsHgLPvH3c1G3bQ9lAsqXdhBkJY4SEJ2eVW4woQsvQdnDe2Xxy200EvgIshADf9cAQXvxIzVHfWIkN0oDe+p2sEaZQ/L24AR7fDOFRBW7guQ0uyhAe4RI+4RRe4RZ+4Rie4Rq+4Rze4R7+4SAe4iI+4iRe4iZ+4kXrHYgCyyh+sWR4IsPb4ojHI3LhIdRQpqTjfWG2JWQm48EGF8oVUz1oXKQSAKA1UNGT1z7uZCEyIFpYbllSGqHlIY+75CtFKMLKD4ySboNq5cGW09/aQv/Fxl3u5XJG2LOoIwIlhhhr5m7+5nAe53I+53Re53Z+53ie53q+53ze537+54Ae6II+6IRe6IZ+BUEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Source: Centers for Disease Control and Prevention. Adapted from: Hepatology 2000; 31:777-82; Hepatology 1997; 26:62S-65S.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_26_32173=[""].join("\n");
var outline_f31_26_32173=null;
var title_f31_26_32174="Schatzki ring ulcerated Endosc";
var content_f31_26_32174=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Schatzki ring",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of the distal esophagus revealed three superficial ulcerations above an esophageal ring.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Gelrud, MD and Helen M. Shields, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_26_32174=[""].join("\n");
var outline_f31_26_32174=null;
var title_f31_26_32175="Lesion location";
var content_f31_26_32175=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80647&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lesion location",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 389px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGFAWUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAoorhdI8WX7fF7XfCWqR26WyWEGoaY6KVeSPOyXcSSCQ5wMY4FAHdUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeS/Fj/iRfE34ceKF+WJr2TRbpuzLcLiPPsGBNetV5l+0hYyXfwi1i4tgftemtDqEDAZ2NFIpJ/wC+d1AHptFVdJvY9T0qyv4f9VdQpOnOeGUMP51aoAKz9X1nTtG+xf2pdxW3226Syt/MP+tmfO1B7nBrQryr4+/804/7HPTf/alAHqtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVhePLAap4I8QWBXd9q0+4hxjPLRsB/Ot2kdVdWV1DKwwQRkEUAcN8C746j8H/CU5OSunxwZ/wCuY8v/ANlruq8r/ZhZh8FtEt3JZ7aW6hLZznFxJ09ua9UoAK8q/aB+Sz8B3B5S28XadKw7kAuOPfmvVa8r/aG/5AXhP/sZtP8A/QmoA9UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACkdlRWZ2CqoySTgAUtYnji/GleC9f1AkL9lsJ5sn/ZjY/0oA4b9l5CPgd4ddwfMlNy7lurE3MvJ/DFeqVwnwJsTp3wf8JQMMFrBJ8f9dP3n/s1d3QAV5V+0OcaD4UJ6f8JNp/8A6E1eq15V+0h/yIunf9hqx/8ARooA9VooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvL/ANpC+lg+Ft5ptmf9P1u4g0u2X+88rjI/FQ9eoV454lu4fF37Q3h3w4sqta+GbSTWrpP7052pGv1Xej/8CoA9Z0qyj03TLOxg/wBTawpAn+6qgD9BVquF+MnjO88FeE4rnRraG81y+vIbDT7aZSySzO3QgEH7oboeuKzfD/xWs5vhHp3jXWLS58sgRagllDv+zSBijsVLbgm4Z7kBh9aAPTK4L4z+HNS8UeFbSx0aFZriPUrW5ZWcJhEkyxyfasnVvippuo+HJ9T0C8vLaxt9Vh08agbBZ4rlmfDLEDIuV6Df2zwDXO+KPiX4i07S/iBPbSWwk0XWrWxtN0IOIpGQMG9T8x5oA91ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiqOtavp2h6fLf6xfW1jZx/fmuJAij2ye/t3ry2T4o634wkktfhR4dk1CEHYdc1MNb2SHuVB+aTHoMH2NAHsFFfO/ijwz4i8P8AjH4f614k8XX2sarea9DbPCgENnCjK25Y4h34xu4JHUV9EUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGN4y8RWXhLwvqWu6m2LWyiMjAHBc9FQe7EgD3NeAfAzStUsfjlJqXiFj/bGv+GJNYuYz/wAsjLeqFQDthETjt07V1+uv/wALW+KUWgwZk8IeFZluNTcfcu70Z2Qe4TBLfiD/AAmtS+/cftO6ZJyv2nwvLBk9G23O/A9+9AG34++HNj448RaDe65cySaZpQlb+zlBVZpHAAZnDAjbgEAenuawbf4Pf2d4W8S+G9E8Q3Gn6Lrd4bhoUg3vBEwxJCjFujAKMkHgHg5zXrFFAHk8HwcjtvCL+GLfXrkaJFqceo2MMkAd7UK+8xBt3zKSc5IyMnrmrGt/CSDVbHxZbNq8sY1/UoNRZhAD5JjKnYPm5zt68V6hXmX7R19daZ8KdQvbK5ntXhubVmmhkKMqGdAeRzjnH40Aem0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUV5Z8QvjHpnh+a80zw3aTeJPEFvE8sttZ8xWqqMs00gyFAxyBz2OM0AemX97a6dZzXd/cw2trCu6SaZwiIPUseAK8ouvilq3iu7k074TaL/aoRjHLrd8GhsID0OOjSEeg9iMis3wZ4HuviZpuleLfiXqr6pb3UaXdnoduDDZW4PK7lBzI2D1J7kHcK9qs7W3srWK2soIre2iUJHFEgREUdAAOAKAPL9G+Dtte6jHrHxH1W48W6wp3IlyNlnAfSOAfLj68HrgV6nDFHBEkUMaRxIAqogwFA6ADsKfRQB5X8b/+Q78M/wDsZrf/ANBevVK8r+N//Id+Gf8A2M1v/wCgvXqlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXm/wAYvF9/pkNj4X8J4k8X68TDZgH/AI9Y/wCO4f0CjOD6gnnaRXV+OPFGneDfDF9rmrybba2TIQfelc8KijuxPH69BXGfB7wtqImvvG/jFP8AiqtcAYQnOLC24KQKD0OMFvfg8gkgHWfDzwjY+B/Ctpomm5cRAvNOw+e4lb78je5P5AAdq4r4tN/YfxJ+G3ic/LAt9LpFy2O1ymEyewDAmvWa4f41+HH8UfDLXLC3B+2xw/arQr94TRHeu30J27f+BUAdxRXN/DfxGni7wLomuIQWvLZXlA6LKPlkH4OGFdJQAV5V+1H/AMkJ8Tf9uv8A6VRV6rXlX7Uf/JCfE3/br/6VRUAeq0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWJ4w8VaL4P0aTVPEV/FZ2icAty0jf3UUcsfYVynxA+JkWiaonhzwvYt4g8YXA/d6fAfkgH9+duiKMg46/QHNVPB/wwlfWI/E/wARr1fEPifrEjD/AESwHXbDGeMg/wARHvgHJIBjAeNvi0QzG78GeB5OQo+XUb9O2f8AnkhH+WBrrdR8JaH4N+FfiPTvDmnw2VsNMuS20ZeQ+S3zOx5Y+5rva5v4mTC3+HHiuYgkR6TduQO+IXNAGd8FP+SR+EP+wZB/6AK7WuP+DkRh+E/g9GIJOk2z8ejRqf612FABRRRQB5V8eR5d18NrhSd6+L7GIDthw4P8q9Vryr4+/wDNOP8Asc9N/wDaleq0AFFFFABRRRQAUUUUAFFFFABRRRQAUjsqKzOwVVGSScAClrx/4p6te+M/Ekfw08LztEZkE2v38Z/49LU/8sgf779Meh9CcAFPRFPxh8frr1wGbwJ4enK6ZEwwuoXanBuCO6L0X/8AaFe2VR0PSrLQ9ItNL0uBbextIxFDGvRVH8z6nuavUAFFFFAHjvw4ceAfiZrfgK4zHpeps+r6Gx4UBv8AXQL/ALpBIHoCT1r2KvO/jd4Wutd8LxapoWU8S6DL/aOmyKMszry0XuHAxjuQueK6P4f+KLXxn4O0rX7LAjvIQzIDny5Bw6fgwI/CgDoa8z/aVjWT4IeKVcZAiib8RPGR+or0yvNf2kf+SJeKf+uMf/o5KAPQtNdpNOtXclnaJGJPckCrFVdJ/wCQVZ/9cU/9BFWqACiiigAooooAKKKKACiiigAooooAKKKZPNHbwyTTyJFDGpd3dgqqoGSST0AoAeTgZPSvHNf8b61491i58MfCuRI7aE+XqXiVhuhtvVIP78nuOnb+8KF7q2qfG3UrnSPDFzPpvw/tnMOoaqg2y6iwwTDDnkJjGW9Dz6H2Hw9oem+HNHttL0Szis7C3XbHFGOB6knqSepJ5NAGN8PvAmjeBdLa20iJpLqc77u+nO+e6k6lnfvyTx0Gfc11VFFABXK/Fj/klnjL/sC3v/oh66quf+IYz4A8TA/9Ay6/9FNQBnfDK7trP4S+Dpry4ht4Ro1kC8rhFz5CcZNdVZXtrfRGWyuYLiMHG+GQOM+mRXzd8Q1LfsmeEVCLISmnjYx4bpwaW78O+KvhzoPjjxnp+naX4dkube3t4dO0xjcR2yiRRJcspUKWVSxAAxySRwcgH0vTJJEiXdK6opOMscDNfOF3401nT5fFmn+E/HcOtabBo9vdRa1qLxPHZXclwsflGVFC/MhJG7hTjOMMa5HxB4hvfEPw41RbzWtZ26TrOnGaWe7tb6FN5bLJcwoFcD5SRj5SFBzkigD2v4+/804/7HPTf/aleq14l8T5IZfDvwse21o67EfGOn7dRLxt5/zS85jAU46cDtXttABRRRQAUUUUAFFFFABRRRQAUUVleKdf0/wvoF7rOsziCxtIzJI3c+igd2JwAO5NAHNfFrxu3hDRYINKg+2+JtUk+y6VZDkySnjcR/cXIJP0GRnIm+FPghPBXh1ormb7Zrl+/wBq1S+Y5a4nbk89doyQB9TjJNcz8JdA1HX9an+JHjCAx6rfx+XpVk/I06zP3QP9twSSfQnpuIHrVABRRRQAUUUUAFeRfCsDwr8T/HHgs/u7SaVdd01M8eXLxKFHZVcAAfWvXa8i+NufDHiLwj8QIRti0u7+wamR3s5ztLH12scgerUAeu15z+0VE03wV8VKpAItlfn0WRCf5V6KCGAIIIPIIrgfj9/yRrxZ/wBeTfzFAHYaBKLjQtOmUELJbRuAeoBUGr9ZXhP/AJFXRv8Aryh/9AFatABRRRQAUUUUAFFFFABRRRQAUUUUANkdIo2kkZURQWZmOAAOpJrxC/ub74361PpumTy2fw3sJvLvLyJir6vKpyY0PaIHqe/5YseM9Rvfip4qufA3hu4kt/DVgwHiHU4jgyH/AJ9Ij6n+I+xHQYb13R9MstF0u107S7aO1sbZBHFDGMKqj/PXvQB5h+zZbQ2XhbxJa2saxW8HiO+ijjXoqqygAfQCvW68r/Z5/wCQF4s/7GbUP/Qlr1SgAooooAKwPiF/yIPiX/sGXP8A6Kat+srxaM+FdZB6fYpv/QGoA5z4MxRzfCHwgsqI6/2ZAcMMj7grtyAwIIBB4INcD8Af+SNeE/8AryX+Zrv6AKsOnWUFs9tDZ20dvJnfEkShGz1yMYNEen2UVm1nHZ26WjZBgWJQhz1+XGKtUUAeTfHiCKy074ftbxJFbWni7TpDHGoUBQXGFA46mvWa8r/aG/5AXhP/ALGbT/8A0Jq9UoAKKKKACiiigAooooAKKKKAEZgqlmICgZJPQCvlv4neLLrxprel+IFgSb4Y6FrdtbTGXOy/cuRJPjoyJwozwd3fJA9C+JerX3jvxM3w38KTvDbhQ/iLUo+ltAf+WCn++/THpx03Y7TxJ4F0zUfhle+DbG3itbB7M21ugHyxsOUY+pDgMT3NAHX0VwHwO8TSeJPh/Zrf5TWNLY6ZqMTfeSeL5Tn3IAb8T6V39ABRXC/HDxNqPg/4Xa1ruitGuoWnkeUZU3qN08aHI78Ma868HfGC+tdc1uLxDrGmeIdA07SBqU2paXbGMwSFgotz821mOeMHr34IAB7/AEV5fH8X7SzF4vifQNW0OaLTW1aCOby5TcwLgHbsY4fkfK2MdTiub8UfGvUf+FY6z4i0DQjDNaG2MU0l1b3cAWSQKS/lSEqwHG04ILL2zgA90rG8ZaDb+KPCmraJd4EN/bPBuIzsJHyt9QcH8Kn8Pahc6ppcV1e6XdaVO5YG1umQyLg4BJRmXnr1rSoA86+AevXGtfDmzttSyuraNI+k3yHqssJ28+5XaT7k1N8fv+SNeLP+vJv5isPw6D4W/aC8QaVyth4nsU1WAfwrcRHZKo92Hzn8K6b41jPwj8X5/wCgZP8A+gGgDoPCf/Iq6N/15Q/+gCtWsD4e/wDIg+Gv+wZbf+ilrfoAKKKKACiiigAooooAKKKKACvMPjB4r1KO4sPBXg5/+Kr1wECYdLG26POx7cAhfcHHIAPaeNfEtj4Q8Lajruqti1s4i5UHBkboqL7sSAPrXG/BbwzfwW994x8VJnxT4hInmUj/AI9IP+WcC9wAMEj1wD93NAHW+A/Cem+CfDFpomjoRDCMvK3355D96Rz3Yn8uAOAK6CiigDyv9nn/AJAXiz/sZtQ/9CWvVK8q+AIwPiKBwB4y1IAen+rr1WgAooooAKo67Es+h6jC+dkltIhx1wVIq9UN7EZ7OeFSA0kbICegyMUAeffs6StN8FfCrPjIt2Xj0EjgfoK9HrzD9mabz/gd4XcDbhJ0x/u3Ei/0r0+gAooooA8r/aG/5AXhP/sZtP8A/Qmr1SvKv2jfk8H6JcL9+216xlUHoSJMc+3Neq0AFFFFABRRRQAUUUUAFec/Fzxtd6Ill4c8KIt14y1omKyh6i3T+K4k9FUZxnqR3ANbfxK8a2XgXw1JqV2jXF1IwgsrOP8A1l1O33Y1H8z2HrwDhfCTwVfaS174o8XSLdeMtZAe6k6i1i4K28foq4GcdSB1wDQBufDPwTZ+BfDaafBI11fTObi+vpOZLqduWdieevQdh6nJPWUUUAeM+JW/4Vj8WoPEg/d+FvFTJZ6oeiW14P8AVTH0DDIJ/wB4ntXs1ZPizw/YeKvDmoaJq0fmWV7EY3A6r3DD0IIBB9QK4H4M+INQs5734f8AiyTPiHQkAgnJ/wCP+z6RzL6kDCn8M85wAdl8QvCdr448H3/h3UJ57e1vPL3yQY3rskVxjII6oB0pdW8HaNqnhG98OT2iRaddw+TKIFWNjwMOMDG4EAg46iuhooA80sfhWUuZ73VPFWsajqYsDptndSLChtISQflUJhmOMFmzkZBrLt/gVo39h+JLG+1K5mn12OKKee3toLVUETiRCsUSKmdwBJIJP516/RQBmeHLC90zSIbXU9Vn1e6QnddzRJGz5PA2oABgYH4Vp0UUAeSfHZjoGp+CfHCgiHQ9S8i8Yfw2twBG7H1wQv4tXTfGkg/CLxcQcg6XOQR/uGt/xboVr4n8Manol+P9Gvrd4GOMlcjhh7g4I9wK8c0XWbnWP2dPGWh60xXXPDmn3mmXo5yxhiby356hlUc9yCaAPWvh7/yIPhr/ALBlt/6KWt+uZ+F8rXHw08JTOAGk0i0cgdMmFDXTUAFFFFABRRRQAUUUUAFFFc98QvE8Hg3wXq+v3W1lsoC6IxwJJDwifixUfjQB554kU/Ej4w2vh0fP4Z8KFL7UsfcuLxv9VCexCjk/8CB7V7JXAfBDwvP4Z8CW7aoXfXNUkbU9Skk+808uGIP0GF+oJ7139ABRRRQB5T8EcL4h+JsZ4ceJZmK98FVwfx5r1avKvhD8vj/4pRtw41iNip64MQwfoa9VoAKKKKACiiigDyr9l07fgjoMDAiSCS6jcejfaZT/AFr1WvKv2Z+PhZDGeJIr+8R1PVT57nB/MV6rQAUUUUAeV/tIf8iJp/8A2GrH/wBGivVK8q/aU+T4cxXB5S21SylYdyBMo49+a9VoAKKKKACiiigAqG9uoLGznu7yVIbaBGlllc4VFAyST6ACpq8e+LdzP428W6b8M9KldLedRf69PE2DDaKQViz2Zzj6Db1BNAEXw5s5/iR4xb4i65C66RaF7fw3ZyjAWPOGumU/xMRx6Y9lNezVDZWsFjZwWlnEkNtAixRRIMKigYAA9ABU1ABRRRQAV5v8YvCN/qlvY+J/CgEfi/QWM9mQP+PmP+O3b1DDOB6ntkmvSKKAOa+Hni+w8ceFbTWtNygkGyeBj89vKPvRt7g/mMHvXS14r4xik+FHjs+M9ORz4S1qVYdftkHy20zHCXagepPzepJ6lhj2iGRJoklhdZInUMrqchgehB7igB1FFFABRRRQAV86/H1G8D6/rOvxKRpHi3RLrSL8DOFu1gf7O592HyfTca+iq4H486BD4i+EviW1mXc8Fo95CQORJEC4x9dpX6MaANT4T/8AJLPBv/YFsv8A0QldVXIfB+UTfCjwcwBGNItU5/2YlH9K6+gAooooAKKKKACiiigAryL4tr/wlPxE8EeBx81oZm1vU1xwYIeI1b/ZZ8qfwr12vJfhh/xP/i18RPE7fNFazx6DaN2UQjMw/FypoA9aooooAKKKKAPKvhaf+Ls/Fcd/ttl/6INd342uprLwZr11ayNFcQWFxLHIvVWWNiCPoRXCfDv/AJLt8XP+4R/6StXpmp2UGpaddWN4pe2uonglUEglGBBGR04JoA+Qk+LHjofDB9HN3dHxCYxq41bA/wCQdtz1x97zR5ecd8V6jp3xI/sJ9Y1LVU1C8fT/AAvp9/IGvWMc0kiqMLFjajFiMuM9eleof8IPoP8AwhX/AAin2Rv7G+z/AGXy/Mbf5ec7d+d3X3qr/wAK58MMt8sunmVL3TotLnR5XIa3jGEXrwR/eHOec0AcJ4X1/wAW33xs0i38TLBYQ3Hh2S7Wwsr2SWHJlGGdSAvmDkZGeOhr2quM8LfDfQPDWrW+qWJ1GfUILU2cc15fSzlYSQdgDMQAMDAAGK7OgDyr9m8/8UNqS/xLrV8GHcHzehr1WvK/2ef+QF4s/wCxm1D/ANCWvVKACiiigDyv9pr/AJJPd/8AX7Z/+j0r1SvKv2n/AJPgvrNyOTbTWk23+9i5jGPbrXqtABRRRQAUUUUAZXirXbTwz4c1HWtSbbaWMDTPjq2Bwo9ycAe5rxz9mHU5NSvfGdzr9s9v4svbuG/uhJ1NtLEGgC+iqC3HbIz6Da+MYPi7xl4U+HsRLWt1J/a2rgHpaQn5Ub2d+PqBTPi0P+EI8b+HPiJbqVsUI0fWgg4+zSN8khx/cfH1+UUAew0UiMrqrIwZWGQQcgiloAKKQkKCSQAOSTVWPUrGWze7jvbZ7RM7pllUouPVs4oAt0VRg1fTZ79LGDULOS9e3+1rbpOrSNDu2+YFByUzxu6Z4qSbUrGDULawnvbaO+uVZoLd5VEkoXliqk5YDvjpQAmsabaaxpV3pupQrPZXcTQzRt0ZWGCK8w+B2oXWi3etfDnWpmlvvDzhrGWT71xYPzG3vtyFOOBlR2r1qvIPjSv/AAivirwl8Q4BtisLkabqrDobOY43N7IxyPdhQB6/RQDkZHSigAooooAKwPiF/wAiD4l/7Blz/wCimrfrA+IX/Ig+Jf8AsGXP/opqAMn4Kf8AJI/CH/YMg/8AQBXa1xXwU/5JH4Q/7BkH/oArtaACiiigAooooAKKKKAINQuo7GwububiK3jaV/ooJP8AKvNv2bLSSL4SaZe3ODeapNPqE7D+JpJWwf8AvkLXMftjahqdj8MLVNNmnhtrm/SG7aIkboyjkKxH8JIH5Cu1/Z9e7k+DPhRr9NkwtNqjGP3YZhGeg6oFP49+tAHoVFFFABRRRQB5V4I/dfH/AOJapws1tpkjj1YRMoP5V6rXlXhbMP7RPjhByLjS7GU57FcrivVaACiiigAooooA8q+AIwPiMB/0Oepf+069Vryr4HjbrXxLReE/4Si5baOmSqZP1Neq0AFFFFAHlX7Uf/JCfE3/AG6/+lUVeq15n+0oiyfBDxSHAIEUTc+omjI/UV6HprtJp1q7sWZokJJ6k4FAFmiiigAoorlPivrx8MfDfxFq8bbJrezfyW9JWG1P/HmWgDjvgyB4k8ZeOPHMg3xXd7/ZenueR9mtxgsvs7YP1WvTPEOj2fiDQr/SNTjEtnewtBKvswxkehHUHsQKwfhFoA8MfDTw5pOzZJDZo8y+kr/PJ/48zV11AHlnwL1m9gs9R8DeIpN2veGXFuHbj7TaH/Uyr6jbgf8AfOeTXqdeSfGnTrvw7qemfErQYGkvNFBi1OCMc3Vgx+ce5T7wz05PavUNH1K01jSrTUtNmWeyu4lmhkXoysMg0ALq3/IKvP8Ari//AKCa+LPCfhbxVN8DrpbFz/wh+p2N1rF9NvAaGe1M4EQXqQ5ityTj+E9K+3SMjB6VGsESQ+SsSLFgjYFAXB68UAfNXg/xNrGjx6bHpSpN9k+GY1GCDyVJM6zYBzjcRgfdzg+meaTwFqMeq/Fb4a3reL5vEt9c6beT3gd4iLSV4QTGFRQU542tn7vGM19LJBDGwZIo1YLsBCgEL6fT2qO3sbS2Oba1giO4t+7jC8nqeO5oAsVheO/D0XivwdrGhXGAt9bPErEfcfGUb8GAP4Vu0UAef/ArxFL4i+G+nG+JGq6cW02+RvvLND8pz7kbW/4FXoFeP6af+EG+Pd7YN8mjeNITd2/ZUvoh+8Uf76ncT3JAr2CgAooooAKyPGMay+EdcjkG5HsZ1YeoMbVr1leLP+RV1n/rym/9ANAHL/AV2k+DnhJnJJFii8+gJA/QV3tcB8Af+SNeE/8AryX+Zrv6ACiiigAooooAKKKKAOT+LVqt58LvF0LxLKTpN0UVhn5xExU/UEA0vwmn+0/C7whLvLs2kWm5j3YQqD+oNdDqtmmo6ZeWUuPLuYXhbIzwykH+deefs33r3Xwf0SCfIubAzWMyn+Fo5WUD/vnbQB3HinXrDwv4fvta1iUxWFmnmSsBk4yAAB3JJAA9TUPhXxRpXijw3aa7pVwG066BMbyfIQQxUgg9DkEYrh/j14e1/wAY2Gg+HNDgX7DdXwm1G6lAaKKKPlVddwLBmI4H93tXnNx8PfGVp8PfGXg2TTVvoG1a2v8AT5rfbHFMjyK8yIrOSipjoT3PJoA9+8ReKtG8P6BfazqV7GNPsiFnki/eFDkDGFyc5I4rVtLmG8t0ntpFkicAqynIr548X/Ci92/FCx8OeH4otNv7Swk0yGMosck8XMhRc8Ny3JxnPvXsXwygtbbwjaxWXh2bw7GpIaymiSNt+BufCEjBOec5PtQByuj5h/aV8QoORceHreU57FZSuK9VryqH91+1HcIn3Z/CCyvn1W82jH4V6rQAUUUUAFFFFAHlXwbHl+NvijEmRGNcD7c8bmjBJ/GvVa8q+FA8r4ofFWBSfLGo2soB/vPDk/yr1WgAooooA84/aLjaX4KeKlQZIt1b8BIhP6Cu50KVZ9E0+VM7JLeNlz6FQa474/f8ka8Wf9eTfzFdV4T/AORV0b/ryh/9AFAGrRRRQAV5P+0UPt+geGvDowy67r1nZyqe8QYux+g2rXrFeU/En/TPjP8ACvT+qJLf3kg9PLgGw/mSKAPVqKKKAGzRpNE8UyLJE6lWRhkMD1BHcV438OpJPht49ufh7fu39hai0l94cmc8KPvS22fVScj8/wCICvZq4r4teC/+E08LGCzl+za3YyC90u7U4aG4TleewPQ/n1AoA7WiuL+E3jMeNPCq3F3F9l1qzkNnqdmw2tBcJwwx2B6j8uoNdpQAUUUUAFFFFAHn3xw8MXPiLwRJPpG9de0eVdT010HzedFztHruGRj1x6V0Hw/8UWvjPwdpevWWBHeQhnQHPlyDh0P0YEV0NeNeDv8Ai3nxi1XwpJ+70HxNv1XSeyx3A/18I/8AQgOwCjvQB7LRRRQAVneJImuPDuqQoQGktZUBPTJQitGqurf8gq8/64v/AOgmgDhf2epRN8F/CjqCALUpz/suw/pXolea/s3f8kS8Lf8AXGT/ANHPXpVABRRRQAUUUUAFFFFABXk3wpP9gfEz4h+FHO2OS8XXLQZ+8lwB5mB2CuAK9ZryH4vH/hEvHng/x8vyWcUp0fVWH/PtMfkdj/dR8n6kUAevUUUUAFFFFAHlV+Nv7TmlsvDP4XlViP4gLnIB9s816rXlXiLA/aO8IE4BOjXgHv8AMK9VoAKKKKACiiigDyr4YHZ8YPizAwIkF1YSEf7LW5IP6V6rXlXw7/5Lt8XP+4R/6StXqtABRRRQBxPxuRX+EXi8OoIGmzHB9QpI/UVseAGZ/AfhtnYszabbEknJJ8pazvjDD5/wo8YqTjGkXT5/3Ymb+lWfhhMbj4a+E5mABk0i0cgdswoaAOmooooAK8q8Ufvv2ivBCMcLBpV9KuO5bCnPtivVa8p8en7N8e/hhO4Hl3EOpW4b0YQqwz9egoA9WooooAKKKKAPGfiJFJ8NvHtt8QdPRv7B1FksvEUEYOFBOI7rHqpwD+X8RNexwyxzwxywuskTqGR1OQwPIIPpVfV9OtNY0u707UYVns7qJoZo26MrDBFeWfCHUrvwlr938MvEUzSS2KG40S7k4+12WThP95ORj0BxwuSAevUUUUAFFFFABXnfxy8OXes+Dv7S0QEeIdBmXVNOdRkl4+WT3DLkY7nFeiUUAYXgbxJa+L/COla9Y8Q30Ak2Zz5bdGQ+6sCPwrdrx/4XgeCvib4p8COBHp11/wATzR16KI3O2WMf7rjgegJr2CgAqrq3/IKvP+uL/wDoJq1QRkYPSgDzX9m7/kiXhb/rjJ/6OevSq8q/Zc/5IT4Z/wC3r/0qlr1WgAooooAKKKKACiiigArG8Z+HrXxX4V1TQr8f6PfQNEWxkof4XHurAMPcVs0UAea/AnxHd6n4Xm0HXiV8SeHJf7NvkY8uF4jl9wyjr3Kk969Krx34q29x4F8ZWHxK0qJ3sdq2HiG3jGTJbEgJPgdWQ498bRwM165ZXUF9ZwXdnKk1tOiyxSocq6kZBB9CDQBNRRRQB5X4z/5OC+HX/XlqP/ota9Uryr4hjHx3+EhHBI1cE+o+yrXqtABRRRQAUUUUAeVeBcw/H74noCCs8GlytkcgrCygCvVa8q8Ifu/2hfiAj8NLp+nyIPVQjAn869VoAKKKKAOX+KcbTfDHxfHGMu+j3iqPUmF8VF8IZFl+FPg5kOQNHtF/EQqD+oq98QgT4B8Sgf8AQMuf/RTVk/BMg/CPwgQQR/ZkA4/3BQB2tFFFABXk/wAeT/Zt34C8Rfw6Zr8EczD+GGYFHP6L+desV8e/tna/raeMNO0QXNxDon2JLhYUYrHNLvbLN2YjauM9PxoA+wq5H4s+K/8AhCvh7rOuJtNzBDstlYZDTOQqcdxuIJHoDTvhP4hfxV8OPD2szzLNc3NonnuowDKvyycdvmVqX4g+B9P8dQaVbazNN9hsb1L1rZMbLllBASTI5XBOQPWgDhPA3xZuo/hf4g1rxnb79Y8OXb2uoQWgUF/nARlGduPmx152E1JrvxhuI9F8WJaeHdSsNc0rTRqVvDfLGRLCzBRKdr4AGclc5wDjnitC8+Cfh108TQabLcaXYa/bQ29xZ2aosUZiYMroMcHg57fMa2NX+Gul6rqmr3t1dXgOpaL/AGJKiFQFiyTvXj73Pfj2oA0/hxr994m8JWOpappdxptzLGhKylMTZjVvMTazYQljgHnjkVjfGTwddeJdCt9Q0B/I8VaLJ9t0ucdS45aI+quBjB4zjPGa3/Avh+68MeH4tLu9ZudXWDCQS3EUcbRxKiqsfyAZA25yck5OTXQ0Act8NPGFt458IWes26GGZsw3Vs33redeHjI68HkZ7EHvXU145dIPhv8AGmC7jxF4a8aP5M69Fg1Eco3t5gJHuxJPQV7HQAUUUUAFFFFAHk3x7tZ9ITw94+06Nnu/DN2HuVTrJZy4SZfyI+nJr1Oxu4L+yt7uzlWa2uI1likU5DowyGHsQQabqNlb6lp9zY30SzWtzE0MsbdHRhgg/UGvLPgbfT6Fc618ONWkZr3w9JvspXPNxYucxt/wHIU+mQO1AHrdFFFAHlX7Ln/JCfDP/b1/6VS16rXlX7MP7v4NaRbdVtp7uJT3IFxIcn869VoAKKKKACiiigAooooAKKKKAIb21gvrOe0vIkmtp0aKWJxlXUjBBHoQa8c8CXk/wu8ZL4B1uV28O6g7S+HL2Q/dyctaO394E8Hvn/aAHtNc38QfB+m+OPDNxo2rKQj4eGdB+8t5R92RD2I/UEjvQB0lFeVfDHxpqNprD+A/H7rF4ps1/wBFujkR6rABxKhPV8A7h14J6hgPVaAPKvid+7+MHwnnTiRbnUIwf9lrcBh+leq15V8XRs+IXwsmXiQavLGG/wBloiGH44r1WgAooooAKKKKAPKtD/dftJ+Jo26z6DbSrjphZCpz75r1WvKk/cftRSKDtS58Ihzn+J1u8cfh2r1WgAooooAyvFn/ACKus/8AXlN/6Aa5X4A/8ka8J/8AXkv8zXZ6yqvpF8rqGVoJAQRkEbTXBfs4MW+CfhUsST5Djn2legD0miiigArO1fQtJ1o251jS7DUDbtvhN1bpL5Teq7gcH3FaNFAHj3wuYeCviV4n8BT/ALuxu3Ot6NnhTFIcSxL/ALrDgegY17DXm/xr8L32q6TY+IfDS48U+HZfttjgZMygfvIDjkh17dyAO5rp/AHiyw8beFLHXNLOIp1xJET80Mg4aNvcH8xg9DQB0NFFFABRRRQBx3xc8J/8Jn4B1PSoTtvwouLKQHBjuI/mjIPbJG0n0Y0vwl8Wf8Jp4B0vV5BsvWTybyMjBSdPlcEduRnHoRXYV4/4cP8Awgvxy1bQn+TR/FyNqtjnhUvEH79B7sPn/wC+RQB7BRRRQAUUUUAFeTfHDS7vSJ9J+IugQmTU/DrH7ZCnW6sW/wBah91BLD0+Y9QK9ZpsiJLG0ciq6MCrKwyCD1BFAFTQ9Us9c0ey1TTJhPZXkSzQyDurDI+h9R2q7XjPw+lf4a/EC68AXzsNA1MvfeHZnJwmTmW1ye4JyB/VgK9moA8r/Zl/5JPaf9ft5/6PevVK8q/Zn+X4WxRHiSK/vEdf7ree5x+or1WgAooooAKKKKACiiigAooooAKKKKAOR+JPgay8caRFBNPLY6naSCew1KDia0lHRlPocDIyM4HQgEc58PfH+oR62fBnxEjisfFcPFvcKNsGqR9pIj03YHK/kByo9RrmPiB4I0fx1ov9na3C25Dvt7qI7ZraTs8bdj09j3oA5H45futX+Glwwwi+KbWLd6F1cAfjivVa+W/iTqni7wyfCmh+PFF9aad4hsr6x8Sp8scscbEFbgH7rgNnrzg9cbj9RQyJNEksLrJE6hldTkMD0IPcUAOooooAKKKKAPKtazD+0p4bkHP2jQLmEj0Cyhs16rXlXjr9z8fvhhIQCLi31SEY6grCrc16rQAUUUUANljWWN45BuRwVYeoNeXfsvu0nwL8MFyScXK8+guZQP0Fep15V+zENnwe0yAE+XBc3caA9lFxIf6mgD1WiiigAooooAK8V8V2d58JfF114x0O2lufB+pvu17T4FybWT/n6jHp/eH19QV9qps0aTRPFMiyROpVkYZDA9QR3FAEGmahaarp9tf6dcR3NncIJIpozlXU9CDVmvEr7Rdb+Duo3GreELS41bwLO3mX2iRktLYH+KW3yeV7lf6cr6p4S8T6P4u0WHVfD99FeWcnG5D8yN3Vl6qw9DQBs0UUUAFecfHfw9d6v4MGqaISmv8Ah+ZdVsHUZJaPlk9SGXPHcgV6PRQBieCvEdn4t8K6ZrunH/R76EShc5KN0ZD7qwIP0rbrxvwIR8OvinqfgqUGPQddL6pojH7scn/La3H0+8B2AHdq9koAKKKKACiiigDjvir4MTxt4We0hl+y6vauLrTbxeGt7hOVYEcgHofY56gVW+EXjZ/GGgSx6pF9k8SaXIbPVbM8GOZeNwH91sEjt1HOM13VeS/FPw/qXh7xBD8R/Btu02pWkflavp8fH9o2g6/9tEAyD14HXGCATfs3/wDIiah/2Gr7/wBGmvVK8i/Zfu47/wCGtxdwbhFPqt3KobqA0mRn3wa9doAKKKKACiiigAooooAKKKKACiiigAooooAq6rp1lq+nz2OqWsN3ZzrskhmQOjj3BryJ/Cfiz4XSvc/Dxn17wvuLy+HbuX97bjqTbSH8flOfoxOR7PRQBx3gL4j+HvGyyQ6bcPb6pD/x8aZeL5VzAR1DIeuPUZFdjXGePPht4d8aMlxqNvJa6rFjyNTsn8m6iI6YcdcehyK5COb4n/D/AClzCnj3QU6SxEQ6jEvuvIlx7ZYnuKAPYqK4Dwr8XPB/iKf7IupjTNVU7X0/VF+yzo393DcMfZSa78HIyOlAHlXxRxH8XPhPOPlYXd9EH9A8ABH44r1WvKvjL+78ZfC+dv8AVjXfKJ/2njIH8q9VoAKKKKACvKv2ax5fw7uLcEmO31W9iTPXaJif6mvVa8q/Z1+Twx4jtwf3dv4iv4kz12hwefzNAHqtFFFABRRRQAUUUUAFeWeKvhfPba1N4m+Guor4e8RP808BGbK/9pY+xP8AeA9TjJzXqdFAHlXh74uw22pRaF8R9Ofwpr7fKpnObO57bopvu4PoTx0yTXqaOsiK8bBkYZVlOQR6iqOu6Lpmv6dJYa3YW1/ZyfeiuIw6/UZ6H3HIry+X4Ya74Nf7X8KfEE1tAjbjoOqyNPZOOpCH70ZPr1PqKAPYKK8lt/jLFo0qWnxJ8Pap4VushPtDxm5s5D/szID+WOPWvRNA8S6J4hh83QtXsNQTGT9mnWQj6gHI/GgDm/jF4Pn8W+FQdJfyPEWmSrf6VcDAKTpyFyezYxzxnBPSrvwu8ZQeOPCFrqqJ5F6pMF9anhre4Xh0IPI55GexFdbXi/jaOT4WePx44sYnbwtrLpb+IIIxkW8mcJdAD3OG+p6lhgA9ooqO3miuII54JEkhkUOjocqykZBB7gipKACiiigAooooA8p/Z0RYvDXiWCMBYYfEd/HGg6KocYAr1avK/wBnn/kBeLP+xm1D/wBCWvVKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAwfFPg/w94rt/J8RaNZagoBVWmiBdB/suPmX8CK4QfBiLSG3+BfFviPw3j7lslybm1H/bKTr+Jr1migDwPxf4R+LU93oFxPd+H/E0WiajHqEQVTZXEzICNrf8swCCeneuj/4XBc6SAPGngTxNouPvTwwi8tl+sqY/lXrNFAHDeH/i14D1/aNO8Uab5jdI7iT7O5PoFk2kn6V20Msc0SyQukkbDKshyD9CKw9f8GeGfEO463oGl3zt1kntkZ/wbGR+BriZPgR4RgkaTw/Nrnh2VjuL6TqcsRz6/MWFAHqteVfs/wDyW3j+AH93B4v1GJB6KCh/qaQfDnxtYnGi/FbV4o+mNQ0+G9bH1Yj2rofhZ4JufBGmatDf6y2s3up6lLqdxcm2W3BkkC7sICQMlc8HHPAFAHa0UUUAFFFFABRRRQAUUUUAFFFFADJoo54nimjSSNxhkcAgj0INcBr/AMGfAWtzNPN4et7S7J3CewZrV1b+8PLIGfqDXoVFAHk4+EuraYP+KX+JHiqwUA7Ir2Rb6JPorAcVW1Lwv8WH0+5sJfEnhTxDZ3EbRSx6rpzwCRCMEEQ+oz0r2GigDwP4faf8Xvh94fXRjoWjeIbGBybYJqflPCh58sM45UHpnkZxnHTp/wDhYfjq2/5CXwo1OPt/omqQXP06AV6rRQB5UPjDND/yEPh14+gHUumlCVFHqSG4o/4Xn4Yi/wCQhp/iTT8fe+1aTKu30zgHrXqtFAHl8Hx7+G0rFG8RiGQD5kms7hCvscpjNdHovxI8Ga3cLb6X4n0me4c7Vi+0qrsfQK2CfwrqLi3huFC3EMcqjoHUN/OuZ1/4deDtftXg1Xw3pcqsMb1t1jkH0dcMPwNAHK/s+fJpvja3b79t4r1CJiOhIKHj25r1WvBtHtZ/gR4ljspJWu/h9r17xcy8zadduoA8xv4kYKBk9MZ6g7veaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDC8deHLbxb4Q1bQrwL5V7btEGI+4/VH+qsAfwrm/gPr9z4g+GWlvqRP8Aadjv068B6iWFtnPuVCk+5r0GvJ/g4P7O8e/FLRV+VIdYTUAnobmPeTj320AesUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRXnPx78V6v4O8APqnh5oV1A3UMCGZA64c4PBrzWb45azqev+A7DRoIoVuLy1sfEHmRZMVxLKUaFc9DiOVs88FaAPpCivPfhN4q1PxNfeNotUeJk0nX7nTrby024iQ4UH1PvXAWXjT4g+I/A2s/EPRdU0qz0ayM81ro0tl5nn28JO4vNuDKxCtwB1HbNAH0DRWR4P1tPEnhTSNaijMS6haRXPlk52F1BK574JxmtegAooooAKKKKACvKvA48r4/8AxMVCds1tpkjj1YQso/SvVa8q+Hf+kfHL4rXHLLH/AGZbxt0xi3Ysv54oA9VooooAKKKKACiiigAooooAKKKKACiiigAooqC/uo7GxububPlQRtK+OuFBJ/lQBPRXjfw91L4i+N9J0/xdFrej6fpd5Pvj0ZrHzB9nWQqd0+dwchT0GOnToIPC2ufEH4iQapr/AIb1vSdG0uC8ltrGwuLHz/tAjON0sm4MmT/dB/xAPa6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5n4h+DrPxz4fXSNQuLi3hFxHcb4MbsocgcgjFUfEXw30PWb3S7qOIafNZaxHrbm0jRftNwneTjnPc9a7SigDzGw+E7aZr+qalpHi/xBYR6lqMmpXFpA0QiaR33EcpnHbr0qnefBSzddS0/T/Euuad4a1Kdri60e3ePyizEFlRipZVOBlRXrVFAFfTbG30zTrWxsYlhtLWJIIY16IigKqj6ACrFFFABRRRQAUUUUAFeUfA4/btd+JOsY4uPEc1qjY+8sCqoI9uf59K9Xqho2j6doltLb6TZw2cEsrTukK7QXY5ZsepoAv0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAU10WRGSRQyMCGVhkEehp1FAHl+h/CX+wLmO30Txd4gsfD0dyLpdIikTYp3bygcruEZPVe4J55zSP8ACJbW/wBSPh3xZr+g6Vqc7XF1p9i6BN7feMbFSY84HT+WAPUaKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of CC and MLO views. The breast is divided into anterior, middle and posterior depths to aid lesion localization.",
"    <div class=\"footnotes\">",
"     CC: craniocaudal; MLO: mediolateral oblique; Ant: anterior; Mid: middle; Post: posterior; Axill: axillary.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_26_32175=[""].join("\n");
var outline_f31_26_32175=null;
